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Similar to high glucose (HG) levels, ablation of nucleoside diphosphate kinase B (NDPK-B) 
causes a diabetic retinopathy-like vascular pathology. NDPK-B deficient retinae and 
endothelial cells (ECs) showed increased levels of Angiopoietin 2 (Ang-2) and protein O-
GlcNAcylation. In this study we investigated the regulation of the Ang-2 receptor, Tie-2, the 
Hexosamine Biosynthesis Pathway (HBP), and the protein O-GlcNAc removing enzyme O-
GlcNAcase (OGA) in NDPK-B deficiency. 
The Ang-2 elevation in NDPK-B-/- retinae was found to be crucial for the development of 
vasoregression. The regulation of Tie-2 was observed in NDPK-B-/- retinae, specifically in the 
deep capillary layer. In vitro, the upregulation of Tie-2 was mirrored in NDPK-B-depleted ECs 
from different origins, whereas no alteration of Tie-2 expression was observed by HG 
treatment. Tie-2 enrichment occurred at the endothelial plasma membrane upon NDPK-B 
depletion. Similar to HG, NDPK-B depletion blunted Tie-2 receptor phosphorylation. Although 
both HG and NDPK-B deficiency elevated the secretion of Ang-2, intracellular and released 
Ang-2 was higher in NDPK-B depleted ECs. Interference with Tie-2 expression and Ang-2-
binding attenuated NDPK-B depletion-induced, but not HG-induced Ang-2, upregulation. 
Mimicking NDPK-B depleted conditions, the overexpression of recombinant Ang-2 promoted 
the upregulation of Tie-2 in ECs.  
NDPK-B deficiency induced an increase in protein O-GlcNAcylation. Mass spectrometry 
measurements showed that NDPK-B depletion in ECs elevated the HBP end product, UDP-
GlcNAc, without changes in glycolysis, indicating a shift from glycolysis to the HBP. Although 
NDPK-B accounted for about 20% of the total NDPK activity in ECs and 35% in retinae, its 
ablation did not alter nucleotide triphosphate levels. NDPK-B depletion led to an increase in 
the protein content of glutamine:fructose-6-phosphate amidotransferase (GFAT), the rate-
limiting enzyme of the HBP, accompanied  by an EC-specific suppression of OGA activity. 
Both together resulted in an increase in protein O-GlcNAcylation and Ang-2 levels which was 
independent of the catalytic activity of NDPK B. It was similarly rescued by adenoviral re-
expression of either wild type or a catalytically inactive mutant of NDPK-B.  
In summary, NDPK-B depletion directly influences the participation of the HBP in glucose 
metabolism via alteration of GFAT levels and suppression of OGA activity, which 
subsequently further increases protein O-GlcNAcylation and upregulates Ang-2. NDPK-B 
deficiency additionally induces an increase in Tie-2 levels which further supports Ang-2 
production and secretion in a positive feedback loop. As enhanced Tie-2 expression was 
detected on the vasculature of NDPK-B-deficient mice, showing early stages of pathological 
vasoregression, it likely contributes together with enhanced protein O-GlcNAcylation to this 




Ähnlich wie ein Hyperglykämie, verursacht die Ablation der Nucleosiddiphosphatkinase B 
(NDPK-B) eine der diabetischen Retinopathie-ähnliche Gefäßpathologie. Sowohl die Retina 
als auch Endothelzellen (ECs) mit vermindertem NDPK-B-Gehalt zeigen erhöhten 
Angiopoietin 2-Gehalt (Ang-2) - und verstärkte Protein-O-GlcNAcylierung. In dieser Arbeit 
untersuchten wir die Regulation der Ang-2-Rezeptors Tie-2- und der Protein-O-
GlcNAcylierung bei NDPK-B-Mangel.  
Wie in der Hyperglykämie, erwies die Erhöhung von Ang-2 in der NDPK-B-/- Retina  als 
maßgeblich  für die Entwicklung der Vasoregression. Eine Hochregulation von Tie-2 trat 
insbesondere in der tiefen Kapillarschicht der Retina von NDPK-B-/- Mäusen auf. In vitro 
konnte die Hochregulation von Tie-2 in ECs aus verschieden Teilen des Gefäßbetts durch 
Depletion der NDPK-B induziert werden, während eine Behandlung mit hohen 
Glukosekonzentrationen  (HG)-Behandlung keine Veränderung in Tie-2 hervor rief. Bei 
NDPK-B-Mangel konnte eine Anreicherung von Tie-2- in der Plasmamembran beobachte 
werden. Ähnlich wie HG reduzierte eine NDPK-B-Depletion die Phosphorylierung des Tie-2-
Rezeptors. Obwohl sowohl HG- als auch NDPK-B-Mangel die Sekretion von Ang-2 
erhöhten, war der Anstieg an intra- und extrazellulärem Ang-2 in ECs nach NDPK-B-
Depletion deutlich stärker ausgeprägt. Durch Verminderung  der Funktion bzw. Expression 
von Tie-2 konnte die durch NDPK-B-Depletion, nicht aber die HG-induzierte Ang-2-
Hochregulation. Ähnlich wie die NDPK-B-Depletion, erhöhte die Überexpression von 
rekombinantem Ang-2 in ECs die Ang-2-Sekretion und förderte die Hochregulation von Tie-
2.  
In vorausgegangen Arbeiten unseres Labors, in denen ein durch NDPK-B-Verlust bedingter 
Anstieg der Protein-O-GlcNAcylierung beobachtet werden. Durch massenspektrometrische 
Analysen konnte hier nachgwiesen werden, dass ein NDPK-B-Verlust  mit einem Anstieg in 
der Menge des Endprodukts des Hexosamin-Biosynthesewegs (HBP), UDP-GlcNAc, 
einhergeht, ohne dass es dabei zu Veränderungen Glykolyserate -kam. Dies deutet was auf 
eine Verschiebung des Metabloismus von der Glykolyse zum HBP hin. Obwohl NDPK-B 
etwa 20% bzw. 35% der gesamten NDPK-Aktivität in ECs und Retinae ausmachte, änderte 
deren Verlust nichtsam Nukleotidtriphosphatgehalt. Die NDPK-B-Depletion führte dagegen 
zu einer Erhöhung des Proteingehalts der Glutamin:Fructose-6-phosphat-Amidotransferase 
(GFAT), dem geschwindigkeitsbestimmenden Enzym des HBP, die mit einer EC-
spezifischen Reduktion der Aktivität der die O-GlcNAc-Modifkation reduzierenden O-
GlcNAcase (OGA) einherging. Die daraus resultierende Zunahme der Protein-O-
GlcNAcylierung modifizier war unabhängig von der katalytischen Aktivität der NDPK-B, da 
sie in ähnlicher Weise durch adenovirale Reexpression entweder des Wildtyps oder eines 
xiv 
 
katalytisch inaktiven Mutanten von NDPK-B ausgeglichen wurde. 
Zusammenfassend induziert ein NDPK-B-Verlust eine Erhöhung des Glucosestoffwechsel 
HBP durch Anstieg in GFAT, welcher zusammen mit der Reduktion der OGA-Aktivität die 
Protein-O-GlcNAcylierung erhöht und damit Ang-2 hochreguliert. Expression verändert und 
anschließend die unterdrückt Die Zunahme in Tie-2 verstärkt die Produktion und Sekretion 
von Ang-2 in einer positiven Rückkopplungsschleife weiter. Da eine Zunahme sowohl von 
Tie-2 als auch der Protein-O-GlcNAcylierungin den retinalen Gefäßen von NDPK-B-
defizienten Mäusen festgestellt wurde, die bereits frühe Stadien der pathologischen 
Vasoregression aufwiesen, trägt wahrscheinlich beides zu dieser Ang-2-induzierten 
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1.1 Diabetes and diabetic retinopathy 
1.1.1 Diabetes mellitus  
Diabetes mellitus (DM) is a long-standing metabolic disorder that has reached epidemic 
proportions. The fundamental feature of DM is hyperglycemia resulting from defects in 
insulin secretion and action [1]. Statistics indicate that more than 425 million individuals 
worldwide suffer from diabetes. Current and past statistics predict the dramatic rise of 




Fig.  1: Global prevalence of diabetes from 2017 to 2045. Adapted from IDF Diabetes Atlas 2017, 
International Diabetes Federation [2] 
 
DM was categorized in 1980 by the World Health Organization (WHO) and subsequently 
subdivided into several types, the most common being Type 1 and Type 2 DM. Type 1 DM 
refers to the elevation of blood glucose due to a loss of insulin production as a result of 
autoimmune destruction of pancreatic β-cells or genetic inheritance [1]. Type 2 DM (T2DM) 
makes up 90-95% of DM cases. In this subtype, the disease develops due to a combination 
of impaired production of insulin and resistance to insulin action [3]. Some of the influencing 
factors for the development of T2DM are obesity, due to poor diet or sedentary lifestyle, and 
genetic background. The common symptoms of hyperglycemia are polyuria, thirst, blurred 
vision and weight loss. These symptoms vary with duration and intensity of the disease. 
Long-term complications of diabetes vary from microvascular in nature, such as, retinopathy, 
neuropathy and nephropathy to macrovascular, such as coronary heart disease, heart 
failure, hypertension, peripheral arterial disease, and stroke [4].  
 
1.1.2 Diabetic retinopathy (DR) 
Amongst the eye-related late-stage complications of diabetes are retinopathy (DR), macular 
edema, cataracts, and glaucoma. DR is one of the most prevalent complications of DM, 
affecting 100 million people worldwide leading to visual impairment and eventually blindness 
[4, 5]. DR is currently the 5th leading cause of blindness and is predicted to increase to 191 
million people by 2030, making it one of the leading causes of acquired vision loss [6]. 
Although DR currently ails 35% of people worldwide, there has been a decline in retinopathy 
and its sight-threatening stages due to early detection and new treatment options [7, 8]. 
Screening for DR in Europe uncovered that over 13% of newly diagnosed type 2 diabetics 
showed signs of DR, indicating that at the point of diagnosis, the disease is well-advanced 
and tackled only via glucose lowering therapy [9-11]. The costs of treatment and 
development of technologies for effective treatment and diagnostic screening for DR in 
diabetic patients makes it not only a public health burden but also an economic burden [8, 
12]. Apart from chronic hyperglycemia, certain genetic and inflammatory markers, sex of the 
patient, duration of the disease; blood pressure and lipids provide associations with the 
development of DR and have been studied intensively [12-14]. DR also leads to pathologies 
in various important cells types of the retina such as the neurons and glial cells, making it 
larger than only a microvascular disease [15].  
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1.2 Development and pathogenesis of DR 
1.2.1 The classification of DR 
The vasculature starts to develop in the late embryonic stage in humans and postnatally in 
mice allowing for study of initial angiogenesis in animal models. The astrocyte macroglia 
produce a VEGF gradient that directs the formation of the first plexus in the retina. The 
endothelial cells (ECs) specialize into three different subtypes to carry out angiogenesis; of 
which pre-quiescent stalk and quiescent phalanx ECs attract pericytes (PCs) and remain in 
contact with them [16-19]. Retinal vasculature may be easily visualized by quantitative retinal 
morphometry and shows similar structural phenotype of EC and PC interaction across 
species (Fig. 2 ) [20].   
 
Fig.  2: Retinal digest preparations from several species depicting standard EC and PC 
interactions phenotype. Adapted from Dietrich, Methods Mol. Biol. 2012 [20]. 
 
1.2.2 The pathogenesis of DR 
The disease severity scale developed for DR was based on findings of Early Treatment of 
Diabetic Retinopathy Studies (ETDRS) and Wisconsin Epidemiologic Study of Diabetic 




Table 1: Classification of observable diabetic retinopathy stages according to ETDRS and 
WESDR [21-24] 
Severity level Observable findings 
No apparent retinopathy No changes found 
Mild NPDR  Few microaneurysms 
Moderate NPDR  Microaneurysms, hemorrhaging and venous beading 
Severe NPDR  
 
Any of the following (4:2:1 rule): 
• More than 20 intraretinal hemorrhages in each of 4 
quadrants 
• Venous beading in 2 or more quadrants 
• Intraretinal microvascular abnormalities in 1 or more 
quadrant 
PDR One or more of the following: 
 Neovascularization of the retina, iris, disc, angle 
 Vitreous hemorrhaging 
 
The microvascular and neuronal changes that classify the development of DR occurs in two 
broad stages: 
• Non-proliferative diabetic retinopathy (NPDR): 
This stage marks the importance of PCs in predicting the incidence of vascular 
damage in DR [25]. Extensive animal studies show that the hallmark of this stage is 
the loss of two major cell types: the PCs and the ECs. Biochemical changes in ECs 
cause the loss of PCs, which are essential for vessel quiescence and maturity. PC 
dropout is, therefore, by far the earliest morphological change seen in DR, occurring 
2 months after the onset of diabetes [26-28]. Normally, PC recruitment is mediated 
by the PDGFB receptor and the Ang-2-Tie-2 system. Dysfunction of these recruiting 
pathways generates DR-like phenotype, indicating the indispensability of PCs [29, 
30]. In the absence of the stabilizing effect of the PCs, ECs die or deteriorate leaving 
behind a husk of a vessel that does not support blood flow. Acellular capillaries (AC), 
occur around 6 months after onset of diabetes and can be quantified in retinal digest 
preps of the retina and represent the degree of vasoregression. Apart from the 
disintegrating neuro-vascular unit (NVU), other features of this stage are 
microaneurysms, hemorrhaging, abnormal glial activity and lipid exudates from 
damaged capillaries [5, 28]. Neurodegeneration begins at 6 weeks and can be 
measured via electroretinography [31]. 
• Proliferative diabetic retinopathy (PDR): 
5 
 
The non-perfusion of the NPDR stage leads to an ischemic buildup in the retina leading 
to the release of pro-angiogenic factors such as VEGF and the formation of 
neovascularizations. Aberrant formation of immature blood vessels in combination with 
the degeneration of pre-existing vessels, cause vascular leakage into the vitreous and 
hemorrhages. In certain cases, tractional retinal detachment occurs, leading to 
blindness [5, 28]. Curiously, no animal models with PDR have been established so far 
[32]. 
 
The pathogenesis of DR cannot be singularly isolated. Intensive research over the years 
have uncovered several mechanisms such as inflammatory responses, gliosis, altered 
neural responses, the loss of protective cell-cell interactions and an increase in vessel 
permeability due to barrier breakdown that lead to DR development. DR is now considered a 
disease of the NVU instead of a disease of the vasculature alone [33, 34]. The Muller glia 
(MC) form a link between the neurons and the vasculature and are indispensable for the 
tightness of the blood-retinal barrier (BRB) and the survival of the neurons and blood vessels 
(Fig. 3 ). The microglia form immunological gatekeepers and defend against inflammatory 
signals [35, 36]. Together the micro- and macroglia support the vasculature to form the NVU 
[14, 37]. Initial chemical changes originating from high blood glucose can be further 
examined by investigating cellular biochemical pathways in response to high glucose fluxes.  
 
Fig.  3: DR and the retinal microenvironment. Left panel: The microaneurysms (solid arrow), 
haemorrhages (asterisk) and hard (dashed arrow) and soft (arrowhead) exudates are as depicted. 
This stage is classified as severe NPDR. Right panel: Hyperglycemia induced changes to the 
neurovascular unit in STZ-induced rat retina involving vasoregression due to pericyte 
dropout/migration, microglia and macroglia activation and neurodegeneration. Adapted from 




1.3 Biochemical mechanisms of diabetes 
1.3.1 Hyperglycemia and ROS production 
Different cell types respond varyingly to hyperglycemia via their glucose transporters. This 
determines the susceptibility of the cell to glucose-mediated metabolic changes [38, 39]. 
Cells susceptible to hyperglycemia showed consistently high reactive oxygen species (ROS) 
levels than resistant cells [40-42]. Post-TCA cycle, electrons donors NADH and FADH2 
enable the transport of electrons from Complex I to II, II and IV in the electron transport 
chain ETC to be finally converted and reduced to water (Fig. 4). The transmembrane 
pumping of electrons by complexes I, II and IV generates a membrane potential required for 
ATP production. Excess intracellular glucose drives the flux through the ETC causing the 
membrane potential to reach a threshold beyond which the ETC is arrested at complex III. 
The buildup of electrons in coenzyme Q results in electron donation to the oxygen available 
for production of water, making superoxide instead. Hyperglycemia therefore drives 
increased ROS production. 
 
Fig.  4: Hyperglycemia-induced production of ROS. Excessive glucose increases flux through the 
ETC, which proceeds until threshold membrane potential is reached. Subsequent blockade of the 
ETC at complex III generates electron buildup at coenzyme Q, which donates electrons to O2 for 




1.3.2 Hyperglycemia and GAPDH activity 
The crucial enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the 
formation of 1-3-diphosphoglycerate. Diabetes consistently dampens GAPDH activity in cells 
and animals with the exception of those without the ability of ROS production [40]. ROS 
production induces DNA damage that activates PARP, which subsequently dampens the 
activity of nuclear GAPDH. Thus, there is a link between increased ROS and lower GAPDH 
activity. 
 
1.3.3 Pathways activated by hyperglycemia 
Prior research highlights four cardinal mechanisms that are altered intracellularly (Fig. 5).  
i. Polyol pathway: focuses on the conversion of high amounts of intracellular glucose 
to fructose by aldose reductase, a reaction that requires NADPH [44]. By utilizing 
NADPH for countering excess glucose, it depletes the reserves for the production of 
the antioxidant, reduced glutathione, thereby increasing susceptibility to oxidative 
stress. Treatment with aldose reductase inhibitor prevented diabetes mediated cell 
damage [45]. 
ii. AGE pathway: increased advanced glycation end products (AGEs) form as a result 
of increased intracellular glucose can damage cells on transcriptional level via 
alteration of gene transcription, modification of extracellular matrix post-secretion and 
via modification of plasma proteins which then bind to AGE receptors and initiate 
secretion of inflammatory cytokines [46-50]. The damage caused due to multi-faceted 
effect of excessive AGEs can be mitigated upon AGE inhibition indicating their 
prevalence in mediating diabetic disorders [51].  
iii. PKC activation: hyperglycemia-mediated elevation in diacylglycerol (DAC) promotes 
the activation of PKC isoforms. These in turn mediate the regulation or multiple 
factors transcriptionally. Regulation of vessel tone via eNOS inhibition, increased 
endothelial permeability via VEGF and heightened inflammation via NF-κB are 
among the few PKC-mediated outcomes. Targeting PKC has been shown to prevent 
vascular dysfunctions in diabetic retina and mesangial cells [52].  
iv. Hexosamine pathway: Fructose-6-phosphate is partially utilized by GFAT for the 
production of UDP-GlcNAc which, not unlike phosphorylation, modifies nuclear and 
cytoplasmic proteins on serine and threonine residues. Modification by O-GlcNAc 
changes functionality and stability of altered proteins [53]. High glucose-mediated 
modification of transcription factor Sp3 causes decreased binding to repressive 
elements in Ang-2 promoter, thereby increasing Ang-2 expression in microvascular 




Fig.  5: Four pathways activated by intracellular hyperglycemia: polyol pathway, hexosamine 
pathway, protein C kinase pathway and AGE pathway all combined under the unifying hypothesis that 
excessive ROS-mediated reduction in GAPDH activity enables accumulation of glycolytic 
intermediates providing substrates for the four pathways. Adapted from Brownlee, Diabetes 2005 [43]. 
 
Lowered GAPDH activity purports accumulation of glycolytic intermediates, thereby 
providing substrates for increased flux through the four pathways [55]. This provides a 
unifying mechanism for the intracellular metabolic effects of hyperglycemia. 
Recent findings show, that the altered bioavailability of the gastrotransmitters iNOS, CO and 
H2S, induce oxidative stress by lowering the protective effects of vasodilation, ROS 
scavenging and survival signaling, in response to hyperglycemia [56]. Although 
hyperglycemia is an antecedent in the development of DR, several factors unaffected by 
high glucose contribute to the pathogenesis of DR. AGE precursor methylglyoxal (MG) 
depends, not on glucose, but on generation and detoxification by the glyoxalase 1 and 2 
systems for its production. Administration of MG, leads to DR-like vasoregression, NVU 





1.4 The Hexosamine Biosynthesis Pathway (HBP) and P rotein O-GlcNAcylation 
1.4.1 O-GlcNAc modification and HBP 
Protein O-GlcNAcylation is a reversible posttranslational modification, resulting in the 
alteration of a wide range of proteins and their activity, interactions, and functions [59-62]. It 
was discovered in the 1980s and occurs exclusively in nuclear and cytoplasmic fractions.  It 
differs from canonical glycosylation by being reversible, not elongated or modified to 
complex structures [63] , and regulates transcription and cell signaling dynamics [59, 61].  
 
 
Fig.  6: The hexosamine biosynthesis pathway (HBP) assembling glucose intermediates, 
glutamine, fatty acids and UTP in the manufacture of UDP-GlcNAc for modification of protein with O-
GlcNAc residue. Adapted from Hart, Annu Rev Biochem 2011 [64].  
 
The hexosamine biosynthesis pathway (HBP) is an offshoot of glycolysis, normally 
accounting for just 2-5% of glucose metabolism. Glycolysis intermediate fructose-6-
phosphate (F-6-P) is utilized to generate HBP end product UDP-GlcNAc [65-67]. Amongst 
the components of the HBP, the key enzyme is glutamine:fructose-6-phosphate 
amidotransferase (GFAT), which catalyzes the formation of glucosamine-6-phosphate 
(GlcN-6-P) in a rate limiting step and controls UDP-GlcNAc availability [68, 69]. In addition to 
glucose metabolism, fatty acid and amino acid metabolism also contribute to the generation 
of the HBP end product, UDP-GlcNAc (Fig. 6 ) [66, 67] [65]. Externally supplied glucosamine 
may bypass the rate-limiting reaction and is directly converted to glucosamine-6-phosphate, 
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thereby altering UDP-GlcNAc levels. The HBP is therefore, in essence, a nutrient-sensing 
pathway. There are several factors regulating the HBP. A moderate change in HBP can 
result in significant changes in O-GlcNAcylation [69]. 
 
1.4.2 Glutamine: fructose-6-P-amidotransferase (GFA T) 
GFAT is the rate-limiting enzyme of the HBP and controls UDP-GlcNAc availability. The 
isoform GFAT1 is ubiquitously expressed while GFAT2 is expressed primarily in the central 
nervous system (CNS), heart, lung, skeletal muscles and placenta [70]. Although GFAT 
activity is robustly regulated by its expression, prior research illustrates phosphorylation of 
GFAT by cAMP-dependent PKA and AMP-kinase (AMPK) in a manner of regulating its 
activity [71-73]. Endothelial GFAT activity is dampened by AMPK-mediated phosphorylation 
in response to VEGF stimulation [73, 74]. GlcN-6-P and UDP-GlcNAc amounts also serve as 
regulators of HBP and inhibit GFAT allosterically [68].  
 
1.4.3 The expression, structure, localization and r egulation of the enzymes regulating 
O-GlcNAc cycling: OGA and OGT:  
UDP-GlcNAc serves as a substrate for the O-GlcNAc cycling enzymes, O-GlcNAc 
transferase (OGT) and O-GlcNAcase (OGA) (Fig. 7). Unlike phosphorylation, O-
GlcNAcylation is cycled reversibly by this single pair of enzymes. 
i. OGT catalyzes the reversible attachment of the GlcNAc moiety to serine/threonine 
residues of proteins. Although OGT active site appears to lack a specific substrate 
recognition motif, it does show preference for Ser/Thr residues flanked by residues in 
extended peptide conformations. Additional specificity is achieved by certain 
structural confirmations on fully-folded proteins or TPR binding sites that allow 
access to the active site [75, 76]. Three isoforms of OGT; ncOGT 
(nucleocytoplasmic), sOGT (short) and mOGT (mitochondrial) can be found in the 
respective cellular compartments. OGT activity is promoted by increasing amounts of 
substrate UDP-GlcNAc. Low GlcNAcylated proteins can become better acceptors at 
high UDP-GlcNAc levels indicating that UDP-GlcNAc levels can also dictate OGT 
selectivity. Other factors influencing OGT selectivity are multimerizations, splicing, 
and post-translational modifications such as the phosphorylation or O-GlcNAcylation 
of its own catalytic domain [77]. 
ii. OGA catalyzes the detachment of the GlcNAc moiety from the proteins. Highly 
conserved in sequence, it is enriched in brain, pancreas and thymus. Two isoforms, 
namely, ncOGA (nucleocytoplasmic) and sOGA (short) are localized in the nucleo-
cytoplasmic fractions and in the endoplasmic reticulum, respectively. OGA 
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localization is however predominantly cytoplasmic. The specificity of OGA is rather 
uncomplex when compared to OGT. Analyses of crystal structure and docking 
simulations show that OGA binding to O-GlcNAcylated proteins involves interaction 
with the peptide backbone and sugar moiety only with the least interference from the 
side chains, similar to the action of global phosphatases [76].  
 
Fig.  7: The regulation of O-GlcNAcylation by O-GlcNAc cycling enzymes. OGT and OGA 
enzymes catalyze the attachment and detachment of GlcNAc group based on the availability of UDP-
GlcNAc from the HBP. The modification of proteins alters several cellular pathways. Adapted from 
Hart, Annu Rev Biochem 2011 [64].  
 
1.4.4 Functions of O-GlcNAcylation: 
Unlike canonical glycosylation that exists in the Golgi, endoplasmic reticulum and the 
extracellular environment, O-GlcNAcylation is rather ubiquitous and thereby plays many 
roles.  
i. Transcription:  The prevalent localization of OGT in the nucleus indicates a role in 
regulation of transcription. Several transcription factors such as FoxO1, NF-κB and Sp3, 
have been reported to be modified by O-GlcNAc thereby influencing glucose 
metabolism, lymphocyte activation and angiogenesis, respectively [54, 60, 78].  The 
modification alters the functions of transcription factors such as DNA binding, 
stabilization via inhibition by ubiquitination and transactivation [62]. In diabetes 
research, Yao et al. show that hyperglycemia promotes methylglyoxal modification of 
mSin3A in ECs, triggering the increased O-GlcNAcylation of Sp3 via recruitment of OGT 
[54]. Modification of Sp3 diminishes its binding to the glucose-responsive GC box of the 
Ang-2 promoter, thereby permitting increased Ang-2 expression. 
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ii. Epigenetics:  The modification of Pol II and transcription factors as well as the 
discovered association of OGT with HDAC corepressor complex implicates O-
GlcNAcylation in parallel with histone deacetylation playing a role in gene silencing [79]. 
iii. Regulation of cell signaling:  GlcNAc groups on Ser/Thr residues not only alter the 
function and specificity of susceptible proteins but also compete with other modifications 
such as phosphorylation and ubiquitination. Elevation of O-GlcNAcylation of Akt 
prevents its phosphorylation on insulin treatment, thereby inhibiting associated survival 
pathways. The reduction of Akt O-GlcNAcylation reverses the process. Since 
phosphorylation and O-GlcNAcylation of Akt occur on the same Ser/Thr residues, 
competition and balance between the two modifications affects major survival related 
cellular functions [80, 81].  
iv. O-GlcNAcylation in diabetes and DR:  Transcription factors regulating insulin; 
NeuroD1 and Pdx-1 possess O-GlcNAcylation sites, and increasing modification causes 
nuclear translocation and elevated insulin expression [82, 83]. Since the prevalence of 
O-GlcNAc in pancreatic β cells is higher than in surrounding cell types, the HBP is 
crucial to normal insulin production but in excess turns deleterious by raising oxidative 
stress, β cell toxicity and apoptosis [84-87]. Members of the insulin signaling pathway 
are also modified by O-GlcNAc [80, 88-90]. Incidentally, O-GlcNAcylation of IRS-1 and 
Akt blunts their phosphorylation. Elevated levels of O-GlcNAc therefore cause 
dysregulated glucose cycling and eventually glucose toxicity.  
In diabetic retinopathy (DR), retinal Ang-2 is elevated and promotes pericyte dropout 
from the retinal microvasculature under hyperglycemia. In the absence of the protection 
of pericytes, the microvasculature is susceptible to vasoregression [28, 91, 92]. O-
GlcNAcylation is heightened in the retinae of diabetic mice [93]. Furthermore, retinal 
ECs and pericytes show increased O-GlcNAcylation in response to high glucose in a 
dose dependent manner. Retinal ECs exposed to HG also show enhanced migratory 
capacity without changes in viability [94]. O-GlcNAc is maintained by a balance in 
activity of OGT and OGA. Both are O-GlcNAcylated and thereby subject to regulation by 
the modification they oversee [95-97]. OGT overexpression studies recapitulated the 
diabetic phenotype where as OGA overexpression reversed cardiomyopathic 
phenotypes [98-100]. Single nucleotide polymorphism of OGA gene is associated with 
the risk of T2DM in Mexican-American population studies. Ablation of OGA in C. 
elegans produces metabolic changes reminiscent of insulin resistance in humans. Gurel 
et al. demonstrate the regulation of OGT/OGA gene and protein expression in healthy 
and diabetic mouse retinae [93]. Pharmaceutical inhibition of OGT with Alloxan blocked 
the hyperglycemia-mediated elevation in O-GlcNAc in retinal PCs and promoted PC 
migration. Similar results were seen upon treatment with GFAT inhibitor DON. In 
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contrast, treatment with OGA inhibitor PUGNAc or Thiamet-G heightened O-GlcNAc 
levels similar to HG and hampered PC migration. These findings show how protein O-
GlcNAcylation in DR can be modulated at several checkpoints in the HBP.  
Endothelial cells are susceptible to changes in blood glucose levels and hence serve as an 
excellent tool for metabolic studies. Elevated blood glucose prompts increased flux through 
the HBP in ECs [101, 102]. O-GlcNAcylation of eNOS can induce endothelial dysfunction via 
inhibition of its phosphorylation [103, 104]. Several publications highlight the crosstalk 
between O-GlcNAcylation and other modifications such as tyrosine phosphorylation, 
methylation, acetylation, ubiquitination and methylglyoxal modification [77]. The crosstalk 
between O-GlcNAcylation and AMPK stress signaling is outlined in reports showing 
phosphorylation of endothelial GFAT by AMPK and the subsequent reduction in enzymatic 
activity [73, 74]. The spontaneous O-GlcNAcylation of proteins on exposure to extracellular 
stress implicates O-GlcNAcylation in survival and stress signaling [63, 74]. Reports, 
however, claim that O-GlcNAcylation is modified not only by nutrient availability but also by 
substrate regulation via modification of OGT and OGA specificity [105, 106]. The 
complicated mechanisms and intimate crosstalk between O-GlcNAcylation and other 
pathways make it a master regulator and influencer of nutrient and stress-driven signaling. 
 
1.5 Angiopoietin-2-Tie-2 system 
Two processes mediate the development of vasculature in any organism. Vasculogenesis is 
the formation of a primitive vasculature in response to external signals and progenitors. The 
formed blood vessels mature and acquire quiescence. The supply of blood is expanded 
throughout the tissue and organs via angiogenesis, the development of blood vessels from 
pre-existing vasculature [107]. Endothelial cells form the basis of any vasculature. They 
migrate and assemble to form monolayers of tight intracellular contacts. Perivascular cells 
such as pericytes and smooth muscle cells support the assembly of endothelial cells into 
blood vessels such as veins, arteries and capillaries. The complex crosstalk that enables 
vascularization is carried out by autocrine and paracrine signaling of vascular ligands 
(VEGF, Ang-1, Ang-2) and their respective receptors (VEGFR-2 and Tie-2/1) [107].  
1.5.1 The Angiopoietins and their receptor Tie-2  
The structure of the angiopoietins consists of an N-terminal angiopoietin specific domain and 
a coiled-coil domain responsible for multimerization, a linker peptide and a C-terminal 
fibrinogen domain essential for receptor binding (Fig. 8 ) [108, 109]. The angiopoietins use 
their fibrinogen-like domain to bind to their receptor Tie-2. Ang-1 and Ang-2 share 60% 
homology and are located side-by-side on chromosome 8 p22 and 23, respectively [110, 
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111]. Ang-1 is incorporated into the extracellular matrix of the ECs and is primarily secreted 
by perivascular cells such as pericytes. Ang-2 on the other hand is stored in Weibel-Palade 
bodies, which are secretory vesicles in the endothelial cytoplasm and is released in 
response to inflammatory stimuli [112, 113]. The mediator of Angiopoietin signaling is the 
membrane-bound receptor tyrosine kinase Tie-2, which is predominantly expressed in ECs 
and mediates functions such as survival and maintenance of vascular integrity, angiogenesis 
and vasoregression [114-118]. 
Tie-2 and Tie-1 form a family of receptor tyrosine kinases. They consist of an extracellular 
multidomain of three EGF-like motifs between two Ig-like loops [119]. Genetic ablation 
studies show that both Tie-2-/- and Tie-1-/- mice are embryonic lethal with vascular defects. 
Tie-2-/- mice have fewer ECs, supporting PCs and SMCs, and poorly organized vasculature 
with fewer branches. Additionally, Tie-2 plays a crucial role in developmental hematopoiesis 
[120-123]. Tie-1 on the other hand is not crucial for hematopoiesis but Tie-1-/- mice lose 
vessel integrity resulting in widespread edema and embryonic death. Both receptors 
however do not partake in the initial assembly of the vasculature [124, 125].  
 
 
Fig.  8: Structure of Tie-2 receptors and Angiopoietin ligands. The Tie-2 receptor consists of N-
terminal Ang binding domain and C-terminal receptor tyrosine binding domain. Rotatory shadow 
techniques show the possible multimerizations of Angiopoietin ligands. Adapted from Augustin, Nat 




The characterization of Tie-1/2 led to genetic ablation studies of their ligands. Ang-1-/- mice 
phenocopy Tie-2-/- mice and are embryonic lethal. This led to the characterization of Ang-1 
as the primary ligand of Tie-2 that mediates critical vascular functions distinct from VEGF 
[126]. Endothelial cells of Ang-1-/- mice are rounded and loosely attached to the ECM 
indicating the importance of Ang-2-Tie-2 in EC-ECM interactions. Development of Ang-2-/- 
mice proceeds unhindered although certain genetic backgrounds report postnatal death. 
C57BL/6 background mice show transient postnatal chylous ascites, making it possible to 
investigate Ang-2 in knockout animals [127, 128].  Although Ang-2 deficient mice are viable, 
detailed researches show consequences in various vascular beds. Ang-2 is dispensable for 
vascularization at development and gains importance postnatally. Angiogenesis is best 
studied in the retina. Ang-2-/- mice show non-regressing hyaloid vessels of the embryonic 
lens and perturbed retinal and renal vasculature [129-131]. Knock-in of Ang-1 into Ang-2 
locus rescues lymphatic abnormalities in Ang-2-/- but not blood vessel defects indicating 
rudimentary roles of Ang-1 and Ang-2 in lymphatic vasculature and ligand-specific roles in 
the formation of blood vessels [132]. 
Conversely, gain-of-function (GOF) experiments have also shed light on the Ang-1/2-Tie-2 
functions. Ang-1 overexpression promotes dermal hypervascularization, whereas delivery of 
recombinant Ang-1 counters VEGF-induced hyperpermeability and inflammation due to 
VEGF-induced release of inflammatory adhesion molecules. A series of findings conclude 
the crucial function of Ang-2 in promoting vessel maturation and quiescence via increased 
signaling through Tie-2 [117, 133, 134]. Contrary to expectations Tie-2 overexpression does 
not phenocopy Ang-1 overexpression and leads to venous malformations and dilated blood 
vessels. This proves the significance of Tie-2 signaling via both ligands and not just its 
preferential binding to Ang-1 [135]. Ang-2 overexpressing mice demonstrate contradictory 
phenotypes and similar vascular defects as seen in Ang-1 and Tie-2 null mice. Hence, Ang-2 
is popularly regarded as the Tie-2 antagonist [134]. Ang-2 GOF has been associated with 
barrier-opening effects in brain endothelial cells thereby increasing permeability to solutes, 
prompting no compensatory elevation response from Ang-1. Furthermore, disrupted 
glycocalyx in GOF brain ECs indicates the anti- EC-ECM action of Ang-2 antagonizing the 
effect of Ang-1-Tie-2 signaling [136]. 
 
1.5.2 The Ang-1/Ang-2 Tie-2 signaling axis 
Ang-1 and Ang-2 bind with equal affinity to Tie-2. Angiopoietin 1 (Ang-1), the canonical 
agonist of Tie-2, is released by perivascular cells and binds to Tie-2 to promote endothelial 
survival, adhesion, and quiescence [108]. Upon the binding of Ang-1, Tie-2 is 
phosphorylated, which further activates survival signaling via phosphorylation of PI3K, Akt, 
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and FoxO1 [137]. The activation of Akt prompts survival pathways such as eNOS and 
inhibition of inflammatory and apoptotic pathways. Akt subsequently phosphorylates FoxO1, 
a transcriptional activator of Ang-2, causing its nuclear exclusion and inactivation (Fig. 9). 
Ang-1-Tie-2 signaling also inhibits vessel permeability via the sequestration of Src, which 
mediates VEGF-induced redistribution, and internalization of VE-cadherin, an adherens 
junction protein [138]. Tie-2 activation is also known to recruit smooth muscle cell migration 
and recruitment to ECs and restore survival in developing retinal models with disrupted peri-
endothelial interactions [139, 140]. Via the recruitment of Tie-2 to basal plasma membrane of 
ECs and activation of Erk1/2 and Dok-R pathways, Ang-1 promotes EC-ECM adhesion. 
Ang-1 also stimulates the production of collagen IV, thereby promoting EC-EC contact, 
stability, maturity and quiescence of the endothelium [141, 142] (Fig.10). 
 
 
Fig.  9: The interplay between Ang-1 and Ang-2 via receptor Tie-2. The Ang-1-Tie-2 signaling 
promotes inhibition of FoxO1 (FKHR) and the subsequent suppression of Ang-2. Adapted from Daly, 
Genes Dev 2004 [137]. 
 
Ang-2 is predominantly expressed in ECs and released upon stimulus from vesicles [113]. 
Thereafter, it binds in an autocrine fashion to Tie-2 on the ECs. [143-145].  Hampering the 
Ang-1/Tie-2 signaling axis maintains active FoxO1 in the nucleus, purporting unchecked 
Ang-2 production (Fig. 9 ) [137, 146]. The binding of Ang-2 to Tie-2, however has context-
dependent outcomes [147]. As an antagonist, it perturbs Ang-1/Tie-2 signaling and promotes 
vascular remodeling via the loosening of matrix contacts. It supports the effects of the 
vascular endothelium-derived growth factor (VEGF) in inducing angiogenic responses. In the 




Fig.  10: The contrasting outcomes of Ang-1 and Ang-2 binding to Tie-2. Ang-1 binding promotes 
vessel stability and integrity whereas Ang-2 binding promotes destabilization and remodeling. 
Adapted from Eklund, Exp Cell Res 2013 [132]. 
 
Paradoxically, several reports indicate that Ang-2 might be a weak agonist of Tie-2, 
promoting its phosphorylation and hence, vascular survival and angiogenesis [148-150]. 
However, in the presence of Ang-1 it reverts to its antagonist role, inhibiting Ang-1-Tie-2 
action in a dose-dependent manner, thus highlighting the complex interplay between the 
angiopoietins and their receptor Tie-2 (Fig. 10 ) [109, 150-152]. The effects of Ang-2 are 
vastly amplified in the presence of inflammatory cytokines [153, 154]. Under pulmonary 
infection conditions, Ang-2 acts as Tie-2 antagonist and suppresses its phosphorylation and 
promotes FoxO1 expression. The effect was mimicked by excessive exogenous Ang-2, anti-
Tie-2 reagents and suppressed by exogenous Ang-1-mediated activation of Akt survival 
pathways. In contrast, under pathogen-free conditions, Ang-2 plays the agonist and 
mediates vascular remodeling via Tie-2 phosphorylation and suppressed FoxO1 activation 
[148]. Thereby, Ang-2 plays a complex role in the regulation of vascular remodeling and 
angiogenesis. 
 
1.5.3 The regulation of Ang-2 in diabetes and diabe tic retinopathy  
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DR is the most prevalent microvascular complication of diabetes [5]. Naturally, the 
angiogenic factors play a large role in its development. In the developing retina, the tip and 
stalk ECs guide the vessel growth along a VEGF gradient with the aid of VEGFR-2. The role 
of VEGF becomes prevalent in the later PDR stage [155, 156]. Once the vessels are formed 
and mature, they are sheathed in pericytes. Healthy pericyte coverage is the mark of a 
quiescent mature vessel. Pericyte-secreted Ang-1 is a mediator of survival signaling in the 
ECs and along with TGF-β1 contributes to the final maturation of the vasculature [157]. As 
postulated by Hanahan and Hammes, the complex interplay between Ang-1/2 and VEGF 
determines the fate of the vasculature [28, 147]. In hypoxic tissues with high VEGF and high 
Ang-2/Ang-1 ratio, vascular remodeling and angiogenesis is promoted. In the absence of 
hypoxia, Ang-2 upregulation leads to vascular regression. The synergistic remodeling effect 
of Ang-2 and VEGF is commonly seen in later stages of DR where hypoxic demand builds in 
a retina with non-perfused vessels (Fig. 11) [28, 147]. 
 
Fig.  11: The mechanism of vascular destabilization in DR. In a mature vessel, pericyte-derived 
Ang-1 binds to endothelial Tie-2 to phosphorylate it and promote quiescence. In the absence of 
hypoxia and in low VEGF conditions, Ang-2 upregulation drives vasoregression. In ensuing hypoxia, 
19 
 
VEGF and Ang-2 destabilize the endothelium to promote vascular remodeling and angiogenesis. 
Adapted from Hammes, Diabetes 2011 [28]. 
 
The very first morphological change in DR is pericyte dropout. This is preceded by an 
elevation of retinal Ang-2 [91]. Intravitreally-injected recombinant Ang-2 in non-diabetic rats 
promoted pericyte dropout similar to DR. Animal models overexpressing human Ang-2 in the 
mouse retina, showed significant pericyte loss and formation of non-perfused capillaries, the 
hallmark of retinal vasoregression. Moreover, heterozygous expression of Ang-2 was 
sufficient to prevent DR-mediated pericyte dropout, implying that Ang-2 is undoubtedly 
mediating the development of DR [91, 92]. In endothelial cells, hyperglycemia-induced 
formation of methylglyoxal modifies transcriptional co-repressor mSin3A which then recruits 
OGT to mSin3A-Sp3 complex. The O-GlcNAcylation of transcriptional factor Sp3 eases its 
binding to the repressor complex of the Ang-2 promoter, thereby increasing Ang-2 
expression [54]. In DR, an elevated Ang-2/Ang-1 ratio inhibits Akt-mediated FoxO1 
inactivation. Increasingly activated FoxO1 allows transcription of Ang-2 which in turn 
destabilizes the vasculature leading to DR. Furthermore, several reports claim that, Ang-2 
may destabilize the vasculature in low-Tie-2 conditions by binding integrins and promoting 
pericyte apoptosis [158-162].  
 
1.6 Nucleoside diphosphate kinase B (NDPK-B) 
1.6.1 The NDPK family and its members 
NDPK-B belongs to the family of NDPKs that were discovered around the 1950s in yeast 
and pigeon breast muscle [163, 164]. NDPKs are housekeeping enzymes that are primarily 
involved in the catalytic transfer of γ-phosphate between a nucleoside 5’-triphosphate (NTP) 
and a nucleoside 5’-diphosphate (NDP) via a ping-pong mechanism which involves the 
formation of a high energy phosphate intermediate, e.g. on Histidine118 of NDPK-B [165, 
166].  
 
The NDPK/Nme/NM isoforms are ubiquitously present throughout the cells, the various 
isoforms localized in one or more cellular compartments. The localization of the isoforms 
dictates their functionality [167-169]. The NDPK family consists of 10 isoforms, highly 
conserved across the taxonomies, of which vertebrates possess 8-10 isoforms. In 
mammalian tissues, the isoforms form heterohexamers of size 17-21kDa [170, 171]. The 
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NDPKs are divided into two groups. Group I consists of NDPK A→D. These isoforms retain 
enzymatic activity unlike the rest and share 58-88% sequence homology. Group II proteins 
share only 25-45% homology. The only exception is Nm23-H6 from group II which retains its 
NDPK activity [168, 170, 172]. Besides their canonical function, an increasing number of 
publications show additional functions and highlight the moonlighting character of several 
isoforms [173-178]. Amongst Group I NDPKs, A and B are well-investigated. At first the 
cDNA of NDPK-A was found to be heavily downregulated in a metastatic murine melanoma 
cell line. Deeper investigation produced mouse models that developed heightened 
metastatic potential when crossed with an NDPK-A deficient transgenic line [179, 180].  
 
1.6.2 NDPK-B and signal transduction 
i. GPCR independent G-protein activation:  
G-protein coupled receptors (GPCRs) are transmembrane proteins that are coupled to G-
proteins, which act as molecular switches in mediated internal signaling. The heterotrimeric 
G-proteins consist of three subunits namely α, β, γ, of which βγ form a stable dimeric 
complex [181, 182]. The GDP bound G-proteins are maintained in an inactive state. During 
GPCR dependent activation of G-proteins, agonist binding dissociates the GDP on Gα and 
the naturally occurring excess GTP binds to the Gα nucleotide pocket, causing a 
conformational change that dissociates Gα from Gβγ. Both subunits bind downstream 




Fig.  12: GPCR-agonist independent activation of G-proteins by NDPK-B. Adapted from Wieland, 
2007 [184]. 
 
NDPK-B and not NDPK-A was found to bind Gβγ and activate G-proteins independent of 
GPCRs. The spontaneous conversion of GDP to GTP in the presence of an NTP 
phosphorylates the His residue on Gβγ, which then converts the dissociating GDP from Gα 
to GTP. Therefore, the binding of this GTP causes activation of G-proteins in a manner that 
does not require an extracellular agonist for the GPCRs (Fig. 12) [185-187]. NDPK-B also 
mediates membrane targeting of G-proteins, a function that is independent of its histidine 
kinase activity [188]. MEFs isolated from NDPK-A/B knockout embryos possess depleted 
G-proteins at the membrane [188, 189]. Recent reports show that another isoform, NDPK-
C, interacts with NDPK-B at the membrane where it facilitates NDPK-B-G-protein complex 
formation. The NDPK-B/C complex synergistically mediates G-protein activation [186, 190]. 
One of the downstream functions of G-protein activation is the production of cAMP, which 
has made NDPK-mediated GPCR-independent G-protein activation of interest in 
cardiovascular research. Knockdown of NDPK-B has been published to diminish cAMP 
levels and induce cardiac contractile dysfunction and overexpression of NDPK-C increases 
cAMP production and elevates cardiomyocyte contractility, thereby reinforcing the concept 
of NDPK-B/C heterohexamers in G-protein signaling [191]. 
 
ii. Histidine phosphorylation:  
Most signaling pathways involve regulation of proteins via phospho/de-phosphorylation 
mediated by kinases and phosphatases on Ser/Thr residues of proteins. A relatively 
unknown method of protein activation/deactivation is by histidine kinases and 
phosphohistidine phosphatases (PHP). The role of NDPKs as histidine kinases emerged 
with their ability to phosphorylate enzyme ATP citrate lyase (ACL) [192]. Phosphorylation 
targets of NDPK-B includes the conductance potassium channel KCa3.1 and the Ca2+-
conducting TRP channel, TRPV5 and annexin I [193-195]. The activation of KCa3.1 is 
required for T cell activation and TRPV5 is required for efficient Ca2+ reabsorption in nephron 
tubules [196]. Mice lacking NDPK-B phenocopy KCa3.1-/- have defective T cell activation, 
thereby, making them susceptible to autoimmune diseases. 
1.6.3 NDPK-B and caveolae 
Caveolae are lipid-raft-like membrane invaginations that house components of signaling 
complexes. They conduct a myriad of functions including cholesterol homeostasis and 
operating as signaling platforms. The caveolin (Cav) proteins form building components of 
the caveolae and the isoforms Cav-1 and Cav-3 have been identified to interact with NDPK-
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B. Several loss-of-function animal and cellular models for Cav and NDPK-B show 
overlapping phenotypes and co-dependency for expression. Several Cav-1 deficient models 
also show impaired angiogenic potential, a phenotype observed in NDPK-B deficient mice. 
This implicates NDPK-B in playing a role in angiogenesis as well as the maintenance of 
caveolae formation. Caveolae are also known to house angiogenic master regulators such 
as VEGFR-2 [197-201]. 
 
1.6.4 NDPK-B and diabetes 
Kowluru et al., conducted analyses of GTP in rat retina and established the functional 
deterioration of G-proteins during streptozotocin-induced diabetes (T1DM) [202]. Based on 
prior reports of NDPKs enabling GTP-mediated agonist-independent activation of G-
proteins, NDPK activity was analyzed in diabetic rat retina and found to be unchanged [203]. 
Similar investigations in pancreatic islet β-cells implicated NDPK enzymatic activity to be 
necessary for glucose-stimulated insulin secretion [204]. Additionally, a rat model for T2DM 
showed reduced NDPK expression and activity in in pancreatic islet β-cells [205]. In vitro 
exposure of β-cells to glucotoxicity as well as glucolipotoxicity caused marked reduction in 
NDPK-A and B expression and activity, implicating the NDPKs in impaired insulin secretion 
under glucolipotoxicity via dysregulated G-protein activation [206].  
 
 
1.7 Role of NDPK-B in angiogenesis and DR 
1.7.1 NDPK-B KO model 
Loss-of-function mouse models have been a popular and indispensable tool for identifying 
protein function. Global knockout models have been developed for the NDPK genes, 
specifically, NDPK-A [207], NDPK-B [196] and NDPK-A/B [208, 209]. NDPK-A-/- and NDPK-
B-/- mice are physiologically normal and retain normal life span and fertility. NDPK-A/B-/- 
develop smaller than WT mice in the embryonic stage and die perinatally due to defective 
erythroid cell maturation and severe anemia [209, 210]. NDPK-B-/- mice have a normal 
phenotype but possess defective K+ KCa3.1 channel activity and thereby defective cytokine 
production in Th1 and Th2 CD4 T cells [196, 211]. Aside from the global KO model, NDPK-B 
has been manipulated in the zebrafish via a morpholino-induced knockdown (MO). MO-
mediated KD of NDPK-B, and not NDPK-A, severely decreased cardiac contractility, lowered 
cAMP production, depleted Gβγ subunits and Cav-1 and 3 [189, 191]. NDPK-B depleted 
zebrafish embryos also possessed malformed blood vessels which were rescued upon 
NDPK-B re-expression establishing its role in angiogenesis [198]. 
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1.7.2 Role of NDPK-B in angiogenesis and PDR 
NDPK-B has been investigated for its role in angiogenesis through a multi-model approach. 
The hindlimb ischemia model in the KO mice demonstrated delayed blood flow recovery and 
lower capillary density in the gastrocnemius muscles as compared to WT littermates [198]. 
Proliferative DR late stages comprise of primarily uncontrolled angiogenesis and elevated 
VEGF-VEGFR-2 signaling. To investigate the role of NDPK-B in PDR, oxygen-induced 
retinopathy (OIR) model was implemented, where mice were introduced postnatally to 
hyperoxia and later returned to room air, inducing relative hypoxia. This mounted an 
angiogenic response in the retina and led to neovascularization. NDPK-B KO retinae 
showed far fewer neovascularization and decreased VEGFR-2 expression than the WT 
retinae. siRNA-mediated gene knockdown of NDPK-B in ECs showed impaired VEGF-
mediated VEGFR-2 recruitment to the membrane, elevated permeability due to altered VE-
cadherin spatial arrangement and stunted EC sprouting in response to VEGF. Cav-1 was 
found to interact with adherens junction proteins such as β-catenin. β-catenin 
phosphorylation by c-Src was found to be essential for barrier breakdown in ECs. 
Collectively, NDPK-B enabled angiogenic responses via the correct localization of caveolae 





Fig.  13: The mechanism for elevation of permeability in NDPK-B deficient ECs via p-c-Src-
mediated phosphorylation of Cav-1 causing re-arrangement of AJ proteins. Adapted from 
Gross, J Cereb Blood Flow Metab. 2017  [212]. 
 
1.7.3 NDPK-B KO model and DR 
As NDPK-B plays a role in the regulation of angiogenesis, its possible involvement in the 
regulation of microvascular complications should be considered. Additionally, the primary 
function of NDPK-B is the catalysis of NTP from NDP. UTP is utilized for the generation of 
UDP-GlcNAc as described in Section 1.4. UDP-GlcNAc is a substrate for protein O-
GlcNAcylation and mediates increased expression of Ang-2 [54]. Ang-2-mediated 
development of DR, a microvascular complication has been described in Section 1.2. The 
hypothesis that NDPK-B plays a role in DR development was investigated.  
Diabetes was induced via streptozotocin injection. NDPK-B KO animals were found to be 
normoglycemic, possess normal HbA1c levels and body weight in contrast to the diabetic 
animals [213]. Retinal analysis of NDPK-B KO mice showed poor PC coverage and large 
number of AC similar to WT diabetic retinae. The concomitant increase in retinal Ang-2 and 
protein O-GlcNAcylation similar to WT diabetic retina imply that NDPK-B normoglycemic 
retinae mimicked WT diabetic retinae. The symptoms of vasoregression were exacerbated in 
KO diabetic retinae indicating a cumulative effect of NDPK-B KO and diabetes, although no 
such accumulative increase was seen in KO diabetic Ang-2 and O-GlcNAc as compared to 
KO non-diabetic groups at the protein level.  
DR develops due to the elevated levels of Ang-2 that initiate vasoregressive effects [91, 92]. 
Both, endothelial cells and Muller cells were identified as one of the major sources of Ang-2 
in the retina [54, 214]. The analysis of retinal cross-sections showed glial activation in 
normoglycemic KO and diabetic WT and KO mice. Ang-2 co-localized with the Muller glia 
and is elevated in normoglycemic KO and diabetic WT and KO mice [215]. Normoglycemic 
NDPK-B deficient ECs mirrored the retina in exhibiting elevated Ang-2 and protein O-
GlcNAcylation similar to HG treated ECs. [213]. These findings signify the parallels between 
NDPK-B deficient and diabetic systems and implicate NDPK-B in the development of DR-like 
vasoregression. 
 
1.7.4 Intracellular mechanisms for vasoregression i n NDPK-B deficiency 
FoxO1 is a transcription factor regulating Ang-2 expression [162]. NDPK-B deficient Muller 
cells and ECs exhibited elevated FoxO1 protein expression in comparison to controls [215, 
216]. Shan et al. and Qiu et al. demonstrated that, FoxO1 is required for basal expression of 
Ang-2 as well as NDPK-B deficiency-induced upregulation of Ang-2 in Muller cells and ECs. 
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Immunofluorescence images showed elevated FoxO1 and O-GlcNAc levels in NDPK-B 
deficient ECs that partially overlap, implying the possible modification of FoxO1 by O-
GlcNAc. While NDPK-B depletion did not induce any changes in FoxO1 phosphorylation, it 
increased FoxO1 O-GlcNAcylation, which was essential for Ang-2 elevation in comparison to 
controls. These findings highlight not only a novel mechanism for Ang-2 regulation in NDPK-
B deficient ECs via FoxO1, but also shed light on the consequences of elevated protein O-
GlcNAcylation on existing pathways (Fig. 14 ). 
 
Fig.  14: Protein O-GlcNAcylation of FoxO1 mediates NDPK-B deficiency induced 







2. Aims of the study 
Retinal vasoregression is a common consequence of endothelial damage caused by 
hyperglycemia or NDPK-B deficiency. Recent findings indicated, that both hyperglycemia 
and NDPK-B deficiency promote protein O-GlcNAcylation and elevation of Ang-2 [213]. Prior 
research provided evidence that hyperglycemia-induced O-GlcNAcylation of transcription 
factors elevates Ang-2, being the causative factor in retinal vascular regression [54, 91]. The 
underlying mechanism of protein O-GlcNAcylation and Ang-2 regulation in the NDPK-B 
deficient models are still unclear. In the current study, we focus on the regulation of Ang-2 
by its receptor Tie-2 and O-GlcNAcylation in NDPK-B deficiency-driven retinal 
vasoregression. 
Aim 1: The importance of Ang-2-Tie-2 signaling in H G and NDPK-B deficiency-
mediated vasoregression : In this part of study, we explore, the importance of Ang-2 in 
vascular regression in NDPK-B-/- retinae, and the role of Tie-2 in the upregulation of Ang-2-
mediated vascular regression in NDPK-B deficiency and high glucose conditions.   
Aim 2:  The importance of protein O-GlcNAcylation in NDPK-B  deficiency : In this part of 
the study, we explore glucose metabolism in NDPK-B deficiency by examining the HBP and 





3.1 Cell culture 
3.1.1 Cell culture medium and supplements 
Table 2: Cell culture medium and supplements 
Components (500ml) Catalog number 
Endothelial cell basal medium (ECBM) C-22110; PromoCell 
Endothelial supplements C-39210; PromoCell 
Endothelial cell growth media (ECGM) ECBM + Supplements 
Microvascular ECGM (ECGM MV) ECBM + Hydrocortisone: 1 µg/ml, ECGS: 40 
µg/ml, PenStrep: 1%, EGF: 5ng/ml 
FCS F7524; Sigma 
DMEM (1000 mg/ml glucose) D-6546; Sigma-Aldrich 
 
3.1.2 Cell isolations and cell lines 
Table 3: Cell isolations and cell lines 
Cell type Catalog number 
HUVECs  Self-isolated from umbilical cords (Section 4.2.1.1) 
HMECs  INS-CI-1008; inSCREENex 
HRMVECs PB-CH-160-8511; Pelobiotech 




3.1.3 siRNA  
Table 4: siRNA 
siRNA Sequence 
Control siRNA (Eurofins) 5´- AGG UAG UGU AAU CGC CUU G -3` 
NDPK-B siRNA (Eurofins) 5´- AAC UGG UUG ACU ACA AGU CUU -3` 
Tie-2 siRNA (Qiagen) SI00604912 
OGT siRNA (Qiagen) SI02631412 
OGA siRNA (Qiagen) SI04187043 
Allstars negative control (Qiagen) SI03650318  
 
3.1.4 Cell culture reagents and enzymes 
Table 5: Cell culture reagents and enzymes 
Reagents Company Catalog number and details 
Lipofectamine RNAiMAX Invitrogen 13778-075 
OptiPROTM SFM  Invitrogen 12309-019 
EDTA Trypsin 0.05% Sigma-Aldrich T3924 
Dispase II Roche 04942078001  
Puromycin Sigma P7255 
Collagenase/Dispase Sigma 10269638001  
DNaseI Sigma-Aldrich 11284932001  
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Rat-tail Collagen Self-made 1mg/ml (Section 4.2.1.4) 
Collagenase II (CLS2) Worthington 4177 
Penicillin/Streptomycin Sigma P4333 
3.2 Buffers and chemicals 
3.2.1 Cell culture buffers 
Table 6: Cell culture buffers 
Buffer Catalog number 
PBS D-5652; Sigma-Aldrich 
 
3.2.2 Protein analysis buffers 
Table 7: Protein analysis buffers 
Buffer Contents 
Ponceau. S (100 ml) 5 ml acetic acid; 95 ml H2O; 0.2 g Ponceau 
Protein Loading buffer (4x) (50 ml) 25 ml 50% Glycerol; 5 ml 10% 2-
Mercaptoethanol; 5 ml 10% 2-
Mercaptoethanol; 0.25% Bromophenol Blue; 
5 ml H2O 
RIPA buffer 150 mM NaCl; 1.0% Triton X-100; 0.5% 
sodium deoxycholate; 0.1%SDS; 50 mM 
Tris, pH 8.0 
Cell lysis buffer RIPA buffer; Protease inhibitor (Roche) (1 
tablet/10 ml) 
NDPK assay buffer 50 mM Tris-HCl pH 7.5; 2 mM MgCl2; 1 mM 
DTT; 0.01% BSA 
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SDS-PAGE Electrophoresis buffer (5X SDS) 0.125 M Tris; 1.25 M Glycine; 0.5%SDS; 
500 ml H2O 
TAE buffer (50X) 2 M Tris; 5.7% Acetic acid; 0.05 M EDTA pH 
8.0 in 1 L H2O 
TBS (10x) 
TBST (1000 ml) 
100 mM Tris; pH: 7.4; 1.5 M NaCl 
100 ml 10x TBS; 890 ml H2O, 10 ml; 1 ml 
Tween 20 
Tris Buffer for stacking gel 1 M Tris, pH: 6.8 
Tris Buffer for separating gel 1.5 M Tris, pH: 8.8 
Western Blot transfer buffer (WB) (10x)  32.5 g Tris; 144 g Glycine; 1000 ml H2O 
 
3.2.3 Immunoprecipitation buffers 
Table 8: Immunoprecipitation buffers 
Buffer Contents 
Tie-2 IP buffer 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% 
Triton X-100, PhosSTOP and Protease 
inhibitor (Roche) (1 tablet/10 ml, each) 
sWGA IP buffer  50 mM Tris-HCl pH7.4, 100 mM NaCl; 1% 
Triton X-100, Protease inhibitor 
sWGA wash buffer 50 mM Tris-HCl pH7.4, 100 mM NaCl; 0.1% 
Triton X-100, Protease inhibitor 
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3.2.4 Immunofluorescence buffers 
Table 9: Immunofluorescence buffers 
Buffer Contents 
Fixation buffer 4% PFA in PBS (for retina fixation) 
4% Roti®-Histofix (for ECs fixation) 
Permeabilization/Blocking buffer 1x PBS; 2% BSA; 0.5% TritonTM X-100 
(Retina) 
1x PBS; 2.5% BSA; 0.3% TritonTM X-100 
(ECs) 
Antibody Dilution Buffer 1x PBS; 1% BSA; 0.5% TritonTM X-100 
Wash buffer 1x PBS 
DAPI  0.1-10 µg/ml 
 
3.3 Chemicals 
Table 10: Chemicals 
Chemicals Company Catalog number 
2-Mercaptoethanol Serva 28625 
Absolute ethanol Riedel-de Äen 32205 
APS Merck 1.012.010.100 
Bromophenol Blue Chroma-Gesellschaft 4F057 
BSA Sigma-Aldrich A9418-5G 
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BSA Sigma-Aldrich B-4287 
Chloroform Merck 2447 
DMSO Sigma-Aldrich D8418 
DAPI Life Technologies 1603428 
D-(+)-Glucose Sigma-Aldrich SLBF1738V 
Ethanol Richter Chemie V-126 
EDTA Roth 8040.1 
Entellan Merck 107961 
Gelatin from porcine skin  BD 214340 
Glycerol Sigma-Aldrich G9012 
HCl Sigma-Aldrich H1758 
Roti histofix Roth P087.4 
KCl Sigma-Aldrich P9333 
Luciferase (ATP-dependent) Promega-Kinase-GLo V6711 
Methanol Roth 4627.5 
NaCl Sigma-Aldrich M7439 
NaHCO3 Sigma-Aldrich S5761 
NaOH Merck 106498 
PFA Merck 1.040.031.000 
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PhosSTOP™ Sigma-Aldrich 4906845001 
Ponceau S Sigma-Aldrich P-3564 
Protease inhibitor Roche 5892970001 
Protein marker ROTH T8512 
Protein A/G beads Santa Cruz sc-2003 
Roti-Block Roth A151.1 
Roti-Mount FluorCare Roth HP19.1 
Rotiphorese Gel 30 Roth 3029.1 
SDS Sigma-Aldrich 74255 
SuperScript IV VILO Master Mix Thermofischer 11755050 
sTie-2 Fc chimera human Promokine B-68028 
Succinylated Wheat Germ 
Agglutinin coated agarose beads 
(sWGA) 
Vector Laboratories AL-1023S 
TEMED Roth T7024 
Thiamet G (TMG) Sigma SML0244 
Tris Serva 37181 
Triton-X-100 Merck 1.080.031.000 
Tween 20 Sigma-Aldrich P-7949 





3.4.1 Primary antibodies for western blot (WB) and immunofluorescence (IF) 
Table 11: Primary antibodies 
Antibody Catalog number; 
Company 
Dilution 
Ang-2 (WB) sc-7017; Santa Cruz 1:500 
 sc-74403; Santa Cruz 1:500 
FoxO1 (WB)                   2880; Cell Signaling 1:1000 
Gβ (WB) Sc-378; Santa Cruz 1:1000 
GFAT (WB) Prof. Weigert, Tübingen 1:3000 
Histone H3 (WB) sc-8654; Santa Cruz 1:1000 
Isolectin-TRITC L5264; Sigma 1:50 
NDPK-B (WB) MC-412; Kamiya 1:1000   
N1-phospho-histidine MABS1330; Millipore 1:1000 
NG-2 (IF) AB5320; Millipore 1:200 
O-GlcNAc (WB)                                               ab2739; Abcam 1:2000 
OGT (WB) O6264; Sigma 1:1000 
OGA (WB) SAB4200267; Sigma 1:1000 
PECAM-1 (IF) sc-1506-R; Santa Cruz 1:200 
Phospho-GFAT1 (WB) s343c; MRC-PPU 1:150 
Phospho-Tyrosine 4G10 05-321; Millipore 1:1000 
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Tie-2 (IP) AF313; R&D systems 2µg/IP 
Tie-2 (IF ECs) sc-324; Santa Cruz 1:100 
Tie-2 (IF retina) AF762; R&D systems 1:100 
Tie-2 (WB) sc-324; Santa Cruz 1:1000 
γ-Tubulin (WB)                                             T5168; Sigma-Aldrich 1:5000 
 
3.4.2 Secondary antibodies 
Table 12: Secondary antibodies 
Antibody Catalog number; 
Company 
Dilution 
Rabbit anti-mouse peroxidase                      A-9044; Sigma-Aldrich 1:20000 
Rabbit anti-goat peroxidase                          A8919; Sigma-Aldrich 1:10000 
Goat anti-rabbit peroxidase                           A-9169; Sigma-Aldrich 1:40000 
Goat anti rabbit Alexa Fluor 488                   A-11008; Life technologies 1:200 
Goat anti mouse Alexa Fluor 488                 A-11001; Life technologies 1:200 
Swine anti-rabbit-FITC F0205; Dako 1:20 
Donkey anti-goat-FITC conjugate R1254F; Acris 1:1000 
 
3.5 qPCR primers and master mix  
Table 13: qPCR primers, genotyping primers (PCR), and master mix 
Primers Catalog number; Company 
18S (qPCR) Hs03003631_g1; applied biosystems   
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GFAT (GFPT1) (qPCR) Hs00899865_m1; applied biosystems   
OGA (MGEA5) (qPCR) Hs00201970_m1; applied biosystems   
OGT (qPCR) Hs00269228_m1; applied biosystems   
Tie-2 (Tek) (qPCR) Hs00945155_m1; applied biosystems 
Taqman Fast Advanced Master Mix 4444556; Thermofischer   
Ang-2 Lac Z (reverse) (PCR) GAG ATC AGC AGC CTC TGT TCC 
Ang-2 Lac Z (forward WT) (PCR) CTG GGA TCT TGT CTT GGC C 
Ang-2 (forward mutant) (PCR) CTT CTC TCT GTG ACT GCT TTG 
NDPK-B (reverse) (PCR) TCC CTA TAT ACC TGC TCT GCC TCA 
NDPK-B (forward WT) (PCR) CCT ATG TGG GAA ACA ATG GGT TTC 
NDPK-B (forward KO) (PCR) TTA GCA GCT CTG GAG CTT GCA GCC 
Mastermixes for PCR M7501; Promega 
PEQL01-1399; PeQLab 
HotShot lysis buffer 10 ml dH2O; 14 µl 50% NaOH; 14 µl 0.5M 
EDTA, pH 8.0 
HotShot neutralization buffer 40 mM Tris-HCl 
  
3.6 Consumables  
Table 14: Consumables 
Consumables Company Catalog number 
3-way stopcock  BD Connecta TM 394600 
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Cell counting chamber Marienfeld 0640010 
Cell culture plate (24 well, 12 well, 6 
well) 
Sarstedt 83.3922, 83.3921, 
83.3920  
Cell culture dish (6 cm, 10 cm, 15 cm) Sarstedt 83.3901, 83.3902, 
83.3903 
Cell culture flask (T25, T75) Sarstedt 83.3910.002, 
83.3911.002 
Cell scraper Sarstedt 83.1830 
Cover slips Carl Roth GmbH 41021070 
Gel combs Bio-rad 1653359 
Cryotube Sarstedt 72.377 
Eppendorf tubes (1.5 ml, 2 ml) Eppendorf 0030 120.086 
Eppendorf tips (1000 µl, 200 µl, 10 µl) Eppendorf 70.760.002, 70.1130, 
70.762 
Falcon tubes (15 ml, 50 ml) Sarstedt 62.554.502, 
62.547.254 
Microscope slides R. Langenbrinck 03-0002; 2642672 
Nitrocellulose membrane Häberle 6267735 
Pipettes Sarstedt 86.1253.001, 
86.1254.001, 
86.1685.001 
Parafilm Parafilm’M’ PM-996 
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Whatman paper VWR 514-8013 
Filtropur S 0.2 Sarstedt 31046103  
Syringe Seidel Medipool 301229 
Syringe needle 30G BD Microlance 30400 
 
3.7 Kits 
Table 15: Kits 
Kits Catalog number; Company 
Lumi-Light Western Blotting 12015200001; Roche 
Super Signal West Femto Maximum 
Sensitivity Substrate 
34095; Thermo Scientific 
Bio-Rad turbo blotting supplements 10026938; Bio-Rad 
Subcellular Fractionation Kit 78840; Thermo scientific 
Seahorse Glycolysis Stress Test Kit 103020-100; Agilent 
Seahorse Mito Stress Test Kit 103015-100; Agilent 
Ang-2 ELISA DY623, R&D Systems 
OGA Activity Kit E-130; BMR services 
 
3.8 Apparatus 




Laminar flow bench Herasafe, Heraeus 
Water bath ThermoScientific 
Incubator (37 °C, 5% CO 2) Memmert 
Centrifuge Eppendorf Hettich Toxixa/K 
Shaker Neolab 
Vortex Janke & Kunkel 
Dounce homogenizer B.Braun Biotech International 
Weighing machine  Sartorius 
Pipettor  Eppendorf 
Multi-pipettor Eppendorf 
Microprocessor pH meter WTW 
Heating block Thermomix comfort, Eppendorf 
Electrophoresis chamber and apparatus Bio-Rad 
Bio-Rad turbo blotter 1704150 
Mini-PROTEAN casting module Bio-Rad 
Voltmeter Biometra 
Gel imager Alpha Imager 2200 
Spectrophotometer Thermolabsystems Multiscan EX 




Fluorescence microscope Olympus 
Confocal microscope model TCS SP2 Leica 
Fluorescence microscope DMRE Leica 
Millipore water machine Milli-QR 
High temperature sterilizer Systec 
-20 °C freezer Bosch/ Liebherr 
-60 °C freezer Revco 
-80 °C freezer Hera 
ELISA plate reader AlphaImager® Innotech 
Envision 2102 multilabel reader Perkin-Elmer 




Table 17: Software 
Software Company 
Image J NCBI 
Fluorescence microscope software Leica 
Confocal microscope software Leica microsystems version 2.16 
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Statistics Graph Pad Prism 6 software 
References Endnote V4 
 
4. Methods 
4.1 In vivo methods 
4.1.1 Maintenance of the animals 
The use of mice in the study was approved by the local ethics committee (Medical Faculty 
Mannheim, Heidelberg University, Germany). The care and experimental use of animals 
were in accordance with institutional guidelines and in compliance with the Association for 
Research in Vision and Ophthalmology (ARVO) statement. All animal experiments in this 
study were approved by the local ethics committee (Regierungspräsidium Karlsruhe, 
Germany). The mice were housed in a separate building and artificial lighting was 
maintained on a 12 h:12 h light-dark cycle. Room temperature was kept constant at 21 °C. 
The mice received tap water for drinking and were fed normal chow diet (ssniff R/M-H) 
containing 9% fat, 33% protein, and 58% carbohydrate. NDPK-B-/- mice were generated as 
previously described [196]. Ang-2 +/- were generated as previously described [91]. The 
NDPK-B-/-/Ang-2+/-, NDPK-B-/-/Ang-2+/+, NDPK-B+/+/Ang-2+/- and NDPK-B+/+/Ang-2+/+ mice 
were generated by breeding the NDPK-B+/-/Ang-2+/- and NDPK-B+/-/Ang-2+/+ mice. The mice 
were numbered marked with 2 mm diameter ear clips. The ear clip tissue taken from the 
mice was used for determination of the genotype by PCR, described in Section 4.1.2. 
 
4.1.2 Polymerase Chain Reaction (PCR) to determine the genotype of animals 
• DNA sample preparation 
Ear clips or tail tips from mice were lysed in 75 µl HotShot lysis buffer containing NaOH and 
incubated at 95 °C for 1 h. Afterwards, 75 µl HotSh ot neutralizing buffer containing HCl was 
added to neutralize the lysate. The lysates were used for the following PCR procedure. 
Unused lysates were stored at -20 °C for later use.  
• PCR 
PCR procedures to amplify Wildtype (WT) and Knockout (KO) sequences were done 
separately. Promega 2× PCR master mix was used for NDPK-B WT PCR, Ang-2 WT PCR, 
and KO PCR; and PeQLab 2× PCR master mix was used for NDPK-B KO PCR. The 2× 
master mixes contain DNA polymerase, dNTPs, magnesium, and buffer. Table 19  gives an 
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overview of the reactions, and the PCR program for the specific genes are illustrated below 
in Table 18 .  
 
Table 18: NDPK-B WT and KO genotyping PCR 
NDPK-B PCR cycle  
94 °C 3 min 
35 cycles:   94 °C 30 s 
       62 °C 30 s 
       72 °C 60 s 
72 °C 10 min 
WT: ~500bp 
KO: 650~700bp 
Ang -2 PCR cycle  
94 °C 4 min 
40 cycles: 94 °C 1 min 
       59 °C 30 s 
       72 °C 30 s 
72 °C 8 min 
WT: 380bp   
Mutant: 240bp 
 
The master mixes, primers, and water were mixed in a tube and added to the PCR tubes 
followed by the addition of DNA to the respective tubes. The components were mixed by 
pipetting or flicking the tubes and transferred to a thermal cycler, which runs the PCR 
program.  
 
Table 19: NDPK-B WT and KO genotyping PCR 
 WT PCR (µl) KO PCR (µl)  
Nuclease free water 7.5 7.5 
2× MM 10 10 
WT primer (20 µM) 0.25 - 
KO primer (20 µM) - 0.25 
Reverse primer (20 µM) 0.25 0.25 
DNA lysate 2 2 




4.1.3 Agarose gel electrophoresis 
The PCR amplicons were separated by gel electrophoresis on a 1% agarose gel containing 
ethidium bromide. Agarose was weighed then mixed with TAE buffer in a glass flask and 
dissolved by heating up the flask in a microwave until the buffer started to boil and a clear 
solution formed. Once the flask was warm to touch, 0.5 µg/ml of ethidium bromide was 
added. The mixture was swirled then poured into a gel-forming cassette with combs and 
allowed to polymerize for 20 to 30 min. Once solidified, the combs were carefully removed 
without disturbing the DNA loading wells. The gel was completely immersed in TAE buffer in 
the electrophoresis chamber. The DNA samples mixed with loading buffer were loaded in 
the wells and run for 1 h at 120 V. The DNA bands were visualized using a UV light imager. 
Amplicons for only WT PCR or KO PCR were determined to be WT or KO mice respectively. 
Amplicons for both WT PCR and KO PCR were determined to be heterozygous (HE) mice. 
Fig. 15  shows the results of an NDPK-B WT PCR and KO PCR.  
 
 
Fig.  15: Examples of an NDPK-B WT PCR and an NDPK-B KO PCR. The left panel demonstrates 
results of a WT PCR and the right panel a KO PCR. WT and KO samples show positive bands for WT 
PCR (500bp) and KO PCR (650-700bp), respectively and HE samples show positive results for both 
WT PCR and KO PCR.  
 
4.1.4 Retinal digestion and quantitative retinal mo rphometry 
Frozen eyes were fixed in 4% Formalin for 48 h. The eyes were then placed under a loupe 
microscope and dissected. The retina was exposed by removing the lens and vitreous then 
the retina was carefully extracted. The isolated retina was incubated at 37 °C in water for 30 
min, and subsequently incubated at 37 °C for 2.5 h in 3% trypsin dissolved in 0.2M Tris-HCl 
buffer (pH 7.0). The retina was then transferred onto a glass object slide and carefully 





be visualized under the microscope. After the vasculature was dried on the object slide, it 
was stained with Period-Acid-Schiff (PAS). The PAS staining was performed as follows: 
dH2O   5 min 
1% Periodic acid 10 min 
dH2O   Brief immersion 
Schiff’s reagent 10 min 
Running tap water 5 min 
ddH2O   Brief immersion 
Mayer’s Hemalum 30 s 
Running tap water 7 min 
ddH2O   Brief immersion 
70% ethanol  Brief immersion 
80% ethanol  Brief immersion 
96% ethanol  5 min 
100% ethanol  5 min 
Roti®-histol ×3 5 min each 
Embed with Entellan® 
The slides stained with PAS were observed under the microscope and photos of 40× 
magnification were taken. The numbers of pericytes and acellular capillaries were quantified. 
For the quantification of pericytes, 10 microscopic fields with 40× magnification were 
randomly selected in the middle one-third of the retina, and the pericytes as well as ECs 
were counted. The cell numbers were recorded and normalized to the relative capillary 
density (quantity of cells per mm2 of capillary area). The capillary area was measured by 
using image analyzing software (AnalysisPro; Olympus Optical, Hamburg, Germany). The 
acellular capillaries were quantified using an integration ocular with a grid of 100 squares. 
The quantity of squares containing acellular capillary segments were counted in 10 randomly 
selected microscopic fields of 40× magnification in the middle one-third of the retina. 
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4.2 In vitro methods 
4.2.1 Cell culture  
The use of Human Umbilical Vein Endothelial Cells (HUVECs) was approved by the local 
medical ethics committee (Medical Faculty Mannheim, Heidelberg University, Germany; 
Approval number: 2012-388N-MA). 
4.2.1.1 Isolation of HUVECs 
HUVECs were isolated from the umbilical cords of newborn infants with the informed 
consent of their mothers according to a previously described protocol [198]. One end of the 
cord was clamped closed and the other end attached to a 3-way stopcock allowing a bi-
directional flow of fluid through the vein, which is the largest vessel in the umbilical cord. The 
vein was then washed with pre-warmed low glucose DMEM until blood no longer visibly 
drained from it. 10X Dispase II was diluted in DMEM to yield 1X DMEM-Dispase II, which 
was then applied to the vein through the stopcock. The cord was then placed in a humidified 
incubator (37 °C, 5% CO 2) for 30-40 min. The detached cells were collected in a falcon tube 
and mixed with 4 ml of FCS to halt the enzymatic digestion. The vein was massaged gently 
to dislodge undetached cells and once again perfused with DMEM. The collected flow was 
centrifuged (5 min; 1000 rpm) and the cell pellet resuspended in ECGM (Table 2) containing 
10% FCS. To enable the attachment of the cells, they were cultured in ECGM 10% FCS on 
a 1% gelatin-coated cell culture dish in a humidified incubator (37 °C, 5% CO 2) for 2 h 
followed by a gentle media change to remove remaining red blood cells. The attached 
HUVECs were maintained in fresh ECGM 10%FCS. 
4.2.1.2 Culture and passaging of HUVECs, HMECs and HRMVECs 
Freshly isolated HUVECs, known as passage 0 (p0), were cultured with ECGM 
supplemented with 10% FCS in a humidified incubator (37 °C, 5% CO 2). The medium was 
replaced every two days. Cells from one umbilical cord were placed in a flask and regarded 
as one isolation. Once the cells reached confluency, they were detached from the flask via 
trypsin digestion. Once detached, the trypsin digestion was neutralized with 10% FCS 
ECGM. The cells were then passaged to p1 at the ratio 1:3 and cultured to confluency. All 
experiments were performed using cells from p1 to p4.  
Human Retinal Microvascular Endothelial Cells (HRMVECs) and Human Microvascular 
Endothelial Cells (HMECs) were cultured in the microvascular ECGM (ECGM MV) 
supplemented with 10% FCS. Cell passaging, culture, freezing, thawing, and experimental 
procedures with HRMVECs and HMECs were identical to those for HUVECs. 
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4.2.1.3 Freezing and thawing of HUVECs  
HUVECs at p0 or p1 were detached by trypsinization and pelleted by centrifugation. The 
pellet was gently resuspended in chilled ECGM supplemented with 10% FCS and 10% 
DMSO. The cell suspension was then transferred to sterile cryotubes and placed in a pre-
chilled closed isopropanol reservoir. Every isolation was divided equally between 2 
cryotubes. The reservoir was then transferred to -60 °C. On the following day, the cryotubes 
were transferred to a liquid nitrogen tank and stored at -190 °C. 
To thaw the HUVECs, the required isolation was extracted from the liquid nitrogen tank and 
thawed rapidly in a 37 °C water bath. Once partiall y thawed, the cells were resuspended in 
pre-warmed ECGM supplemented with 10% FCS until fully thawed and then centrifuged at 
1000 rpm for 5 min. The pellet was resuspended in ECGM with 10% FCS and placed in a 
1% gelatin-coated dish. The culture media was replaced the next day to remove excess 
DMSO and the cells were cultured to confluency before use in experiments.  
4.2.1.4 Isolation and culture of murine brain micro vascular endothelial cells 
(MBMECs) 
• Preparation of rat-tail collagen 
2-3 rat tails were incubated in 70% Ethanol for 15-20 min. With a pair of sterile forceps and 
scissors, the tails were skinned, the vertebrae were broken and the collagen thread 
extracted. The collagen thread was then placed in ethanol and subsequently dried in a 
closed Petri dish for 2 h. The dried collagen was then transferred to a closed sterile 
container of 500 ml 0.1% acetic acid solution and incubated for 48 h at 4 °C. The suspension 
was then placed into centrifuge tubes, weighed, and centrifuged at 17,000 rpm for 90 min. 
The supernatant containing the collagen suspension was collected, aliquoted and stored at 4 
°C for future use. 
 
• MBMEC isolation 
MBMECs were isolated from 10-15-week-old male mice. The mice were euthanized with a 
brief isoflurane application followed by cervical dislocation. The intact brains were extracted 
and placed in cold DMEM. The forebrain cortex was surgically isolated, rolled on sterile 
autoclaved Whatman filter paper to remove the meninges and placed in cold DMEM. The 
brains were minced first by pipetting through a 25 ml pipette and then subsequently through 
a 10 ml pipette. The minced solution was homogenized with 10 strokes of a Dounce 
homogenizer. The pink homogenate was centrifuged at 400 g for 10 min at 4 °C. 
Subsequently, the supernatant was discarded and the pellet was digested in a 0.75% 
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collagenase II solution rocked at 300-400 rpm for 1 h at 37 °C. The digested tissue was 
centrifuged at 400 g for 5 min and the supernatant was carefully discarded without disturbing 
the pellet. The pellet was then dissolved by tapping in sterile 20% BSA-DMEM solution. The 
solution was centrifuged in a swing bucket rotor at 2000 g for 30 min at 4 °C. The separated 
myelin layer was removed with a Pasteur pipette and the pellet was digested in DMEM 
containing 1 mg/ml Collagenase/Dispase and 1 µg/ml DNaseI at 300-400 rpm for 30 min at 
37 °C. The suspension was centrifuged at 400 g for 5 min and the pellet was resuspended in 
ECGM MV supplemented with 10% FCS. The cells were seeded on a plate coated with rat-
tail collagen and incubated at 37 °C in a humidifie d incubator. On the following day, the 
media was replaced with ECGM with 10% FCS containing 4 µg/ml of puromycin to eliminate 
non-endothelial cell types. Puromycin treatment was continued until day 3 post-isolation. The 
cells were cultured to confluency. The MBMECs were detached using trypsin. Detached 
cells were centrifuged at 1000 rpm for 5 min then resuspended in growth media and 
passaged at a density of no more than 1:2. Cells were characterized by immunofluorescence 
and used only up to p1. 
4.2.2 siRNA transfection 
Cells were seeded according to the cell numbers mentioned in Table 20  in order to allow 
them to attach to the coated dish overnight at 37 °C. 
Table 20: Cell seeding in culture plates / dishes for siRNA transfection 
Dish / plate 
Surface area 
per well / dish (mm 2) 
Cell number  
well / dish 
Medium (ml) 
24 well 200 50,000 0.5 
12 well 401 100,000 1 
6 well 962 250,000 2 
6 cm 2827 550,000 4 
10 cm 7854 1000,000 8 
 
The siRNA of choice was diluted in OptiPROSFM, as was lipofectamine RNAiMAX (the 
respective volume of reagents is shown in Table 21 ). All procedures were carried out in a 
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sterile manner. The siRNA/OptiPROSFM complex was mixed with the 
lipofectamine/OptiPROSFM complex by pipetting up and down carefully. The mixture was 
incubated for 20 min at RT. Meanwhile, the cells were washed twice with PBS, and the 
required volume of warm OptiPROSFM was pipetted into the respective dishes/plates. The 
siRNA/lipofectamine mixture was then added in a drop-wise manner to the culture 
dishes/plates. The plates were incubated for 4 h at 37 °C followed by a media change to 
ECGM 10% FCS. The transfected cells were then used for assays from 24 to 96 hpt.  
 














12 well 100 2 100 100 800 
6 well 250 5 250 250 2000 
10 cm 1000 20 1000 1000 10000 
 
4.2.3 Stimulation of ECs 
On the day following the transfection, HUVECs were starved in ECGM 0.5% FCS for 24 h 
followed by further stimulation with the respective reagents (high glucose (HG) 30 mM 4 h, 
sTie-2 5 µg/ml 24 h, TMG 10µM 24 h). For HMECs and HRMVECs, on the day following the 
transfection, the cells were starved in ECGM MV with 0.5% FCS for 48 h followed by 
harvesting for analysis.  
 
4.2.4 Adenovirus-mediated overexpression of human A ng-2 
HUVECs were transfected with NDPK-B siRNA then starved in ECGM 0.5% FCS for 24 h, 
followed by infection with Ad-Ang-2 [158] in ECGM 0.5% FCS for 24 h. ECs infected with 
Ad-GFP served as the control. Infected cells were monitored for GFP expression.  The cell 
supernatant was collected for confirmation of Ang-2 overexpression using the Ang-2 ELISA 





4.2.5 Adenovirus-mediated overexpression of NDPK-B and H118N kinase-dead mutant 
HUVECs were transfected with NDPK-B siRNA, then starved in ECGM 0.5% FCS for 24 h, 
followed by infection with recombinant adenovirus encoding green fluorescent protein (Ad-
GFP) and overexpression of WT NDPK-B (Ad-NDPK-B-GFP) or overexpression of NDPK-B 
kinase dead mutant (Ad-H118N-GFP) [217] in ECGM 0.5% FCS for 24 h. Cells were 
monitored for GFP expression for successful and identical transfection in groups and then 
harvested in RIPA buffer for the analysis of protein expression via WB or for the assessment 
of OGA activity. 
 
4.2.6 Mass spectrometric analysis 
4.2.6.1 Preparation of HUVECs and retinae for mass spectrometric analyses 
HUVECs were seeded and cultured in 15-cm dishes and subjected to NDPK-B knockdown 
via siRNA. 24 hpt, the cells were starved in 0.5% FCS ECGM for 48 h, then washed with 150 
mM ammonium acetate. The dishes were flash-frozen in liquid nitrogen and stored at -80 °C 
for further mass spectrometric analysis. The retinae from 5-month-old mice were isolated 
and flash-frozen in liquid nitrogen and stored at -80 °C for further mass spectrometric 
analysis. 
4.2.6.2 Determination of metabolite levels via UPLC -PDA 
Determination of nucleotides and sugar-nucleotides was adapted from Kochanowski et al 
[217]. Either HUVEC cell pellets (10x106 cells per sample) or one mouse retina were lysed 
and extracted in 0.37 ml ice-cold 0.5 M perchloric acid with sonication on ice. Samples were 
neutralized with 86 µl ice-cold neutralization solution (2.5 M KOH in 1.5 M K2HPO4) after 5 
min sonication. To remove precipitated potassium perchlorate neutralized samples were 
centrifuged at 4 °C and 16,400 g for 10 min and fil tered with 0.2 µm filters. Nucleotides and 
sugar-nucleotides were immediately analyzed and separated via ion-pair reverse phased 
chromatography using an Acquity HSS T3 column (150 mm x 2.1 mm, 1.7 µm, Waters) 
connected to an Acquity H-class UPLC system. The column temperature was set to 40°C 
and the column was equilibrated with solvent A (50 mM potassium phosphate buffer, 8 mM 
tetrabutylammonium hydrogen sulfate, pH 6.5) at a flow rate of 0.45 ml/min. Autosampler 
temperature was maintained at 6 °C. The elution gra dient was as follows: after 2.6 min 0% B 
(30 % acetonitrile in 70 % solvent A) to 17 min 77% B, hold for 1 min at 77% B, followed by 
return to 0% B and conditioning of the column to initial conditions for 10 min. Nucleotides 
were detected by Acquity PDA detector (Waters, 260 nm) and quantified using ultrapure 
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standards (Sigma). Data acquisition and processing was performed with the Empower3 
software suite (Waters).  
4.2.7 Seahorse analyses 
Seahorse cartridges were hydrated on the day prior to the assay according to the instruction 
manual. HUVECs were detached and seeded into pre-coated 96-well plates and allowed to 
adhere for 2 h in a humidified incubator at 37 °C. The cells were then washed and starved in 
non-buffered serum-free Seahorse medium in a CO2-free incubator for 1 h. The hydrated 
cartridges were prepped with the inhibitors and stimulators provided in the kit and placed on 
the 96-well plate containing the starved HUVECs. The cartridge-plate combination was then 
placed in the Seahorse XFe 96 Analyzer and assessed using the protocol for Glycolysis 
Stress Test or Mito Stress Test. Respective catalog numbers can be found in Table 15 . The 
glycolytic stress test injects glucose, oligomycin, and 2-deoxy-D-glucose (2DG) at 20 min 
intervals on the EC monolayer to measure short-term changes in glycolysis, glycolytic 
capacity, and additional glycolytic reserve potential, respectively. Extracellular acidification 
rate (ECAR) is the measure of changes in pH due to lactate production at the end of 
anaerobic glycolysis. The Mito stress test injects oligomycin, FCCP, and electron transport 
chain inhibitors Antimycin A and Rotenone at 20 min intervals on the EC monolayer to 
measure the basal and spare respiratory capacity in real-time. Oxygen consumption rate 
(OCR) is used as the read out for mitochondrial respiration by oxidative phosphorylation. 
Results were analyzed with the Wave software and the Seahorse Report Generator. 
 
4.3 Immunofluorescence staining 
4.3.1 Seeding and fixation of cells on coverslips 
Coverslips were briefly sterilized with 75% ethanol and subsequently with 100% ethanol. 
They were then placed in 24-well plates, dried off and coated with 1% gelatin or 1mg/ml rat-
tail collagen. HUVECs were seeded on the coverslips, then treated according to the 
experimental conditions. HRMVECs/MBMECs were seeded in a 24-well plate containing 
coverslips and cultured in ECGM MV with 10% FCS. Then the cells were washed in PBS 
fixed with 4% Roti®-Histofix (fixation solution) for 15 min at RT. Then, the cells were washed 
thrice with PBS to remove excess Histofix.  
 
4.3.2 Immunofluorescence staining and quantificatio n 
On the day of staining, the cells were permeabilized and blocked with 2.5% BSA and 0.3% 
Triton X-100 for 1 h. After blocking, the cells were incubated with the primary antibody at 4 
°C overnight. The following day, the cells were was hed thrice with PBS to remove unbound 
antibody and incubated at RT for 1 h in secondary antibodies. After 3 washes with PBS, the 
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cells were incubated at RT for 15 min with DAPI, followed by 3 more washes with PBS. The 
coverslips were then carefully picked out from the wells with forceps and mounted on an 
object slide with mounting medium (Roti®-Mount FluorCare). Photos were taken by confocal 
laser scanning microscopy (Leica Microsystems, Germany).  
For immunofluorescence staining, staining intensity was quantified with Image J (NIH, USA). 
Pixel densities were analyzed by drawing a line across the cell (line scan), such that the cell 
membrane, nuclear and cytoplasmic regions were marked. Approximately 10 cells were 
analyzed per experimental group. This method was used for the quantification of membrane 
protein expression in immunofluorescence staining. The concentrations of the primary and 
secondary antibody are mentioned in Table 11  and 12, respectively. 
 
4.3.3 Retinal whole mount immunofluorescence staini ng for Tie-2 
For whole mount staining, mouse eyes were fixed in 4% PFA for 15 min. After dissection, the 
retinae were cut into four leaves at the periphery, and fixed in methanol for 15 min. Next, the 
retinae were washed with PBS and incubated with permeabilization/blocking solution (2% 
BSA, 0.5% Triton X dissolved in PBS) for 1 h at room temperature. Post-incubation, the 
retinae were incubated with anti-Tie-2 antibody and anti-Lectin-TRITC overnight at 4 °C. The 
retinae were then washed and incubated for 1 h at RT with the donkey anti-goat-FITC 
secondary antibody. Finally, the retinae were mounted on glass slides with Roti-mount. 
Photos were taken by confocal laser scanning microscopy (Leica Microsystems, Germany). 
The concentrations of the primary and secondary antibody are mentioned in Table 11  and 
12, respectively. 
 
4.4 Protein biochemical methods 
4.4.1 Protein extraction from the retina 
All procedures were performed on ice. The retina from a frozen and unfixed eye was quickly 
extracted under the microscope and placed in an Eppendorf containing 120 µl of ice-cold 
RIPA buffer. Each retina was thoroughly homogenized by passing the suspension through 
syringe needles of descending diameters (22G, 25G, 27G, 30G). The homogenate was then 
centrifuged at 13,000 rpm at 4 °C for 30 min. The s upernatant was moved to a fresh 
Eppendorf for further analysis. 
 
4.4.2 Protein extraction from cells  
All procedures were performed on ice. The cells were washed thrice with ice-cold PBS and 
lysed in chilled RIPA buffer. The volume of buffer per dish is shown in Table 22 . Once the 
RIPA buffer was added to the cells, they were harvested from the dish with the help of a cell 
52 
 
scraper. The collected suspension was transferred to a pre-cooled Eppendorf and incubated 
on ice for 20-30 min. The suspension was then centrifuged at 13000 rpm for 15 min at 4°C. 
The supernatant containing the cell contents was collected in a fresh tube. Protein amounts 
were subsequently quantified and equalized before use. 
 
Table 22: Optimization of lysis buffer 
Wells perCulture plates 
/ dishes 
Seeding density Confluence Lysis buffer ( µl) 
24 well 50,000 0.5x105 30 
12 well 100,000 1.2x105 60 
6 well 250,000 4.0x105 150 
6 cm 550,000 3.0x106 300 
10 cm 1000,000 6.0x106 500 
 
4.4.3 Estimation of protein amount using BCA assay 
Bicinchoninic Acid (BCA) assay is a colorimetric technique used to estimate protein amount 
prior to SDS-PAGE and other experiments. Peptide bonds in proteins reduce the copper ion 
in CuSO4.5H2O which then chelates to the Bicinchoninic acid resulting in a color change 
from green to purple. The amount of protein is directly proportional to the optical density 
(OD) of the final product which can be detected at 565 nm. 
The assay was performed in flat-bottomed 96-well plates. BSA with concentrations 0, 0.25, 
0.5, 1, and 2 µg/µl were used to generate a standard curve as shown below. 10 µl of whole 
or diluted protein lysate was pipetted in duplicates. 100 µl of BCA solution was added to 
each well. The BCA solution was prepared as follows: 
 
BCA A: Dissolve in 40 ml H2O 3.420 g Na2CO3, 0.800 g NaOH, 0.132 g Na. K-tartrate.4H2O, 
adjust the pH to 11.25 with NaHCO3, adjust the volume to 50 ml with H2O 
BCA B: Dissolve in 4 ml H2O 0.2 g BCA.Na2, adjust the volume to 5 ml with H2O 
BCA C: Dissolve in 5 ml H2O 0.2 g CuSO4.5H2O 




The plate was covered and incubated at 60 °C for 30  min. The OD for the samples were 
then read using a spectrometer at 595 nm. A standard curve was created by making linear 
regression of the OD values against the concentrations. The protein concentrations of the 
samples were extrapolated from the standard curve (Fig. 16). Protein amount was equalized 





Fig.  16: Standard curve of a BCA assay. The curve was generated using different concentrations 
of BSA and the corresponding OD. The protein concentrations of the samples were extrapolated from 
the standard curve. 
 
4.4.4 Protein denaturation 
Prior to investigation via SDS-PAGE, the protein lysates from cells and retinae were 
denatured with 4X SDS loading buffer (Laemmli buffer) and boiled at 95 °C for 5 min on a 
heating block. The mixture was then cooled on ice and used for SDS-PAGE or directly 
stored at -20 °C until further analysis. If the lys ates were used to detect N1-phospho-
histidine, then after addition of Laemmli buffer, the lysates were denatured by incubating 
overnight at 4 °C. 
 
4.4.5 Western blotting/immunoblotting 
4.4.5.1 SDS-polyacrylamide gel electrophoresis (SDS -PAGE) 
SDS-PAGE is a technique used to separate polypeptides according to their sizes. The 
polypeptides travel along the SDS polyacrylamide gel through an electricity gradient that 
separates the peptides according to their sizes, the largest migrating the slowest. The 
separated proteins were then blotted onto a nitrocellulose membrane, where they were 
stained with antibodies specific to the target protein. Further visualization, analysis, and 
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quantification of the amount of protein bound to the membrane is indicative of the expression 
of target proteins. 
 
4.4.5.2 Gel casting 
An SDS-PAGE gel consists of a stacking gel and a separating gel. The size of the target 
protein decides the percentage of polyacrylamide in the gels as seen in Table 23 . The 
reagents for making the stacking and separating gels are shown in Table 24 and 25. The 
two solutions were carefully prepared and pipetted between glass plates held together on a 
gel-casting stand; the stacking gel was layered above the separating gel. The separating gel 
was allowed to polymerize for 20-30 min before adding the stacking gel. A gel comb was 
used to create wells in the stacking gel for protein loading. The stacking gel polymerized in 
15 min. The whole gel was either used immediately or stored at 4 °C. 
 
Table 23: Size of proteins and gel percentage 







Table 24: Components and volumes for casting of separating gels (ml) 
Components 5% 6% 8% 10% 12% 15% 
H2O 5.6 5.3 4.6 4.0 3.3 2.3 
30% polyacrylamide 1.7 2.0 2.7 3.3 4.0 5.0 
1.5 M Tris (pH 8.8) 2.5 2.5 2.5 2.5 2.5 2.5 
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10% SDS 0.1 0.1 0.1 0.1 0.1 0.1 
10% APS 0.1 0.1 0.1 0.1 0.1 0.1 
TEMED 0.01 0.008 0.006 0.004 0.004 0.004 
 
Table 25: Components and volumes for casting of stacking gels (ml) 
Components 4% 5% 
H2O 7.2 6.8 
30% polyacrylamide 1.3 1.7 
1 M Tris (pH 6.8) 1.25 1.25 
10% SDS 0.1 0.1 
10% APS 0.1 0.1 
TEMED 0.01 0.01 
 
4.4.5.3 Gel loading and protein separation 
The fully polymerized SDS-PAGE gel was mounted on a gel cassette and placed in an 
electrophoresis chamber with 1X SDS running buffer. The comb separating the wells was 
removed and the denatured protein lysates and a suitable protein marker were applied to the 
sample-loading wells. The anode and cathode were correctly connected to a power source. 
A voltage of 90 V was applied until the proteins were past the stacking gel. The voltage was 
then increased to 120 V to separate the proteins according to their molecular size. The 
protein separation was stopped when the bromophenol blue staining of the lysates reached 




4.4.5.4 Transfer of proteins onto a nitrocellulose membrane 
Following SDS-PAGE, the proteins were transferred from the gel to a nitrocellulose 
membrane. The materials required were pre-soaked in western transfer buffer and stacked 
according to Fig. 17 . The gel was extracted from between the glass plates and placed 
together with the nitrocellulose membrane in a sandwich between pre-soaked Whatman’s 
filter paper. The combination was smoothed with a roller to eliminate air bubbles between 
the membrane and the gel. The sandwiched transfer stack was placed in the cassette in a 
chamber filled with 1X Transfer buffer. The sandwich was organized as follows: anode side - 
sponge - Whatman paper X 2 - nitrocellulose membrane - gel - Whatman paper X 2 - sponge 
- cathode side. An ice cooling unit was placed beside the transfer stack to prevent 
overheating of the transfer assembly. The unit was connected to a power source and the 
transfer was conducted at 100 V for 60 min. Post-transfer, the membrane was extracted 
from the sandwich and stained with 0.2% Ponceau S solution to confirm the successful 
transfer of protein. The membranes were washed with 1X TBST and blocked for 1 h in 1X 
Roti®-Block at RT. 
 
 
Fig.  17: Assembly of the transfer stack sandwich 
 
4.4.5.5 Antibody incubation 
After blocking, the blots were washed shortly in TBST buffer and incubated with primary 
antibody specific to the protein of interest. The incubation was performed at 4 °C overnight. 
After incubation, the membrane was washed thrice in 1X TBST and incubated on a shaker 
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for 1 h at RT with the secondary antibody specific to the host of the primary antibody. The 
secondary antibody was usually HRP-conjugated. The membranes were washed thrice with 
1X TBST and were ready to be visualized. The dilution of the primary antibodies and 
secondary antibodies were as mentioned in Table 11 and 12. 
 
4.4.5.6 Protein visualization 
The immunoreactive proteins were visualized with enhanced chemiluminescent substrate in 
an imager (Vilber). Highly expressed proteins were visualized by the Lumi-Light Western 
Blotting Substrate and weakly expressed proteins with the Super Signal West Femto 
Maximum Sensitivity Substrate. The obtained images were analyzed and quantified with 
Image J software.  
 
4.5 Tie-2 immunoprecipitation 
Cells seeded on 10 cm dishes were washed with ice-cold PBS and harvested by scraping in 
400µl lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100) containing 
protease inhibitor 1 tablet/10 ml protease inhibitor (Roche, Germany) and PhosStop 
(phosphatase inhibitor, 1 tablet/10 ml Sigma Aldrich, Germany). The lysate was incubated 
on ice for 20-30 min and centrifuged at 13000g for 15 min at 4 °C. The supernatant was 
collected and 60 µl of the supernatant was set aside as Input control. The remainder was 
incubated with the Tie-2 antibody (AF313, 2 µg per IP) on a rotator at 4 °C for 2 h. For each 
sample, 40 µl beads were washed with lysis buffer. The beads were added to the lysate 
antibody mixture and incubated on a rotator overnight at 4 °C. After the incubation, the 
beads were collected by centrifugation, and washed with lysis buffer containing PhosStop. 
The immune complexes on the beads were then denatured with 1X Laemmli buffer and the 
lysates were investigated by western blotting. Detection of Tie-2 was performed with rabbit-
anti-Tie-2 (Santa Cruz, 1:500) and phosphorylation with mouse-anti-pTyrosine 4G10 
(Millipore, 1:1000). 
 
4.6 Precipitation of O-GlcNAcylated proteins with s WGA beads 
Succinylated WGA-conjugated agarose beads were implemented to precipitate the O-
GlcNAcylated proteins according to the manufacturer’s instructions. In brief, HUVECs in 
10cm dishes were harvested in 400 µl WGA lysis buffer (50 mM Tris-HCl pH 7.4, 100 mM 
NaCl, 1% TritonX-100) containing a protease inhibitor (1 tablet/10 ml, Roche). The lysate 
was incubated on ice for 20-30 min and centrifuged at 13000g for 15 min at 4 °C. The 
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supernatant was collected and 60 µl of the supernatant was set aside as Input control. For 
each precipitation, 40 µl beads were washed with WGA washing buffer (50 mM Tris-HCl pH 
7.4, 100 mM NaCl, 0.1% TritonX-100). The remainder of the lysate was mixed with the 
prepped beads and incubated on a rotator at 4 °C ov ernight. Post-incubation, the beads 
were collected by centrifugation and washed thrice with WGA washing buffer. The beads 
were then suspended in 1X Laemmli buffer, and denatured for 5 min at 95 °C to extract the 
immunocomplexes for the analysis by western blotting. 
 
4.7 Experimental analyses with kits 
4.7.1 Cell fractionation kit 
Fractionation of cells was performed with a commercially available kit (78840, 
ThermoFischer Scientific, Germany). HUVECs were cultured and treated accordingly. The 
cells were trypsinized and subjected to cytoplasm, nuclear, and membrane isolation buffer 
as described in the manufacturer’s protocol. After separation, the respective fractions were 
dissolved in 4x Laemmli sample buffer and denatured at 95 ° C for 5 min. The obtained 
fractions were used for further western blotting. 
 
4.7.2 Ang-2 ELISA 
HUVECs were treated as illustrated in the results. The supernatants were collected and 
centrifuged to exclude cellular debris. These cleared supernatants were then used to detect 
secreted Ang-2 using the human Angiopoietin-2 DuoSet kit (DY623, R&D Systems, 
Germany) according to the manufacturer’s instructions. 
 
4.7.3 OGA activity 
OGA activity was measured with a commercially available O-GlcNAcase assay kit (E-130, 
BMR Service, SUNY, Buffalo, USA).  5 retinae per genotype were each homogenized in 120 
µl of an SDS-free buffer provided with the kit. Similarly, NDPK-B deficient HUVECs were 
harvested from 6 cm dishes in 200 µl buffer and homogenized. The homogenates were 
centrifuged, and the supernatant was incubated for 5 min on ice with intermittent agitation 
and centrifuged for 15 min. The homogenate was then centrifuged, and the supernatant was 
collected.  10 µl of the supernatant was used to measure OGA activity according the 
manufacturer’s instructions. 
 
4.7.4 NDP kinase activity assay 
HUVECs and retinae were lysed in RIPA buffer and immediately subjected to the NDP 
kinase activity assay (Fig. 18). The test utilizes NDPK catalytic activity to transfer the 
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phosphate in GTP to ADP, generating ATP. The ATP is measured by the Kinase-GLo kit, in 
which ATP catalyzes the conversion of D-Luciferin to Oxyluciferin in the presence of the 
enzyme luciferase. The luminescent signal recorded correlates with the amount of ATP 
produced and is in turn proportional to the NDP kinase activity. A standard curve was 
generated using different concentrations of ATP (0.5 - 10 µM) dissolved in water. The NDP 
kinase activity in lysates was measured in a 384-well plate. Lysates were diluted in assay 
buffer (50 mM Tris-HCl, pH 7.5, 2 mM MgCl2, 1 mM DTT, 0.01% BSA) constituting the 
reaction mixture. Lastly, an ATP dependent luciferase was added to the reaction mixture and 




Fig.  18: Working principle of the NDP kinase activity assay 
 
4.8 Quantitative PCR  
4.8.1 Isolation of RNA from HUVECs  
On the day of isolation, the HUVECs were washed thrice in ice-cold PBS and scraped in 
Trizol reagent. The Trizol reagent containing the cells was homogenized by pipetting up and 
down. Chloroform was then used to extract the RNA from the homogenate and the mixture 
was centrifuged at 12000 g for 15 min at 4 °C. The aqueous layer containing the RNA was 
carefully removed and placed in a fresh Eppendorf. The RNA was then precipitated with an 
equal volume of isopropyl alcohol and centrifuged at 12000 g for 10 min at 4 °C. The 
supernatant was siphoned off and replaced with 75% ethanol to purify and wash the RNA 
extract. The suspension was centrifuged at 9000 g for 5 min at 4 °C. The purified pellet was 
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allowed to air dry and dissolved in RNase-free H2O for 10 min at 60 °C with shaking. The 
pellet was either used for RNA estimation or stored at -80 °C for further use. 
 
4.8.2 Preparation of cDNA and qPCR 
RNA concentration was measured with a Nanodrop machine. Recorded RNA concentrations 
were used to create a suspension containing at least 1 µg of RNA. A reaction mixture was 
created with RNA, 4 µl of Superscript VILO cDNA synthesis reagent, and volume made up to 
20 µl with RNase-free H2O. Program for cDNA synthesis is as follows: 
 
25 °C 10 min  42 °C 60 min 85 °C 5 min 
 
cDNA was used in the dilution 1:5 with H2O for qPCR. 2 µl of cDNA was pipetted into the 
Microwell qPCR plates. A reaction mixture containing Taqman Fast advanced mastermix, 
the respective primers, and H2O was assembled and 18 µl of the mixture was pipetted into 
the wells containing cDNA. The plate was then briefly centrifuged and placed in the 
Quantstudio 3 (Applied Biosystems) for qPCR. The CT values obtained were used for 
analysis by the comparative CT (∆∆CT) method [218]. 
 
4.9 Data quantification and statistical analysis 
For western blot analysis, the images from protein visualization were used for quantification. 
Images were loaded in Image J software and individual bands were selected using the 
‘Select tool’. The area of the select tool was adjusted in a way to allow the maximum amount 
of the band and the minimum amount of the background to be selected. The ‘measure’ 
function was used to measure the density of the selected band. Keeping the ‘Area’ 
parameter the same, successive bands on the same membrane were measured. ‘Median’ 
measurement was used for all quantification purposes.  
All of the experiments were then analyzed statistically using the GraphPad Prism 6 software 
(GraphPad Software, La Jolla). For statistical analysis, data were presented as mean±SD. 
Statistical significance was established with paired/unpaired Student’s t-test or Analysis of 






Most of the data shown are also part of two submitted manuscripts. This is stated here to 
acknowledge this correctly. 
5.1 The importance of Ang-2-Tie-2 signaling in HG a nd NDPK-B deficiency-
mediated vasoregression 
5.1.1 Ang-2 mediates NDPK-B deficiency-induced vasc ular regression 
 
Fig.  19: Ang-2 is the mediator of NDPK-B deficiency-induced vasoregression. Retinal 
vasculature was visualized by retina digestion method and PAS staining. PCs and AC were assessed 
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using quantitative retinal morphometry. A: Representative retinal digestion preparations from retinae. 
PCs and AC are indicated by arrowheads and arrows respectively. B: Quantification of PC numbers, 
(n=9, 8, 7, 8). C: Quantification of AC numbers, (n=9, 8, 7, 8). Cap. area: capillary area. Results are 
displayed as mean±SD. * p<0.05. Magnification: 40×. Scale bar: 50 µm. 
 
As illustrated in published findings, NDPK-B deficient retinae exhibited DR-like pathology 
accompanied by an elevation of Ang-2 [213]. Early morphological changes in DR are 
mediated by an elevated expression of Ang-2. In order to investigate if upregulation of Ang-2 
is responsible for the DR-like pathology observed in NDPK-B deficient retinae, we crossbred 
the NDPK-B deficient mice with Ang-2 deficient mice to obtain NDPK-B-/-/Ang-2+/- mice. 8-
month-old mice from groups NDPK-B+/+/Ang-2+/+ (WT), NDPK-B-/-/Ang-2+/+ (NDPK-B KO), 
NDPK-B+/+/Ang-2+/- (Ang-2 KO), and NDPK-B-/-/Ang-2+/- (NDPK-B/Ang-2 KO) were sacrificed 
and their retinae were isolated. The isolated retinae were then digested, and the vasculature 
was assessed by retinal morphometry, where the PCs and the number of AC were quantified 
(Fig. 19A ). In agreement with prior findings, NDPK-B KO retinae demonstrated significant 
loss in PC coverage (Fig. 19B ) and increase in AC (Fig. 19C ) than the WT controls. Ang-2 
KO (Ang-2 haplodeficiency) yielded no observable morphological changes in the retinae. 
Interestingly, NDPK-B/Ang-2 KO mice reversed the vasoregression seen in NDPK-B KO 
retinae. 50% deletion of Ang-2 in the NDPK-B/Ang-2 KO animals was sufficient to rescue the 
PC dropout seen in NDPK-B KO. These data indicate that NDPK-B deficiency induces 
retinal vasoregression via elevated Ang-2.  
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5.1.2 Tie-2 is upregulated in NDPK-B deficient reti nae  
 
Fig.  20: Tie-2 is upregulated in NDPK-B deficient but not in diabetic retinae. A: Representative 
immunoblots of Tie-2, Ang-2, and γ-Tubulin in NDPK-B-/- retinal lysates. B and C: Quantification of 
Ang-2 and Tie-2, respectively, normalized to γ-Tubulin (n=5). D: Expression of Tie-2 (green) and 
Isolectin (red) in the deep capillary layer of WT and KO retinae. The pictures shown are 
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representative of staining from the 3 animals in each group. E: Representative immunoblots of Tie-2 
and γ-Tubulin in diabetic and non-diabetic retinal lysates. F: Quantification of Tie-2 normalized to γ-
Tubulin (n=5). Results are displayed as mean±SD. WT: wild type, KO: NDPK-B-/-, WTNC: wild type 
non-diabetic, WTDC: Wild type diabetic. * p<0.05. 
 
To address a potential role of Tie-2 in Ang-2 signaling in the context of NDPK-B deficiency, 
we investigated the expression of Tie-2 in 5-month-old NDPK-B-/- (KO) mouse retinae by 
immunoblot. Similar to prior findings, Ang-2 was significantly upregulated in KO retinae 
compared to WT by about 30% (Fig. 20A and B ). Similarly, the level of Tie-2 in the KO 
retinae was also about 30% higher than in the WT retinae (Fig. 20A and C ). To verify that 
this increase occurs in the endothelium, we assessed the localization of Tie-2 in the retina 
via whole mount immunofluorescence staining. Isolectin staining distinguished the 
vasculature from the surrounding retinal tissue (Fig. 20D). Tie-2 was predominantly 
expressed in the vasculature. Its expression was unaltered in the KO and WT arterioles, 
venules, as well as in the superficial capillary layer (data not shown). However, in the deep 
capillary layer, where vasoregression commonly originates, higher Tie-2 expression was 
observed in the KO than in the WT retinae (Fig. 20D ). Taken together, the data show that 
Tie-2 is upregulated in the KO retinae, especially in the deep capillary layer, suggesting a 
potential contribution of Tie-2 signaling to the upregulation of Ang-2. NDPK-B KO retinae 
largely mimic diabetic retinae in regards to the upregulation of Ang-2 and the subsequent 
development of vasoregression [213]. To determine whether Tie-2 expression in diabetic 
retinae resembled the NDPK-B KO retinae, 3-month-old diabetic mouse retinal lysates were 
assessed by immunoblot. Tie-2 expression in the retina was not altered in the diabetic 
retinae (Fig. 20E and F ). Thus, the phenotype of NDPK-B KO retinae apparently differs from 




5.1.3 NDPK-B depletion but not high glucose induces  upregulation of endothelial Tie-2  
 
Fig.  21: NDPK-B depletion upregulates endothelial Tie-2 but high glucose does not. HUVECs 
were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +). A: 
Representative immunoblots of Tie-2, Ang-2, NDPK-B, and γ-Tubulin in NDPK-B depleted HUVECs 
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treated for 24 h with (HG, -) or without high glucose (HG, +). B, C, and D: Quantification of NDPK-B, 
Ang-2, and Tie-2, respectively, normalized to γ-Tubulin (n=4). E: Tie-2 mRNA expression in NDPK-B 
depleted HUVECs with and without HG treatment normalized to GAPDH (n=4). Results are displayed 
as mean±SD. * p<0.05.  
 
To further compare the Ang-2-Tie-2- axis in NDPK-B depletion and high glucose, we treated 
cultured ECs (HUVECs), in which an efficient siRNA-mediated NDPK-B knockdown was 
established (Fig. 21A and B , [213]), with and without high glucose (HG). HG had no 
influence on NDPK-B levels (Fig. 21B ). In accordance with published data, an upregulation 
of Ang-2 occurred in NDPK-B depleted as well as HG ECs (Fig. 21A and C ). The increase 
in Ang-2 levels was however more pronounced in NDPK-B depleted than in HG-treated ECs. 
As reported before [213], the combination of NDPK-B depletion and HG treatment did not 
further increase Ang-2 levels. In accordance with the data obtained from NDPK-B-deficient 
and diabetic retinae, Tie-2 was significantly elevated upon NDPK-B knockdown, however it 
remained unaltered upon HG treatment (Fig. 21A and D ). HG treatment of NDPK-depleted 
ECs did not further alter Tie-2 levels. To determine whether Tie-2 upregulation upon NDPK-
B knockdown occurs due to transcriptional regulation we analyzed its mRNA expression. 
Neither NDPK-B depletion nor HG treatment altered Tie-2 mRNA content (Fig. 21E). Taken 
together, these findings show that the elevation of Ang-2 in NDPK-B deficiency is distinctly 
higher than in HG. This enhanced Ang-2 upregulation in NDPK-B knockdown in ECs is 
associated with an increase in endothelial Tie-2 levels.  
 
5.1.4 NDPK-B depletion widely upregulates Ang-2 and  Tie-2 in microvascular 
endothelial cells 
To verify that the increase in Tie-2 levels is dependent on NDPK-B depletion and a common 
regulation in ECs, two microvascular EC cell lines were analyzed. Human microvascular 
ECs (HMECs) are commercially available immortalized microvascular ECs of dermal origin. 
Like in HUVECs, NDPK-B was successfully depleted in HMECs via siRNA-mediated gene 
knockdown. Ang-2 levels were increased by 1.75-fold in NDPK-B depleted HMECs (Fig. 
22A and B ). Concomitant with the Ang-2 elevation, Tie-2 expression increased by about 2-
fold. (Fig. 22A and C ). To further corroborate these findings, NDPK-B was also depleted in 
human retinal microvascular ECs (HRMVECs). Unlike HMECs, HRMVECs are a non-
immortalized primary cell population isolated from the retina of a single donor. HRMVECs 
used at late passages were characterized by staining with the endothelial marker PECAM-1 
and found to be 100% endothelial in nature (Fig. 22D). NDPK-B knockdown induced a 
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significant elevation of Ang-2 and Tie-2 compared to the control group (Fig. 22E, F and G ). 






Fig.  22: NDPK-B depletion upregulates Ang-2 and Tie-2 in HMECs and HRMVECs. HMECs and 
HRMVECs were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, 
+). A: Representative immunoblots of Tie-2, Ang-2, NDPK-B, and γ-Tubulin in NDPK-B depleted 
HMECs. B and C: Quantification of Ang-2 and Tie-2, respectively, normalized to γ-Tubulin (n=3). D: 
Expression of PECAM-1 (green) and DAPI (blue) in the HRMVECs at passage 15. The pictures 
shown are representative of staining from the 2 independent experiments. E: Representative 
immunoblots of Tie-2, Ang-2, NDPK-B, and γ-Tubulin in NDPK-B depleted HRMVECs. F and G: 
Quantification of Ang-2 and Tie-2, respectively, normalized to γ-Tubulin (n=5). Results are displayed 
as mean±SD.  * p<0.05. 
 





Fig.  23: NDPK-B depletion promotes Tie-2 localization at the cellular membrane. HUVECs were 
transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) and treated for 
24 h with (-) or without high glucose (HG, +), as indicated. A: Representative immunofluorescence 
images of Tie-2 expression in NDPK-B depleted ECs with and without HG treatment. B: Quantification 
of membrane Tie-2 as pixel density in panel A. C: Membrane (M), Cytosolic (C), soluble nuclear (Sol. 
N), and chromatin nuclear (Chr. N) fractions were assessed to show the subcellular localization of 
Tie-2. D: Tie-2 was quantified relative to membrane protein Gβ (n=4). Results are displayed as 
mean±SD * p<0.05. 
 
Subsequently, we investigated the localization of endothelial Tie-2. Immunofluorescent 
staining showed that Tie-2 was localized at the cell membrane as well as in intracellular 
compartments (Fig. 23A ). After NDPK-B knockdown, the overall Tie-2 content appeared 
elevated throughout EC, especially at the plasma membrane. HG treatment did not 
unambiguously alter the subcellular localization of Tie-2. The quantification of Tie-2 levels 
showed a significant increase at the plasma membrane by about 1.5-fold upon NDPK-B 
knockdown, but no alteration was detected upon HG treatment (Fig. 23B ). To substantiate 
these findings, we performed subcellular fractionation to analyze the Tie-2 content in 
different cellular compartments of control and NDPK-B depleted ECs by immunoblot. As 
shown in Fig. 23C , the identity of the membrane fraction was validated by Gβ and the 
chromatin containing nuclear fraction by Histone H3. As expected, γ-Tubulin was present in 
the membrane, cytoplasmic and soluble nuclear fraction. NDPK-B was detected largely in 
the cytoplasmic fraction and partially at the membrane. Its knockdown reduced its 
expression in both of these cellular compartments. Tie-2 was predominantly detected at the 
membrane and to a much lesser extent in the other fractions. Tie-2 was also detected in the 
nuclear fractions. In accordance with the immunostainings, the membrane content of Tie-2 
was increased about 1.8-fold in NDPK-B depleted cells (Fig. 23D), suggesting that NDPK-B 





5.1.6 NDPK-B depletion and high glucose reduce Tie- 2 phosphorylation 
 
Fig.  24: NDPK-B depletion and high glucose lower Tie-2 phosphorylation. HUVECs were 
transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) or were treated 
for 15 min with (-) or without high glucose (HG, +), as indicated. A: Representative immunoblots of 
tyrosine phosphorylation (pTyr) of Tie-2 after immunoprecipitation (IP), Tie-2, and γ-Tubulin content in 
whole cell lysates (Input) are also shown. B: Quantification of Tie-2 phosphorylation relative to the 
total amount of precipitated Tie-2 (n=3).  Results are displayed as mean±SD * p<0.05. 
 
At the plasma membrane Tie-2 functions as a receptor for the angiopoietins. Its activity can 
be monitored by the autophosphorylation of Tie-2 on tyrosine residues [109]. Therefore, Tie-
2 was immunoprecipitated and its phosphorylation was detected by immunoblot with a 
phospho-tyrosine (pTyr) specific antibody (Fig. 24A ). Also, upon immunoprecipitation the 
increase in total Tie-2 levels after NDPK-B depletion was detected, whereas no significant 
change was caused by HG treatment. Similarly, the total phosphorylation of Tie-2 was 
elevated after NDPK-B depletion. However, the relative Tie-2 phosphorylation (pTyr/Tie-2), 
which monitors the proportion of activated receptors, revealed an approximate 40% 
decrease upon HG treatment and a 25% decrease after NDPK-B depletion (Fig. 24A and 
B). These data indicate a decreased activation of Tie-2 receptors despite the higher amount 
of membranous Tie-2 after NDPK-B depletion. As Ang-2 is generally believed to act as 
antagonist of Tie-2, such a reduction could be caused by an enhanced Ang-2 secretion by 




5.1.7 NDPK-B depletion in ECs elevates Ang-2 secret ion 
 
Fig.  25: NDPK-B depletion and HG in ECs promotes secretion of Ang-2. HUVECs were 
transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) or treated for 24 
h with (-) or without high glucose (HG, +). A and B: Detection of secreted Ang-2 via ELISA in the 
supernatant of HG-treated (n=7) and NDPK-B depleted ECs (n=5), respectively. Results are 
displayed as mean±SD * p<0.05. 
 
As a mediator of vascular remodeling, endothelial Ang-2 is stored in Weibel-Palade bodies 
and secreted rapidly upon stimulation [113]. To investigate whether the increase in the 
cellular content of Ang-2 levels is reflected in its secretion, we quantified Ang-2 in the 
supernatants of cultured ECs by ELISA. HG treatment caused a 1.25-fold increase in Ang-2 
secretion compared to low glucose treated controls (Fig. 25A ). Similarly, NDPK-B 
knockdown induced an elevation in Ang-2 secretion. In accordance with the data on the 
increase in total Ang-2 levels in NDPK-B depleted cells (see Fig. 21C ), the secreted Ang-2 
levels in the supernatant were about 1.6-fold higher than in the supernatant of control 
transfected cells (Fig. 25B ). The amount of Ang-2 secreted from NDPK-B knockdown ECs 
was approximately 300 pg/ml higher than in HG-stimulated ECs.  
 
5.1.8 Ligand-Tie-2 interaction is not required for HG-induced Ang-2 upregulation   
In order to examine the importance of this increase in extracellular Ang-2 levels for the Tie-2 
receptor function in HG-treated ECs, we interrupted the binding of Ang-2 to membranous 
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Tie-2- by adding soluble Tie-2-Fc (sTie-2), the naturally occurring ectodomain of the Tie-2 
receptor. It acts as a scavenger of extracellular angiopoietins, thus blocking the activation 
and phosphorylation of membranous Tie-2 [219]. Addition of sTie-2 had no effect on Ang-2 
levels in control ECs (Fig. 26). As shown before, HG treatment induced a 1.5-fold increase 
in Ang-2 expression (Fig. 26A and B ).  sTie-2 treatment did not alter HG-induced increase 
in Ang-2 (Fig. 26B ).  
 
 
Fig.  26: Tie-2 receptor function is not required for HG-induced Ang-2 upregulation. HUVECs 
were treated with (-) or without high glucose (HG, +) and without (-) and with sTie (+) for 24 h. A: 
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Representative immunoblots for Ang-2, FoxO1, O-GlcNAc,, and γ-Tubulin, as indicated B, C, and D: 
Quantification of Ang-2, FoxO1, and O-GlcNAc,, respectively, normalized to γ-Tubulin (n=4). Results 
are displayed as mean±SD *p<0.05. 
 
These data imply that membrane Tie-2 receptor function has no role in Ang-2 upregulation 
induced by HG. According to prior work, Ang-2 expression is regulated by FoxO1 [216]. 
Enhanced protein O-GlcNAcylation upon a loss of NDPK-B increases Ang-2 via O-
GlcNAcylation of FoxO1. Therefore, we assessed the involvement of Tie-2 in FoxO1 and O-
GlcNAc-mediated regulation of Ang-2. FoxO1 was neither altered by HG nor by sTie-2 
treatment (Fig. 26C ). O-GlcNAc modifications is an off shoot of glucose metabolism and 
hence susceptible to changes in glucose levels [102, 213]. In accordance with published 
reports, protein O-GlcNAcylation was significantly increased by HG treatment (Fig. 26D ). 
However, sTie-2 had no influence on HG-induced protein O-GlcNAcylation.  
 
5.1.9 Ligand-Tie-2 interaction is required for NDPK  B-related Ang-2 upregulation   
In order to examine the importance of the increase in extracellular Ang-2 levels for the Tie-2 
receptor function in NDPK-B depleted ECs, we interrupted the binding of Ang-2 to 
membranous Tie-2- by adding soluble Tie-2-Fc (sTie-2). NDPK-B depletion in ECs was 
achieved via siRNA-mediated knockdown (Fig. 27A and B ). Addition of sTie-2 had no effect 
on Ang-2 levels in control ECs (Fig. 27C ). Tie-2 expression was again elevated in the 
knockdown ECs but not altered in the presence of sTie-2 (Fig. 27A and D ). Interestingly, 
sTie-2 altered the upregulation of Ang-2 upon NDPK-B depletion. Whereas NDPK-B 
knockdown induced the previously described 2-fold increase in Ang-2 levels, this increase 
was abrogated in the presence of sTie-2 (Fig. 27A and C ). These data imply that membrane 
Tie-2 receptor function contributes to Ang-2 upregulation upon NDPK-B depletion. 
According to prior work, FoxO1 was significantly elevated in NDPK-B depleted ECs and 
sTie-2 treatment did not influence this increase in FoxO1 (Fig. 27A and E ). In line with the 
findings in Qiu et al., protein O-GlcNAcylation was also elevated in NDPK-B depleted ECs 
(Fig. 27A and F ) [213]. Similar to FoxO1, O-GlcNAc elevation was unaffected by sTie-2 
treatment indicating that the Tie-2-mediated regulation of Ang-2 in NDPK-B depleted ECs 




Fig.  27: Tie-2 receptor function is required for NDPK B-related Ang-2 upregulation. HUVECs 
were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +), and 
treated without (-) or with sTie (+) for 24 h. A: Representative immunoblots for Ang-2, Tie-2, FoxO1, 
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O-GlcNAc, NDPK-B, and γ-Tubulin, as indicated. B, C, D, E and F: Quantification of NDPK-B, Ang-2, 
Tie-2, FoxO1, and O-GlcNAc, respectively, normalized to γ-Tubulin (n=4). Results are displayed as 
mean±SD *p<0.05. 
 
5.1.10 Tie-2 receptor expression is required for ND PK-B-induced Ang-2 upregulation 
To verify the requirement of Tie-2 for NDPK-B knockdown induced Ang-2 upregulation, we 
also suppressed Tie-2 levels in ECs via siRNA-mediated gene depletion. NDPK-B was 
depleted via siRNA (Fig. 28A and B ). Tie-2 was diminished significantly by about 40% upon 
knockdown (Fig. 28A and C ). In the Tie-2-depleted cells, the NDPK-B knockdown-induced 
elevation of Tie-2 was completely suppressed (Fig. 28A and C ), suggesting an essential 
role of Tie-2. Although the Tie-2 depletion had no effect on the basal levels of Ang-2, it 
effectively inhibited the NDPK-B knockdown-induced elevation of Ang-2 (Fig. 28A and D ). 
Taken together, the data indicate that the expression of membrane Tie-2 contributes to the 




Fig.  28: Tie-2 expression is required for NDPK-B deficiency-induced Ang-2 upregulation. 
HUVECs were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) 
or Tie-2 (siTie-2, +). A: Representative immunoblots for Ang-2, Tie-2, NDPK-B, and γ-Tubulin in cells 
depleted of NDPK-B and Tie-2. B, C, and D: Quantification of NDPK-B, Tie-2, and Ang-2, 
respectively, normalized to γ-Tubulin (n=4). Results are displayed as mean±SD * p<0.05. 
 
5.1.11 An excess of secreted Ang-2 promotes upregul ation of Tie-2  
As proof of concept that the upregulation of Tie-2 upon NDPK-B depletion occurs in 
response to an increase in Ang-2 secretion, we mimicked this condition by adenoviral 
overexpression. As shown in Fig. 29A , Ang-2 was robustly overexpressed 24 h post-
infection. The quantification of Ang-2 by ELISA confirmed about 80-fold higher Ang-2 levels 
in the supernatant of infected ECs (Fig. 29B ). Interestingly, Tie-2 was elevated to a similar 
extent in ECs overexpressing Ang-2 as in those with NDPK-B-depletion (Fig. 29A and C ). 
Collectively, our findings prove that Tie-2 upregulation is mediated by increasing 
extracellular levels of Ang-2. As shown in Fig. 21  and 25, the expression and secretion of 
Ang-2 is more pronounced after NDPK-B depletion than in HG. The strongly secreted Ang-2 
drives Ang-2-Tie-2 signaling via the elevation of membrane Tie-2, specifically when NDPK B 
expression is suppressed. 
 
 
Fig.  29: An excess of extracellular Ang-2 upregulates Tie-2. HUVECs were transfected with either 
scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) and infected with an Ang-2 
overexpressing adenovirus (Ad-Ang-2, +) or Ad-GFP (-) as control. A: Representative immunoblots of 
Tie-2, Ang-2, NDPK-B, and γ-Tubulin in NDPK-B depleted cells without and with Ang-2 
overexpression. B: Quantification of secreted Ang-2 in cells without and with Ang-2 overexpression 
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(Ad-Ang-2, n=4). C: Quantification of Tie-2 normalized to γ-Tubulin (n=6). Results are displayed as 
mean±SD * p<0.05. 
 
5.2 The importance of protein O-GlcNAcylation in ND PK-B deficiency 
5.2.1 Loss of NDPK-B activates the HBP in ECs by el evating UDP-GlcNAc 
 
Fig.  30: NDPK-B deficiency activates the HBP in ECs by elevating UDP-GlcNAc. NDPK-B WT 
and KO retinae isolated from 5-month-old male mice and HUVECs transfected with either scrambled 
control (-) or siRNA against NDPK-B (siNDPK-B, +) were assessed via mass spectrometry (MS) for 
UDP-GlcNAc. A: MS quantification of UDP-GlcNAc in the retinae (n=5 mice per genotype). B: 
Confirmation of NDPK-B knockout via western blotting. C: Quantification of UDP-GlcNAc in NDPK-B 
depleted and control ECs (n=3). D: Confirmation of NDPK-B knockdown via western blotting. Results 
are displayed as mean±SD. *p<0.05.  
 
To study the possible regulation of the HBP by NDPK-B, we first examined the HBP end 
product, UDP-GlcNAc, in control and NDPK-B deficient retinae as well as in control and 
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NDPK-B depleted ECs by mass spectrometry. Successful knockout and knockdown of 
NDPK-B in the retina and ECs, respectively, was confirmed by western blotting (Fig. 30B 
and D ). Approximately 150 pmol of UDP-GlcNAc was detected per retina. This UDP-GlcNAc 
level was not altered in KO retinae compared with WT retinae (Fig. 30A ). In cultured ECs, 
i.e. HUVECs, about 580 pmol UDP-GlcNAc was detected per 106 cells. NDPK-B knockdown 
significantly increased UDP-GlcNAc levels by about 20% (Fig. 30C ). Since the retina is a 
complex organ consisting of many cell types of which ECs are a small subset, the data 
indicate that NDPK-B deficiency might activate the HBP in a cell-type-specific manner.  
 
5.2.2 Loss of NDPK-B in ECs causes a shift in gluco se metabolism from glycolysis to 
the HBP 
 
Fig.  31: NDPK-B depletion in ECs does not influence glycolysis or mitochondrial respiration. 
HUVECs were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) 
and assessed for glycolytic rate and mitochondrial respiration. A: Glycolysis measured as ECAR 
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(mpH/min) (n=7). B: Mitochondrial respiration measured as OCR (pmol/min) (n=7). C: Quantification 
of glycolysis, glycolytic capacity, and glycolytic reserve. D: Quantification of basal respiration, spare 
respiratory capacity, proton leak, and ATP production. ECAR: Extracellular acidification rate; OCR: 
Oxygen consumption rate. Results are displayed as mean±SD. 
 
 
As increased flux through glycolysis also elevates HBP flux [101, 102], we measured 
glycolysis and mitochondrial respiration in control and NDPK-B deleted ECs. As shown in 
Fig. 31A , addition of glucose increased the extracellular acidification rate (ECAR) as a 
surrogate for the glycolytic activity. The subsequent addition of oligomycin, which inhibits 
mitochondrial respiration, maximized the glycolytic output. Addition of 2-DG, a glucose 
mimetic unmetabolized by glucose-6-phosphate isomerase, terminated glycolysis. NDPK-B 
depleted ECs acted similar to control cells and did not exhibit altered glycolysis, glycolytic 
capacity, or reserve (Fig. 31A and C ). Mitochondrial respiration was monitored as oxygen 
consumption rate (OCR). Control ECs showed a basal respiration at around 50 pmol/min 
(Fig. 31B ). Addition of oligomycin largely inhibited respiration. This was overcome by adding 
the ionophore FCCP which maximized respiration after 10-20 min. As expected, subsequent 
addition of antimycin A and rotenone completely blocked mitochondrial oxygen consumption. 
The difference in OCR before and after oligomycin addition is a surrogate for ATP 
production. The difference in OCR between oligomycin and antimycin A/rotenone addition 
corresponds to the proton leak and is used as indication of mitochondrial damage. NDPK-B 
depletion did not alter basal respiration, respiratory capacity, proton leak, or mitochondrial 
ATP production as compared with the controls (Fig. 31B and D ). Collectively, these data 
show that NDPK-B depletion in ECs did not alter glycolysis and mitochondrial respiration but 
resulted in an elevation of UDP-GlcNAc (as seen in Fig. 30C). This indicates a shift in 
glucose metabolism from glycolysis to the HBP independent of the glycolytic flux.  
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5.2.3 Loss of NDPK-B in EC alters nucleotide metabo lism without changing NTP levels  
 
Fig.  32: Loss of NDPK-B in EC alters nucleotide metabolism but does not change NTP levels. 
NDPK-B WT and KO retinae isolated from 5-month-old male mice, HUVECs transfected with either 
scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +), and HUVECs treated without (-) or 
with HG (HG, +) were assessed for NDP kinase activity and for nucleotide metabolism via mass 
spectrometry (MS). A: Overall NDP kinase activity for NDPK-B KO and WT retinae (n=10, 6), B: 
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NDPK-B depleted ECs (n=8), and C: HG treated ECs (n=9). D: MS analysis of the retinae showing 
absolute nucleotide values measured as pmol/retina. E: MS quantification and comparison of 
nucleotides between KO and WT retinae (n=5 per genotype). F: MS analysis of ECs showing absolute 
values for nucleotides in pmol/million cells. G: MS quantification and comparison of relative change in 
nucleotide content of NDPK-B depleted ECs (n=3). AMP: Adenosine monophosphate; UDP: Uridine 
monophosphate; ADP: Adenosine diphosphate. Results are displayed as mean±SD. *p<0.05.  
 
The HBP combines elements of glucose, amino acid, fatty acid, and nucleotide metabolism. 
For example, UTP formed from ATP and UDP in nucleotide metabolism is required for the 
synthesis of UDP-GlcNAc in the HBP. As NDPKs catalyze the formation of NTPs, including 
UTP, we analyzed the influence of NDPK-B deficiency in the retina or depletion in ECs on 
the overall NTP/NDP transphosphorylase, i.e. NDPK activity and nucleotide levels. Although 
NDPK-B is completely absent in the retina of KO mice and largely reduced in its expression 
upon siRNA-mediated knockdown in ECs (siNDPK-B) (see Fig. 30B and D ), the overall 
NDPK activity was reduced only by about 35% in the KO retina (Fig. 32A ) and by 20% in the 
siNDPK-B-treated ECs (Fig. 32B ). This is in agreement with the presence of other NDPK 
isoforms, e. g. NDPK-A, in the retina and ECs [198, 213]. Previous publications indicate a 
diminished activity of NDPKs in pancreatic islets β-cells of diabetic rats by >50% [205]. HG 
treated ECs lost 21% overall NDPK activity compared to controls (Fig. 32C ). The reduction 
of overall NDPK activity in HG indicates a role of NDPKs also under HG, but it does not 
allow conclusion on a specific function of NDPK-B.  
To determine whether NDPK-B depletion activates HBP via changing nucleotide 
metabolism, we performed analyses by mass spectrometry in the NDPK-B deficient retinae 
and NDPK-B depleted ECs. In the retina, the highest nucleotide levels of GDP were 
observed at around 4500 pmol/retina and GTP at 2500 pmol/retina (Fig. 32D). This likely 
reflects the important role guanine nucleotides in signal transduction in the photoreceptors of 
the retina [220]. Retinae contain rather low amounts of UTP/UDP compared to GTP/GDP. 
No differences in nucleotide content of KO retinae compared to WT retinae were detected 
(Fig. 32E ). As shown in Fig. 32F , cultured ECs exhibit a completely different nucleotide 
content pattern than the total retina. They contain much more NTPs, in particular the general 
energy donor ATP, at approximately 7500 pmol/million cells, followed by UTP and GTP at 
1500-1800 pmol/million cells (Fig. 32F). ADP and GDP were present at levels below 1000 
pmol/million cells. UDP and AMP were also detected, but only at very low levels. NDPK-B 
knockdown ECs did not show differences in NTP levels but displayed a relative increase in 
AMP, UDP, and ADP levels by about 50% (Fig. 32G ). This accumulation of NDPs indicates 
a slower nucleotide metabolism due the loss of one of the major NDPK isoforms. 
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Nevertheless, as the NTP pool was unchanged, the data also demonstrate that NDPK-B 
depletion in ECs can be compensated by other isoforms at least for the upkeep of NTP 
formation from ATP and the respective NDP. This includes UTP, an important co-factor for 
the formation of UDP-GlcNAc. 
5.2.4 NDPK-B deficiency activates the HBP by elevat ing GFAT expression and activity 
 
Fig.  33: NDPK-B deficiency elevates GFAT expression and activity. A: HUVECs were transfected 
with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) were assessed by western 
blotting for GFAT and pGFAT and γ-Tubulin. B and C: Quantification of NDPK-B and GFAT, 
respectively, normalized to γ-Tubulin. D: Quantification of pGFAT/GFAT. E: qPCR quantification of 
GFAT mRNA expression relative to 18S. Results are displayed as mean±SD (n=5). *p<0.05. 
 
GFAT is a rate limiting enzyme in the HBP, catalyzing the conversion of fructose-6-
phosphate to glucosamine-6-phosphate, an important precursor of UDP-GlcNAc. To 
investigate the role of GFAT, we first examined its protein content in NDPK-B knockdown 
ECs (Fig. 33A ). NDPK-B depletion was performed via siRNA mediated knockdown (Fig. 
33B). GFAT was upregulated nearly 1.7-fold in NDPK-B depleted ECs compared to the 
controls (Fig. 33A and C ). It has recently been reported that increased phosphorylation of 
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endothelial GFAT at serine 243 diminishes its enzymatic activity and results in reduced 
protein O-GlcNAcylation [73, 74]. In the NDPK-B depleted cells, GFAT phosphorylation was 
significantly reduced by about 35% compared to the controls, indicating an enhancement of 
GFAT activity (Fig. 33A and D ). The amount of mRNA encoding GFAT, measured via 
qPCR, was however not altered (Fig. 33E), pointing to a post-transcriptional mechanism 
causing the elevation of GFAT levels upon NDPK-B knockdown. Taken together, the data 
indicate that the upregulation of GFAT content and activity likely account for the increase in 
the UDP-GlcNAc level upon NDPK-B depletion shown above.  
 
5.2.5 NDPK-B depletion in ECs does not alter the ex pression of O-GlcNAc cycling 
enzymes OGT and OGA 
 
Fig.  34: NDPK-B depletion in ECs does not alter the expression of OGT and OGA. A: HUVECs 
were transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) were 
assessed by western blotting for OGT, OGA, and NDPK-B and γ-tubulin.  B, C, and D: Quantification 
of NDPK-B, OGT, and OGA, respectively, normalized to γ-tubulin (n=9). E and F: qPCR results show 




UDP-GlcNAc is the substrate for OGT in the protein O-GlcNAcylation cycle controlled by the 
enzymes OGT and OGA. OGA removes O-GlcNAc moieties from Serine and Threonine 
residues of modified proteins. We therefore assessed the content of OGT and OGA in 
control and NDPK-B depleted ECs (Fig. 34A ). NDPK-B depletion was again performed by 
siRNA mediated knockdown (Fig. 34B ). OGT and OGA protein levels were unaltered 
between knockdown and control ECs (Fig. 34C and D ). Similarly, qPCR data showed that 
the content in mRNA encoding OGT or OGA was not changed in NDPK-B depleted ECs 
compared to control cells (Fig. 34E and F ).  
 
5.2.6 Reduced OGA activity enhanced protein O-GlcNA cylation in NDPK-B depleted 
ECs  
As the activity of OGA is not only regulated by its expression level, we further assessed the 
enzyme activity of OGA in KO retinae, NDPK-B knockdown ECs, and NDPK B-deficient ECs 
isolated from the murine brain (MBMECs). The average OGA activity in a 5-month-old 
mouse retina was 4 IU/L (Fig. 35A ). MBMECs isolated from murine brains had an OGA 
activity of 9 IU/L (Fig. 35C ), whereas ECs had approximately 65 IU/L activity (Fig. 35B ). No 
obvious change in OGA activity was detected in the total retinal lysate NDPK-B KO and WT 
mice (Fig. 35A ). In ECs, NDPK-B knockdown caused a significant reduction of roughly 12% 
in OGA activity compared to controls in Fig. 35B . In order to investigate if an NDPK-B 
depletion-induced alteration in OGA activity and protein O-GlcNAcylation is a general 
phenomenon in ECs, especially in microvascular ECs, MBMECs were isolated from NDPK-B 
KO mice and cultured [212]. The quality of the MBMEC preparation was validated by 
staining with the endothelial marker PECAM-1 and pericyte marker NG2. More than 95%-of 
the isolated cells were positive for PECAM-1 (Fig. 35F ). Western blotting experiments 
verified the absence of NDPK-B in MBMECs isolated from the KO mouse line (Fig. 35D) As 
shown in Fig. 35C , KO MBMECs exhibited a significantly, lower OGA activity, approximately 
12%, than WT MBMECs. Similar to NDPK-B depletion in ECs, protein O-GlcNAc was 
significantly higher in KO than in WT MBMECs (Fig. 35D and E ). Taken together, these data 
reveal that the increased formation of UDP-GlcNAc via the HBP and a reduction of OGA 
activity are likely working together in the elevation protein O-GlcNAcylation upon the loss of 





Fig.  35: Suppressed OGA contributes to elevated protein O-GlcNAcylation in upon loss of 
NDPK-B in ECs. NDPK-B WT and KO retinae from 5-month-old male mice, HUVECs were 
transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) and MBMECs 
isolated from WT and KO brains of 10-15-week-old male mice were assessed for OGA activity. A: 
OGA activity of KO and WT retinae (n=10, 8), B: in control and NDPK-B knockdown ECs (n=7), and 
C: in WT and KO MBMECs (n=60). OGA activity is expressed in IU/L. D: Western blotting analysis of 
WT and KO MBMECs detecting NDPK-B and O-GlcNAc and γ-Tubulin. E: Quantification of O-GlcNAc 
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normalized to γ-tubulin (n=4). F: Expression of PECAM-1 (green) and DAPI (blue) in MBMECs, 
depicting their endothelial nature. The pictures shown are representative of staining from the 2 
independent experiments. Results are displayed as mean±SD. *p<0.05. 
 
5.2.7 Ang-2 is O-GlcNAcylated in WT and NDPK-B depl eted ECs 
 
Fig.  36: Ang-2 is modified by O-GlcNAc in WT and NDPK-B depleted ECs. HUVECs were 
transfected with either scrambled control (-) or siRNA against NDPK-B (siNDPK-B, +) and were 
assessed by precipitation of O-GlcNAcylated proteins using succinylated WGA-bound agarose beads 
(sWGA). A: Immunocomplexes were probed for Ang-2, O-GlcNAc, and NDPK-B and γ-Tubulin. Whole 
cell lysate (Input) was used to establish knockdown efficiency and probed for total Ang-2. B, C, D, and 
E: Quantification of NDPK-B, O-GlcNAc, Ang-2, and O-GlcNAcylated Ang-2, respectively, normalized 
to γ-Tubulin. F: Quantification of O-GlcNAcylated Ang-2 relative to Ang-2 in ‘Input’. Results are 




Prior findings indicate that Ang-2 is a crucial mediator of vasoregression in NDPK-B 
deficiency and its content is regulated by O-GlcNAcylation [213, 216]. To study whether Ang-
2 itself is modified by O-GlcNAc, O-GlcNAcylated proteins were pulled out of cell lysates by 
succinylated-WGA-bound to agarose beads (sWGA) and subjected to SDS-PAGE and 
western blotting. The blots were probed with antibodies against O-GlcNAc and Ang-2 (Fig. 
36A). NDPK-B depletion was achieved by siRNA mediated knockdown (Fig. 36B ). In 
accordance with the published data, total protein O-GlcNAcylation was significantly 
increased in NDPK-B depleted ECs compared to control cells. O-GlcNAcylated proteins 
were enriched on the sWGA-beads and the overall increase in protein O-GlcNAcylation was 
reflected in the bound fraction (Fig. 36A and C ). An O-GlcNAcylation of NDPK-B was not 
detected in ECs. In line with the reported data [213, 216], the Ang-2 content was significantly 
higher in NDPK-B depleted ECs than control ECs (Fig. 36A and D ). Notably, Ang-2 turned 
out to be an O-GlcNAcylated protein already under basal conditions. Relative to Tubulin in 
the cell lysates used for enrichment, the amount of O-GlcNAcylated Ang-2 was nearly 1.5-
fold higher in NDPK-B depleted ECs than in the respective controls (Fig. 36A and E ). With 
respect to the total Ang-2 level in the cell lysate, the relative fraction of O-GlcNAcylated Ang-
2 was not different between NDPK-B depleted and control cells (Fig. 36F).  
 
5.2.8 Enhanced protein O-GlcNAcylation increased An g-2 content  
To determine if the upregulation of Ang-2 in NDPK-B depleted ECs is a result of 
dysregulation of the OGT/OGA, we modulated OGA activity by other means than NDPK-B 
depletion. When OGT was depleted from ECs by siRNA transfection to about 50%, overall 
protein O-GlcNAcylation was reduced (Fig. 37A ). As shown in Fig. 37B , we effectively 
depleted OGA via siRNA-mediated knockdown. As expected, this resulted in increased 
protein O-GlcNAcylation. Additionally, we inhibited OGA activity with the potent inhibitor 
Thiamet G (TMG, 10µM for 24h). Protein O-GlcNAcylation in the OGA knockdown cells was 
about 1.25-fold higher compared to control siRNA treated cells (Fig. 37C and D ). TMG 
treatment increased protein O-GlcNAcylation even stronger (about 2-fold, Fig. 37D). 
Interestingly, Ang-2 content was significantly upregulated in TMG and siOGA treated cells by 
about 1.3 - 1.5-fold (Fig. 37E ). Ang-2 receptor Tie-2 was however unaffected by OGA 
knockdown and TMG treatment (Fig. 37F ). Taken together, the data indicate that Ang-2 
levels in ECs correlate to changes in the overall O-GlcNAcylation of endothelial proteins 





Fig.  37: Enhanced protein O-GlcNAcylation increased Ang-2 content. ECs were depleted of 
OGT or OGA via siRNA-mediated gene knockdown, followed by treatment with Thiamet G (TMG: 
OGA inhibitor) at 10µM and assessed by western blotting. A: Detection of OGT and O-GlcNAc in OGT 
knockdown ECs. B: Detection of OGA and O-GlcNAc in OGA knockdown ECs. C: Detection of Ang-2 
and O-GlcNAc and γ-Tubulin. D, E, and F: Quantification of O-GlcNAc, Ang-2 and Tie-2, respectively, 






5.2.9 The enzymatic NTP/NDP transphosphorylase and protein histidine activity of 
NDPK-B does not contribute to the regulation of pro tein O-GlcNAcylation 
 
 
Fig.  38: The transphosphorylase and histidine activity of NDPK-B kinase does not contribute 
to the regulation of protein O-GlcNAcylation. A: HEK293T cells were used to demonstrate the 
function of the NDPK-B overexpression constructs. The cells were transduced with adenovirus 
expressing GFP (Ad-GFP), overexpressing NDPK-B (Ad-NDPK-B), and the kinase dead mutant 
H118N (Ad-H118N). Recombinant NDPK-B (rNDPK-B with 6xHis-Tag) and recombinant NDPK-C 
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(H135A with 6xHis-Tag) were used as controls for the enzyme autophosphorylation. The lysates were 
investigated for N1-phospho-histidine, NDPK-B, and γ-Tubulin. B: HUVECs were transfected with 
siRNA against NDPK-B (siNDPK-B, +) and were transduced with Ad-GFP, Ad-NDPK-B and Ad-
H118N, and examined for O-GlcNAc, NDPK-B and γ-tubulin. C and D: Quantification of NDPK-B and 
O-GlcNAc, respectively, normalized to γ-tubulin. All results are represented as mean±SD (n=8). 
*p<0.05, **p<0.01. 
 
Besides its NTP/NDP transphosphorylase [165] and its protein histidine kinase activity [221], 
which are both dependent on the presence of a histidine residue in position 118 (H118), 
NDPK-B can function as a scaffold protein, regulating for example caveolae formation in 
ECs [198, 212]. To determine whether enzymatic activities of NDPK-B are required for the 
regulation of protein O-GlcNAcylation in ECs, we performed experiments with adenoviral re-
expression of either wild type NDPK-B or an enzymatic inactive mutant H118N after siRNA-
mediated depletion. As the autophosphorylation H118 is part of its enzymatic activities [165, 
221, 222], we used the detection of its autophosphorylation with an N1 phospho-histidine 
specific antibody (N1-pHis) to monitor the catalytic activity in NDPK-B [221]. To validate the 
used adenoviruses and the detection of N1-pHis, we first transduced HEK293T cells and 
used purified recombinant NDPKs as controls. As shown in Fig. 38A , similar levels of 
NDPK-B overexpression were achieved with Ad-NDPK-B and Ad-H118N. Recombinant 
NDPK-B (rNDPK-B) and a recombinant kinase activity deficient mutant of NDPK-C (H135A) 
served as a positive and negative control, respectively, for N1-pHis detection. In cells 
transfected with a control virus (Ad-GFP), the detection of N1-pHis correlated to the modest 
expression of endogenous NDPK-B. A strong increase in NDPK-B autophosphorylation 
occurred only in Ad-NDPK-B but not in Ad-H118N transduced cells. Therefore, the 
constructs were used to re-express NDPK-B in NDPK-B knockdown ECs. A similar 
overexpression of NDPK-B by more than 5-fold was achieved in Ad-NDPK-B and Ad-H118N 
infected cells (Fig. 38B and C ). Both re-expression of wild type NDPK-B or its kinase 
deficient mutant diminished overall protein O-GlcNAcylation to a similar extent in NDPK-B 
depleted ECs (Fig. 38B and D ). Taken together, these data demonstrate that the regulation 
of protein O-GlcNAcylation by NDPK-B is not dependent on its role in nucleotide metabolism 





Both the hyperglycemia- as well as NDPK-B ablation-induced retinopathy are initiated by the 
upregulation of Ang-2, causing pericyte drop out and subsequent vasoregression [213]. In 
this study, we investigated the contribution of Tie-2 and protein O-GlcNAcylation in high 
glucose- and NDPK-B deficiency-dependent Ang-2 regulation. The modulation of these 
pathways distinctly regulates Ang-2 in multiple ways, mediating retinal vascular regression. 
6.1 Excess Ang-2 initiates retinal vasoregression i n NDPK-B KO retina 
Qiu et al. showed the similarities between HG and NDPK-B deficiency in the retina in terms 
of the development of vasoregression [213]. In the diabetic retina, dropout of PC and AC 
formation is mediated by hyperglycemia-induced upregulation of Ang-2 [91]. In NDPK-B KO 
retina, similar to DR, PC dropout and AC formation occurs in the absence of hyperglycemia. 
In this study, we showed that the Ang-2 upregulation in the normoglycemic NDPK-B KO 
retina is indeed a crucial initiator of vasoregression. Since ECs are one of the major sources 
of Ang-2 in the retina, it was of importance to investigate the regulation of endothelial Ang-2 
in NDPK-B deficiency in more detail. 
6.2 Tie-2 regulates Ang-2 in NDPK-B deficiency diff erently than in HG 
We demonstrated that, concomitant to a stronger upregulation of Ang-2, NDPK-B deficiency 
but not hyperglycemia increases retinal and endothelial Tie-2 content at the plasma 
membrane. The upregulation of Tie-2 in the NDPK-B-/- retina occurred predominantly in the 
deep capillary layer. Therefore, the question arose whether this upregulation is specific to 
the microvasculature or occurs also in ECs of other origin. As NDPK-B depletion in ECs of 
micro- and macrovascular origin induced similar increases in the amounts of Ang-2 and Tie-
2, our data suggest that the regulation of Tie-2 and Ang-2 is conserved across diverse 
vascular beds. Notably, the increase in Tie-2 levels occurred at the plasma membrane and 
was not reflected by an increase in Tie-2 gene transcription. With regard to the concomitant 
upregulation of Ang-2, we have already shown that this is likely linked to an enhanced O-
GlcNAcylation, and therefore also the enhanced stability of the transcription factor FoxO1 
[216]. In addition, we have also shown that NDPK-B depletion in ECs interferes with 
caveolin-1 transport and caveolae formation [189, 212]. Therefore, an increase in the 
membrane content of Tie-2, as detected herein, might be a result of its stabilization 
preventing its internalization and degradation [223]. The interpretation that more than one 
mechanism might be involved in the NDPK-B-depletion induced increase in Tie-2 levels is 
further corroborated by the notion that HG treatment, although causing enhanced protein O-
GlcNAcylation, is not able to elevate Tie-2 levels. Our findings, however, support reports by 
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others showing the decrease in Tie-2 phosphorylation as a measure of its activity by 
hyperglycemia [224, 225]. This suppression of the phosphorylation of Tie-2 likely occurs via 
the inhibitory action of the secreted Ang-2 on Tie-2. In line with this interpretation, the 
fraction of phosphorylated Tie-2 was reduced upon NDPK-B depletion although the total 
amount of Tie-2 was increased.  
As mentioned before, Ang-2 acts as an antagonist to Tie-2 by competing with the agonist 
Ang-1 [109].Thus, the upregulation of Ang-2 in pathological conditions is believed to be the 
driving force of vascular regression by inhibiting the endothelial quiescence-promoting Ang-
1-Tie-2 signaling [28]. Interestingly, NDPK-B depletion induced more Ang-2 secretion than 
HG. As we hypothesized, this increase in Ang-2 secretion is of relevance for the observed 
increase in Tie-2 levels upon NDPK-B depletion. We adenovirally overexpressed Ang-2 in 
ECs thereby strongly increasing also the amount of secreted Ang-2. Interestingly, although 
the amount of secreted Ang-2 exceeded that induced by NDPK-B-depletion by far, a similar 
increase in Tie-2 levels was observed. The elevation of Ang-2 in HG not causing an increase 
in Tie-2 suggests a minimum required concentration of Ang-2 required to induce Tie-2 
regulation. 
Numerous studies have elaborated that the effect of Ang-2 on Tie-2 signaling is context 
dependent [148, 150, 151, 226]. For example, in pathological conditions, Ang-2 inhibits the 
survival-promoting Tie-2 activation by Ang-1, whereas under non-pathological conditions, it 
can act as an agonist, promoting Tie-2 phosphorylation [148]. Ang-1 is secreted from peri-
endothelial cells, for example pericytes and monocytes, but was recently reported to be 
released from activated platelets [159-161, 227]. It is however generally believed not to 
secreted from ECs. Thus, we could use sTie-2 to address the role of secreted Ang-2 upon 
NDPK-B depletion. Interestingly, by sequestering secreted Ang-2, the increase in the 
amount of cellular Ang-2 upon NDPK-B depletion was prevented, whereas the smaller 
increase in Ang-2 levels upon HG treatment was not. This indicates that after reaching a 
threshold, Ang-2 might foster its own expression and secretion from ECs in a manner 
dependent on the Tie-2 expression level. Although Ang-2 is able to interact with other 
receptors on endothelial cells, such as integrins and thrombomodulin, to modulate vascular 
remodeling [158-161, 227], the data obtained upon Tie-2 depletion point to the Ang-2-Tie-2-
interaction as major mediator of such a feed forward loop. A 40% reduction in Tie-2 





Fig.  39: Putative role of Tie-2 in the regulation of Ang-2 initiated by a loss in NDPK-B 
expression in comparison to HG  
 
Our study outlines a novel modulation in the Ang-2-Tie-2 axis in endothelial cells which is 
induced by NDPK-B deficiency but not by hyperglycemia/HG (Fig. 39). Although NDPK-B 
and HG induce an upregulation of Ang-2, likely influencing Tie-2 signaling, only NDPK-B 
deficiency induces a positive feedback loop in which Tie-2 is upregulated, inducing a further 
enhancement of released Ang-2 that further promotes its elevation and is in accordance with 
the important role of Ang-2 in NDPK-B driven vasoregression [216].  Our findings identify 
Tie-2 as a key regulator in NDPK-B deficiency-driven vascular regression.  
6.3 Protein O-GlcNAcylation is a central mediator i n the regulation of Ang-2 
upon the loss of NDPK-B  
The connection between NDPK-B and protein O-GlcNAcylation in ECs was analyzed in 
detail. The data obtained collectively show that a loss in NDPK-B protein expression 
activates the HBP without altering glycolysis in ECs. Despite altering nucleotide metabolism 
in ECs, the loss of NDPK-B expression does not alter nucleotide triphosphate levels in ECs. 
NDPK-B depletion increases the level of the rate-limiting enzyme of the HBP, GFAT, in ECs 
and diminishes its inhibitory phosphorylation at Ser243; both promoting UDP-GlcNAc 
production. Reduced NDPK-B expression is further associated with a reduction of OGA 
activity. The loss of NDPK-B therefore enhances protein O-GlcNAcylation in ECs via HBP 
activation and the suppression of OGA activity. Enhanced protein O-GlcNAcylation in ECs is 
driving the upregulation of Ang-2, which itself is O-GlcNAcylated. The NTP/NDP 
transphosphorylase and protein kinase activity of NDPK-B are dispensable for their effect on 
protein O-GlcNAcylation.  
It has been shown before that high glucose leads to the activation of the HBP and increased 
UDP-GlcNAc levels in ECs [101, 102]. As a result of the HBP activation, diabetic conditions 
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in animals or HG treatment of cultured ECs increase protein O-GlcNAcylation [93, 101, 213, 
216]. As also confirmed herein, by directly interfering with OGA activity, the level of protein 
O-GlcNAcylation governs Ang-2 content in ECs and in the retina [213, 216][213, 216][213, 
216][213, 216]. Enhanced protein O-GlcNAcylation and upregulation of Ang-2 upon NDPK-B 
depletion are apparently common to ECs of all vascular beds. Besides in HUVECs, it 
occurred in human microvascular ECs from the dermis and retina. Also, in MBMECs isolated 
from NDPK-deficient mice enhanced protein O-GlcNAcylation was clearly evident. Another 
feature, which became apparent in this study, is that Ang-2 is highly O-GlcNAcylated itself. 
O-GlcNAcylation of a protein is often associated with an increased stability of the protein due 
to the inhibition of proteasomal degradation [62, 228]. Therefore, a rather complex regulation 
of the Ang-2 levels in ECs can be envisioned. Taking into account that the upregulation of 
GFAT as well as the suppression the OGA activity were independent of gene transcription, 
many of the alterations similarly induced by hyperglycemia/high glucose or loss of NDPK-B 
are also caused by similar changes in post-transcriptional modification patterns. 
The increase in protein O-GlcNAcylation as well as the upregulation of Ang-2, caused by 
NDPK-B deficiency, were detected before in whole retinal lysates [213]. The increase in 
UDP-GlcNAc levels, which was detected upon NDPK-B depletion in cultured ECs, was 
however not detected in the NDPK-B deficient retina. The retina is a complex organ 
consisting of many cell types of which the ECs are a small subset. Therefore, changes in 
such a small subset of cells may escape detection, especially when the detection method 
performed analyses of components which are present in any cell type such as nucleotides or 
their derivates. Assuming that the elevation of UDP-GlcNAc upon NDPK-B deficiency is 
specific for ECs and possibly Müller glia cells, another source of elevated retinal Ang-2 [229], 
it escaped detection in the pool of total UDP-GlcNAc in the retinal lysate. This interpretation 
is corroborated by the results obtained from the nucleotide content analysis. While GTP and 
GDP were the most prominent nucleotides in the total retinal lysates, ATP showed by far the 
highest level in ECs, which is line with their known high glycolysis rate, therefore producing 
ATP as a source of energy [230]. Moreover, none of the changes in the nucleotide pattern 
observed in NDPK-B depleted ECs was reflected in the NDPK-B deficient retinae.  
The NDPKs are originally a family of housekeeping enzymes that replenish the NTP pool by 
their NTP/NDP transphosphorylase activity [165, 166]. As NDPK-B is one of the two major 
isoforms, its depletion in ECs diminished the overall NDP kinase activity by about 20%. The 
similar extent of reduction in overall NDPK activity in HG-treated ECs indicates yet another 
similarity between HG and NDPK-B deficiency. This finding, however, does not allow 
conclusions regarding the importance of NDPK-B specifically [205]. In accordance with the 
NDPK-B knockdown in ECs, 35% of the NDP kinase activity was missing in the NDPK-B 
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deficient retinae. Nevertheless, although the absence of NDPK-B altered slightly the 
nucleotide metabolism in ECs the measured NTP levels are not changed, indicating that the 
activity of the remaining NDPK family members is sufficient to hold up these levels. An 
altered UTP level [231] was therefore excluded as a driving force for the enhanced UDP-
GlcNAc levels upon NDPK-B depletion. In line with this interpretation, the re-expression 
experiments with NDPK-B or its catalytically inactive mutant revealed that its enzymatic 
activity is not required to lower protein O-GlcNAcylation in ECs.  
 
 




In conclusion, the data reported herein shed light on a novel pathway by which the loss of 
NDPK-B in ECs causes a shift from glycolysis to the HBP. By increasing the GFAT content 
and suppressing OGA protein activity protein O-GlcNAcylation is generally enhanced (Fig. 
40). This induces the upregulation of Ang-2. Taken together, these data highlight the 
importance of the HBP in the retinopathy caused by NDPK-B deficiency in mice [213, 216] 
and further validate this model for mechanistic investigations related to diabetic retinopathy 
in humans.  
6.4 The multifaceted regulation of Ang-2 via Tie-2 and protein O-GlcNAcylation 
The increase in Ang-2 content and release has been shown to be responsible for the 
initiation of PC dropout in the retina, the formation of AC, and thus vasoregression [28, 91, 
92]. The same process has now been confirmed to occur in NDPK-B deficient mice. Several 
explanations as to how protein O-GlcNAcylation increases Ang-2 levels have been 
suggested. For instance, hyperglycemia promotes methylglyoxal modification of mSin3A in 
ECs, triggering the increased O-GlcNAcylation of the transcriptional regulator Sp3 via 
recruitment of OGT [54]. A feed forward loop involving Tie-2 in fostering Ang-2 upregulation 
in ECs after a reduction in NDPK-B expression has been shown herein. We and others 
showed that the Ang-2 expression in ECs is dependent on FoxO1, a transcription factor also 
stabilized by O-GlcNAcylation [162, 216]. However, interfering with Ang-2-Tie-2 signalling 
had no effect on FoxO1 or protein O-GlcNAcylation, indicating no discernible crosstalk 
between the two modes of Ang-2 regulation. In accordance, Tie-2 was unchanged upon 
TMG and OGA silencing-mediated increase in protein O-GlcNAcylation. Upon reaching a 
threshold in Ang-2 content and secretion, which is reached upon loss of NDPK-B, but not in 
HG, the Ang-2-Tie-2 interaction further fosters Ang-2 content and secretion in ECs. The 
extent to which the two mechanisms contribute to Ang-2 upregulation in NDPK-B deficiency 
is yet to be determined. However, several publications explore the possibility of targeting 
Tie-2 in vascular disorders, including diabetic retinopathy, featuring high circulating Ang-2 for 
therapeutic intervention [232-235]. Therefore, our data might be of relevance for several 
vascular diseases and provide novel insights into the mechanisms of the Ang-2-Tie-2 
signaling in ECs. 
6.5 Limitations of the study  
However, several questions remain unanswered in this study. On ECs, Ang-2 binds the 
integrins to modulate vascular remodeling. Binding at low Tie-2 conditions promoted 
sprouting angiogenesis in developing vessels and stress fiber formation in quiescent ECs 
[158, 160, 161]. In normal Tie-2 conditions, Ang-2-mediated complex formation between 
integrins and Tie-2 at cell-cell junctions leading to integrin internalization and degradation 
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[236], indicating a possible mechanism for Ang-2-mediated loosening of cell-cell and cell-
matrix contacts. Therefore, the possibility of the involvement of integrins in Ang-2-mediated 
retinal vasoregression cannot be excluded and should be investigated. 
We have extensively investigated the effect of altering nucleotide metabolism in NDPK-B 
deficiency and excluded it as a mediator of HBP activation. The other components of the 
HBP, amino acid metabolism, and fatty acid metabolism also contribute to the regulation of 
the protein O-GlcNAc [237-239]. Alterations in these metabolic pathways, upon loss of 
NDPK-B, might contribute to the observed flux through the HBP and need to be analyzed. 
Alternately, fructose-6-phosphate is the substrate for GFAT, and as we postulated, elevated 
GFAT expression and activity is responsible for HBP activation. Due to the lack of reliable 
tools, we were unable to detect whether fructose-6-phosphate is elevated in NDPK-B 
depleted ECs. At the other end of the O-GlcNAcylation pathway, OGT was not regulated at 
the protein or mRNA level, but we did not assess its enzymatic activity which may also play 
an important part in O-GlcNAc cycling. In accordance, both  OGT and OGA can  be O-
GlcNAcylated which may alter their specificity or activity [62].  
The findings in this study as well as our previous publication confirm that Ang-2 is modified 
by O-GlcNAc [216]. However, tools such as sWGA beads have their limitations in terms of 
specificity. More precise methods such as mass spectrometry need to be employed in order 
to detect the modified residues on Ang-2 [240]. Furthermore, the consequence of Ang-2 O-
GlcNAcylation needs to be addressed as well. O-GlcNAc modification may protect modified 
proteins from proteasomal degradation [62, 228]. An assessment of Ang-2 ubiquitination 
may shed light on the outcome of its modification, and whether it contributes to the function 
of Ang-2 as the mediator of retinal vasoregression.  
Scaffold functions of NDPK-B in the regulation of protein complex formation have been 
reported before and are also seen for other NDPK isoforms, e. g. NDPK-C [188, 190, 191, 
241]. In ECs, NDPK-B is apparently involved in caveolae formation and caveolin transport 
[198, 212]. Thus, the possible contribution of Cav-1 in NDPK-B-dependent vasoregression 
needs to be assessed, and might help to decide whether the overexpression of NDPK-B in 
wildtype and kinase dead mutant forms is an option to be considered to tackle the Ang-2 
upregulation in the retina as a possible therapeutic approach to treat vasoregression. 
6.6 Conclusion 
By comparing NDPK-B with HG, this work further clarified its role in Ang-2-driven 
vasoregerssion in the retina. NDPK-B depletion alters the participation of the HBP in glucose 
metabolism via alteration of GFAT levels and suppression of OGA activity, which 
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subsequently further increases protein O-GlcNAcylation and upregulates Ang-2. NDPK-B 
deficiency additionally induces an increase in Tie-2 expression levels which supports further 
Ang-2 production and secretion in a positive feedback loop. As enhanced Tie-2 expression 
was detected on the vasculature of NDPK-B-deficient mice showing early stages of 
pathological vasoregression, it likely contributed, together with enhanced protein O-
GlcNAcylation, to the Ang-2-driven pathology (Fig. 41 ). Therefore, interfering with protein O-
GlcNAcylation and/or Tie-2 activity seems to be a key target to prevent early stages of retinal 
vasoregression. 
 





1. DeFronzo, R.A., et al., International Textbook of Diabetes Mellitus, 2 Volume Set. Vol. 1. 
2015: John Wiley & Sons. 
2. Cho, N.H., et al., IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and 
projections for 2045. Diabetes Res Clin Pract, 2018. 138: p. 271-281. 
3. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2010. 33 Suppl 1: p. S62-9. 
4. Fowler, M.J., Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes, 
2008. 26(2): p. 77-82. 
5. Duh, E.J., J.K. Sun, and A.W. Stitt, Diabetic retinopathy: current understanding, mechanisms, 
and treatment strategies. JCI Insight, 2017. 2(14). 
6. Leasher, J.L., et al., Erratum. Global Estimates on the Number of People Blind or Visually 
Impaired by Diabetic Retinopathy: A Meta-analysis From 1990-2010. Diabetes Care 
2016;39:1643-1649. Diabetes Care, 2016. 39(11): p. 2096. 
7. Hammes, H.P., Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. 
Diabetologia, 2018. 61(1): p. 29-38. 
8. Yau, J.W., et al., Global prevalence and major risk factors of diabetic retinopathy. Diabetes 
Care, 2012. 35(3): p. 556-64. 
9. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional 
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK 
Prospective Diabetes Study (UKPDS) Group. Lancet, 1998. 352(9131): p. 837-53. 
10. Damato, E.M., et al., Sight-threatening diabetic retinopathy at presentation to screening 
services in Fiji. Ophthalmic Epidemiol, 2014. 21(5): p. 318-26. 
11. Ponto, K.A., et al., Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: 
results from the Gutenberg Health Study (GHS). Diabetologia, 2016. 59(9): p. 1913-9. 
12. Ting, D.S., G.C. Cheung, and T.Y. Wong, Diabetic retinopathy: global prevalence, major risk 
factors, screening practices and public health challenges: a review. Clin Exp Ophthalmol, 
2016. 44(4): p. 260-77. 
13. Forbes, J.M. and M.E. Cooper, Mechanisms of diabetic complications. Physiol Rev, 2013. 
93(1): p. 137-88. 
14. Stitt, A.W., et al., The progress in understanding and treatment of diabetic retinopathy. Prog 
Retin Eye Res, 2016. 51: p. 156-86. 
15. Gardner, T.W. and J.R. Davila, The neurovascular unit and the pathophysiologic basis of 
diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol, 2017. 255(1): p. 1-6. 
16. Augustin, H.G., et al., Control of vascular morphogenesis and homeostasis through the 
angiopoietin-Tie system. Nat Rev Mol Cell Biol, 2009. 10(3): p. 165-77. 
17. Fruttiger, M., Development of the retinal vasculature. Angiogenesis, 2007. 10(2): p. 77-88. 
18. Gariano, R.F. and T.W. Gardner, Retinal angiogenesis in development and disease. Nature, 
2005. 438(7070): p. 960-6. 
19. Kur, J., E.A. Newman, and T. Chan-Ling, Cellular and physiological mechanisms underlying 
blood flow regulation in the retina and choroid in health and disease. Prog Retin Eye Res, 
2012. 31(5): p. 377-406. 
20. Dietrich, N. and H.P. Hammes, Retinal digest preparation: a method to study diabetic 
retinopathy. Methods Mol Biol, 2012. 933: p. 291-302. 
21. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment 
Diabetic Retinopathy Study Research Group. Ophthalmology, 1991. 98(5 Suppl): p. 766-85. 
22. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report 
number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology, 
1991. 98(5 Suppl): p. 823-33. 
100 
 
23. Klein, R., et al., The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year 
incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. 
Arch Ophthalmol, 1989. 107(2): p. 244-9. 
24. Klein, R., et al., The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-
five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology, 2008. 
115(11): p. 1859-68. 
25. Kuwabara, T. and D.G. Cogan, Retinal vascular patterns. VI. Mural cells of the retinal 
capillaries. Arch Ophthalmol, 1963. 69: p. 492-502. 
26. Korn, C. and H.G. Augustin, Mechanisms of Vessel Pruning and Regression. Dev Cell, 2015. 
34(1): p. 5-17. 
27. Pfister, F., et al., Pericytes in the eye. Pflugers Arch, 2013. 465(6): p. 789-96. 
28. Hammes, H.P., et al., Diabetic retinopathy: targeting vasoregression. Diabetes, 2011. 60(1): 
p. 9-16. 
29. Hammes, H.P., et al., Pericytes and the pathogenesis of diabetic retinopathy. Diabetes, 2002. 
51(10): p. 3107-12. 
30. Valdez, C.N., et al., Retinal microangiopathy in a mouse model of inducible mural cell loss. 
Am J Pathol, 2014. 184(10): p. 2618-26. 
31. Dietrich, N., et al., The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic 
Retinopathy. PLoS One, 2016. 11(12): p. e0167853. 
32. Robinson, R., et al., Update on animal models of diabetic retinopathy: from molecular 
approaches to mice and higher mammals. Dis Model Mech, 2012. 5(4): p. 444-56. 
33. Karlstetter, M., et al., Retinal microglia: just bystander or target for therapy? Prog Retin Eye 
Res, 2015. 45: p. 30-57. 
34. Reichenbach, A. and A. Bringmann, New functions of Muller cells. Glia, 2013. 61(5): p. 651-
78. 
35. Arnold, T. and C. Betsholtz, Correction: The importance of microglia in the development of 
the vasculature in the central nervous system. Vasc Cell, 2013. 5(1): p. 12. 
36. Xu, Q., et al., Vascular development in the retina and inner ear: control by Norrin and 
Frizzled-4, a high-affinity ligand-receptor pair. Cell, 2004. 116(6): p. 883-95. 
37. Antonetti, D.A., R. Klein, and T.W. Gardner, Diabetic retinopathy. N Engl J Med, 2012. 
366(13): p. 1227-39. 
38. Heilig, C.W., et al., Overexpression of glucose transporters in rat mesangial cells cultured in a 
normal glucose milieu mimics the diabetic phenotype. J Clin Invest, 1995. 96(4): p. 1802-14. 
39. Kaiser, N., et al., Differential regulation of glucose transport and transporters by glucose in 
vascular endothelial and smooth muscle cells. Diabetes, 1993. 42(1): p. 80-9. 
40. Du, X.L., et al., Hyperglycemia-induced mitochondrial superoxide overproduction activates 
the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by 
increasing Sp1 glycosylation. Proc Natl Acad Sci U S A, 2000. 97(22): p. 12222-6. 
41. Giugliano, D., A. Ceriello, and G. Paolisso, Oxidative stress and diabetic vascular 
complications. Diabetes Care, 1996. 19(3): p. 257-67. 
42. Nishikawa, T., et al., Normalizing mitochondrial superoxide production blocks three pathways 
of hyperglycaemic damage. Nature, 2000. 404(6779): p. 787-90. 
43. Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 
2005. 54(6): p. 1615-25. 
44. Lee, A.Y. and S.S. Chung, Contributions of polyol pathway to oxidative stress in diabetic 
cataract. FASEB J, 1999. 13(1): p. 23-30. 
45. Engerman, R.L., T.S. Kern, and M.E. Larson, Nerve conduction and aldose reductase inhibition 
during 5 years of diabetes or galactosaemia in dogs. Diabetologia, 1994. 37(2): p. 141-4. 
46. McLellan, A.C., et al., Glyoxalase system in clinical diabetes mellitus and correlation with 
diabetic complications. Clin Sci (Lond), 1994. 87(1): p. 21-9. 
101 
 
47. Neeper, M., et al., Cloning and expression of a cell surface receptor for advanced 
glycosylation end products of proteins. J Biol Chem, 1992. 267(21): p. 14998-5004. 
48. Schmidt, A.M., et al., Advanced glycation endproducts interacting with their endothelial 
receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human 
endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of 
diabetes. J Clin Invest, 1995. 96(3): p. 1395-403. 
49. Shinohara, M., et al., Overexpression of glyoxalase-I in bovine endothelial cells inhibits 
intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced 
increases in macromolecular endocytosis. J Clin Invest, 1998. 101(5): p. 1142-7. 
50. Vlassara, H., et al., Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in 
normal tissue remodeling. Science, 1988. 240(4858): p. 1546-8. 
51. Hammes, H.P., et al., Aminoguanidine treatment inhibits the development of experimental 
diabetic retinopathy. Proc Natl Acad Sci U S A, 1991. 88(24): p. 11555-8. 
52. Ishii, H., et al., Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta 
inhibitor. Science, 1996. 272(5262): p. 728-31. 
53. Wells, L. and G.W. Hart, O-GlcNAc turns twenty: functional implications for post-translational 
modification of nuclear and cytosolic proteins with a sugar. FEBS Lett, 2003. 546(1): p. 154-8. 
54. Yao, D., et al., High glucose increases angiopoietin-2 transcription in microvascular 
endothelial cells through methylglyoxal modification of mSin3A. J Biol Chem, 2007. 282(42): 
p. 31038-45. 
55. Du, X., et al., Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three 
major pathways of hyperglycemic damage in endothelial cells. J Clin Invest, 2003. 112(7): p. 
1049-57. 
56. van den Born, J.C., et al., Gasotransmitters in Vascular Complications of Diabetes. Diabetes, 
2016. 65(2): p. 331-45. 
57. Kolibabka, M., et al., Dicarbonyl Stress Mimics Diabetic Neurovascular Damage in the Retina. 
Exp Clin Endocrinol Diabetes, 2016. 124(7): p. 437-9. 
58. Lachin, J.M., et al., Effect of glycemic exposure on the risk of microvascular complications in 
the diabetes control and complications trial--revisited. Diabetes, 2008. 57(4): p. 995-1001. 
59. Holt, G.D. and G.W. Hart, The subcellular distribution of terminal N-acetylglucosamine 
moieties. Localization of a novel protein-saccharide linkage, O-linked GlcNAc. J Biol Chem, 
1986. 261(17): p. 8049-57. 
60. Housley, M.P., et al., O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem, 
2008. 283(24): p. 16283-92. 
61. Torres, C.R. and G.W. Hart, Topography and polypeptide distribution of terminal N-
acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked 
GlcNAc. J Biol Chem, 1984. 259(5): p. 3308-17. 
62. Yang, X. and K. Qian, Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev 
Mol Cell Biol, 2017. 18(7): p. 452-465. 
63. Hart, G.W. and Y. Akimoto, The O-GlcNAc Modification. 2009. 
64. Hart, G.W., et al., Cross talk between O-GlcNAcylation and phosphorylation: roles in 
signaling, transcription, and chronic disease. Annu Rev Biochem, 2011. 80: p. 825-58. 
65. Dorfman, A., et al., The biosynthesis of hyaluronic acid by group A Streptococcus. II. Origin of 
the N-acetylglucosamine moiety. J Biol Chem, 1955. 212(2): p. 583-91. 
66. Ghosh, S., et al., Glucosamine metabolism. V. Enzymatic synthesis of glucosamine 6-
phosphate. J Biol Chem, 1960. 235: p. 1265-73. 
67. Marshall, S., V. Bacote, and R.R. Traxinger, Complete inhibition of glucose-induced 
desensitization of the glucose transport system by inhibitors of mRNA synthesis. Evidence for 
rapid turnover of glutamine:fructose-6-phosphate amidotransferase. J Biol Chem, 1991. 
266(16): p. 10155-61. 
102 
 
68. Broschat, K.O., et al., Kinetic characterization of human glutamine-fructose-6-phosphate 
amidotransferase I: potent feedback inhibition by glucosamine 6-phosphate. J Biol Chem, 
2002. 277(17): p. 14764-70. 
69. Copeland, R.J., J.W. Bullen, and G.W. Hart, Cross-talk between GlcNAcylation and 
phosphorylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol 
Metab, 2008. 295(1): p. E17-28. 
70. Fantus, I.G., et al., The Hexosamine Biosynthesis Pathway, in The Diabetic Kidney, P. Cortes 
and C.E. Mogensen, Editors. 2006, Humana Press: Totowa, NJ. p. 117-133. 
71. Zhou, J., et al., Regulation of glutamine:fructose-6-phosphate amidotransferase by cAMP-
dependent protein kinase. Diabetes, 1998. 47(12): p. 1836-40. 
72. Chang, Q., et al., Phosphorylation of human glutamine:fructose-6-phosphate 
amidotransferase by cAMP-dependent protein kinase at serine 205 blocks the enzyme 
activity. J Biol Chem, 2000. 275(29): p. 21981-7. 
73. Eguchi, S., et al., AMP-activated protein kinase phosphorylates glutamine : fructose-6-
phosphate amidotransferase 1 at Ser243 to modulate its enzymatic activity. Genes Cells, 
2009. 14(2): p. 179-89. 
74. Zibrova, D., et al., GFAT1 phosphorylation by AMPK promotes VEGF-induced angiogenesis. 
Biochem J, 2017. 474(6): p. 983-1001. 
75. Lazarus, M.B., et al., Structure of human O-GlcNAc transferase and its complex with a 
peptide substrate. Nature, 2011. 469(7331): p. 564-7. 
76. Janetzko, J. and S. Walker, The making of a sweet modification: structure and function of O-
GlcNAc transferase. J Biol Chem, 2014. 289(50): p. 34424-32. 
77. Ma, J. and G.W. Hart, Protein O-GlcNAcylation in diabetes and diabetic complications. Expert 
Rev Proteomics, 2013. 10(4): p. 365-80. 
78. Golks, A., et al., Requirement for O-linked N-acetylglucosaminyltransferase in lymphocytes 
activation. EMBO J, 2007. 26(20): p. 4368-79. 
79. Yang, X., F. Zhang, and J.E. Kudlow, Recruitment of O-GlcNAc transferase to promoters by 
corepressor mSin3A: coupling protein O-GlcNAcylation to transcriptional repression. Cell, 
2002. 110(1): p. 69-80. 
80. Vosseller, K., et al., Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin 
resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U 
S A, 2002. 99(8): p. 5313-8. 
81. Soesanto, Y.A., et al., Regulation of Akt signaling by O-GlcNAc in euglycemia. Am J Physiol 
Endocrinol Metab, 2008. 295(4): p. E974-80. 
82. Andrali, S.S., Q. Qian, and S. Ozcan, Glucose mediates the translocation of NeuroD1 by O-
linked glycosylation. J Biol Chem, 2007. 282(21): p. 15589-96. 
83. Gao, Y., J. Miyazaki, and G.W. Hart, The transcription factor PDX-1 is post-translationally 
modified by O-linked N-acetylglucosamine and this modification is correlated with its DNA 
binding activity and insulin secretion in min6 beta-cells. Arch Biochem Biophys, 2003. 415(2): 
p. 155-63. 
84. Akimoto, Y., et al., Elevation of the post-translational modification of proteins by O-linked N-
acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the 
pancreas of diabetic Goto-Kakizaki rats. Glycobiology, 2007. 17(2): p. 127-40. 
85. Akimoto, Y., et al., Localization of the O-linked N-acetylglucosamine transferase in rat 
pancreas. Diabetes, 1999. 48(12): p. 2407-13. 
86. Akimoto, Y., et al., Increased O-GlcNAc transferase in pancreas of rats with streptozotocin-
induced diabetes. Diabetologia, 2000. 43(10): p. 1239-47. 
87. Hanover, J.A., et al., Elevated O-linked N-acetylglucosamine metabolism in pancreatic beta-
cells. Arch Biochem Biophys, 1999. 362(1): p. 38-45. 
103 
 
88. Ball, L.E., M.N. Berkaw, and M.G. Buse, Identification of the major site of O-linked beta-N-
acetylglucosamine modification in the C terminus of insulin receptor substrate-1. Mol Cell 
Proteomics, 2006. 5(2): p. 313-23. 
89. Whelan, S.A., M.D. Lane, and G.W. Hart, Regulation of the O-linked beta-N-
acetylglucosamine transferase by insulin signaling. J Biol Chem, 2008. 283(31): p. 21411-7. 
90. Yang, X., et al., Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. 
Nature, 2008. 451(7181): p. 964-9. 
91. Hammes, H.P., et al., Angiopoietin-2 causes pericyte dropout in the normal retina: evidence 
for involvement in diabetic retinopathy. Diabetes, 2004. 53(4): p. 1104-10. 
92. Pfister, F., et al., Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and 
enhances vascular damages in hyperglycemia. Acta Diabetol, 2010. 47(1): p. 59-64. 
93. Gurel, Z., et al., Retinal O-linked N-acetylglucosamine protein modifications: implications for 
postnatal retinal vascularization and the pathogenesis of diabetic retinopathy. Mol Vis, 2013. 
19: p. 1047-59. 
94. Huang, Q. and N. Sheibani, High glucose promotes retinal endothelial cell migration through 
activation of Src, PI3K/Akt1/eNOS, and ERKs. Am J Physiol Cell Physiol, 2008. 295(6): p. 
C1647-57. 
95. Forsythe, M.E., et al., Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-
1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer. Proc Natl Acad 
Sci U S A, 2006. 103(32): p. 11952-7. 
96. Khidekel, N., et al., Probing the dynamics of O-GlcNAc glycosylation in the brain using 
quantitative proteomics. Nat Chem Biol, 2007. 3(6): p. 339-48. 
97. Lehman, D.M., et al., A single nucleotide polymorphism in MGEA5 encoding O-GlcNAc-
selective N-acetyl-beta-D glucosaminidase is associated with type 2 diabetes in Mexican 
Americans. Diabetes, 2005. 54(4): p. 1214-21. 
98. Hu, Y., et al., Adenovirus-mediated overexpression of O-GlcNAcase improves contractile 
function in the diabetic heart. Circ Res, 2005. 96(9): p. 1006-13. 
99. Hu, Y., et al., Increased enzymatic O-GlcNAcylation of mitochondrial proteins impairs 
mitochondrial function in cardiac myocytes exposed to high glucose. J Biol Chem, 2009. 
284(1): p. 547-55. 
100. McClain, D.A., et al., Altered glycan-dependent signaling induces insulin resistance and 
hyperleptinemia. Proc Natl Acad Sci U S A, 2002. 99(16): p. 10695-9. 
101. Du, X.-L., et al., Hyperglycemia-induced mitochondrial superoxide overproduction activates 
the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by 
increasing Sp1 glycosylation. Proceedings of the National Academy of Sciences, 2000. 97(22): 
p. 12222-12226. 
102. Hammes, H.-P., et al., Benfotiamine blocks three major pathways of hyperglycemic damage 
and prevents experimental diabetic retinopathy. Nature Medicine, 2003. 9(3): p. 294-299. 
103. Du, X.L., et al., Hyperglycemia inhibits endothelial nitric oxide synthase activity by 
posttranslational modification at the Akt site. J Clin Invest, 2001. 108(9): p. 1341-8. 
104. Musicki, B., et al., Inactivation of phosphorylated endothelial nitric oxide synthase (Ser-1177) 
by O-GlcNAc in diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A, 2005. 
102(33): p. 11870-5. 
105. Taylor, R.P., et al., Glucose deprivation stimulates O-GlcNAc modification of proteins through 
up-regulation of O-linked N-acetylglucosaminyltransferase. J Biol Chem, 2008. 283(10): p. 
6050-7. 
106. Taylor, R.P., et al., Up-regulation of O-GlcNAc transferase with glucose deprivation in HepG2 
cells is mediated by decreased hexosamine pathway flux. J Biol Chem, 2009. 284(6): p. 3425-
32. 
107. Risau, W., Mechanisms of angiogenesis. Nature, 1997. 386(6626): p. 671-4. 
104 
 
108. Davis, S., et al., Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap 
expression cloning. Cell, 1996. 87(7): p. 1161-9. 
109. Maisonpierre, P.C., et al., Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo 
angiogenesis. Science, 1997. 277(5322): p. 55-60. 
110. Cheung, A.H., R.J. Stewart, and P.A. Marsden, Endothelial Tie2/Tek ligands angiopoietin-1 
(ANGPT1) and angiopoietin-2 (ANGPT2): regional localization of the human genes to 8q22.3-
q23 and 8p23. Genomics, 1998. 48(3): p. 389-91. 
111. Grosios, K., et al., Assignment of ANGPT4, ANGPT1, and ANGPT2 encoding angiopoietins 4, 1 
and 2 to human chromosome bands 20p13, 8q22.3-->q23 and 8p23.1, respectively, by in situ 
hybridization and radiation hybrid mapping. Cytogenet Cell Genet, 1999. 84(1-2): p. 118-20. 
112. Xu, Y. and Q. Yu, Angiopoietin-1, unlike angiopoietin-2, is incorporated into the extracellular 
matrix via its linker peptide region. J Biol Chem, 2001. 276(37): p. 34990-8. 
113. Fiedler, U., et al., The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon 
stimulation from endothelial cell Weibel-Palade bodies. Blood, 2004. 103(11): p. 4150-6. 
114. Jeon Byeong, H., et al., Tie-ing the Antiinflammatory Effect of Angiopoietin-1 to Inhibition of 
NF-κB. Circulation Research, 2003. 92(6): p. 586-588. 
115. Ramsauer, M. and P.A. D’Amore, Getting Tie(2)d up in angiogenesis. The Journal of Clinical 
Investigation, 2002. 110(11): p. 1615-1617. 
116. Suri, C., et al., Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during 
Embryonic Angiogenesis. Cell, 1996. 87(7): p. 1171-1180. 
117. Thurston, G., et al., Angiopoietin-1 protects the adult vasculature against plasma leakage. 
Nat Med, 2000. 6(4): p. 460-3. 
118. Wong Adrianne, L., et al., Tie2 Expression and Phosphorylation in Angiogenic and Quiescent 
Adult Tissues. Circulation Research, 1997. 81(4): p. 567-574. 
119. Partanen, J., et al., A novel endothelial cell surface receptor tyrosine kinase with extracellular 
epidermal growth factor homology domains. Mol Cell Biol, 1992. 12(4): p. 1698-707. 
120. Dumont, D.J., et al., Dominant-negative and targeted null mutations in the endothelial 
receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes 
Dev, 1994. 8(16): p. 1897-909. 
121. Patan, S., TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis 
by the mechanism of intussusceptive microvascular growth. Microvasc Res, 1998. 56(1): p. 1-
21. 
122. Sato, T.N., et al., Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel 
formation. Nature, 1995. 376(6535): p. 70-4. 
123. Takakura, N., et al., Critical role of the TIE2 endothelial cell receptor in the development of 
definitive hematopoiesis. Immunity, 1998. 9(5): p. 677-86. 
124. Puri, M.C., et al., Interaction of the TEK and TIE receptor tyrosine kinases during 
cardiovascular development. Development, 1999. 126(20): p. 4569-80. 
125. Rodewald, H.R. and T.N. Sato, Tie1, a receptor tyrosine kinase essential for vascular 
endothelial cell integrity, is not critical for the development of hematopoietic cells. 
Oncogene, 1996. 12(2): p. 397-404. 
126. Suri, C., et al., Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during 
embryonic angiogenesis. Cell, 1996. 87(7): p. 1171-80. 
127. Fiedler, U., et al., Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial 
role in the induction of inflammation. Nat Med, 2006. 12(2): p. 235-9. 
128. Gale, N.W., et al., Angiopoietin-2 is required for postnatal angiogenesis and lymphatic 
patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell, 2002. 3(3): p. 411-
23. 
129. Goede, V., et al., Analysis of blood vessel maturation processes during cyclic ovarian 
angiogenesis. Lab Invest, 1998. 78(11): p. 1385-94. 
105 
 
130. Hackett, S.F., et al., Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell 
Physiol, 2002. 192(2): p. 182-7. 
131. Pitera, J.E., et al., Dysmorphogenesis of kidney cortical peritubular capillaries in angiopoietin-
2-deficient mice. Am J Pathol, 2004. 165(6): p. 1895-906. 
132. Eklund, L. and P. Saharinen, Angiopoietin signaling in the vasculature. Exp Cell Res, 2013. 
319(9): p. 1271-80. 
133. Kim, I., et al., Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells 
by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res, 2001. 89(6): p. 477-9. 
134. Suri, C., et al., Increased vascularization in mice overexpressing angiopoietin-1. Science, 
1998. 282(5388): p. 468-71. 
135. Vikkula, M., et al., Vascular dysmorphogenesis caused by an activating mutation in the 
receptor tyrosine kinase TIE2. Cell, 1996. 87(7): p. 1181-90. 
136. Gurnik, S., et al., Angiopoietin-2-induced blood-brain barrier compromise and increased 
stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol, 
2016. 131(5): p. 753-73. 
137. Daly, C., et al., Angiopoietin-1 modulates endothelial cell function and gene expression via 
the transcription factor FKHR (FOXO1). Genes Dev, 2004. 18(9): p. 1060-71. 
138. Gavard, J., V. Patel, and J.S. Gutkind, Angiopoietin-1 prevents VEGF-induced endothelial 
permeability by sequestering Src through mDia. Dev Cell, 2008. 14(1): p. 25-36. 
139. Sullivan, C.C., et al., Induction of pulmonary hypertension by an angiopoietin 
1/TIE2/serotonin pathway. Proc Natl Acad Sci U S A, 2003. 100(21): p. 12331-6. 
140. Uemura, A., et al., Recombinant angiopoietin-1 restores higher-order architecture of growing 
blood vessels in mice in the absence of mural cells. J Clin Invest, 2002. 110(11): p. 1619-28. 
141. Fukuhara, S., et al., Differential function of Tie2 at cell-cell contacts and cell-substratum 
contacts regulated by angiopoietin-1. Nat Cell Biol, 2008. 10(5): p. 513-26. 
142. Saharinen, P., et al., Angiopoietins assemble distinct Tie2 signalling complexes in endothelial 
cell-cell and cell-matrix contacts. Nat Cell Biol, 2008. 10(5): p. 527-37. 
143. DeBusk, L.M., D.E. Hallahan, and P.C. Lin, Akt is a major angiogenic mediator downstream of 
the Ang1/Tie2 signaling pathway. Exp Cell Res, 2004. 298(1): p. 167-77. 
144. Kontos, C.D., et al., The endothelial receptor tyrosine kinase Tie1 activates 
phosphatidylinositol 3-kinase and Akt to inhibit apoptosis. Mol Cell Biol, 2002. 22(6): p. 1704-
13. 
145. Papapetropoulos, A., et al., Angiopoietin-1 inhibits endothelial cell apoptosis via the 
Akt/survivin pathway. J Biol Chem, 2000. 275(13): p. 9102-5. 
146. Tsigkos, S., et al., Regulation of Ang2 release by PTEN/PI3-kinase/Akt in lung microvascular 
endothelial cells. J Cell Physiol, 2006. 207(2): p. 506-11. 
147. Hanahan, D., Signaling vascular morphogenesis and maintenance. Science, 1997. 277(5322): 
p. 48-50. 
148. Kim, M., et al., Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation. J 
Clin Invest, 2016. 126(9): p. 3511-25. 
149. Teichert-Kuliszewska, K., et al., Biological action of angiopoietin-2 in a fibrin matrix model of 
angiogenesis is associated with activation of Tie2. Cardiovascular Research, 2001. 49(3): p. 
659-670. 
150. Yuan, H.T., et al., Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the 
endothelium. Mol Cell Biol, 2009. 29(8): p. 2011-22. 
151. Daly, C., et al., Angiopoietin-2 functions as an autocrine protective factor in stressed 
endothelial cells. Proc Natl Acad Sci U S A, 2006. 103(42): p. 15491-6. 
152. Scharpfenecker, M., et al., The Tie-2 ligand angiopoietin-2 destabilizes quiescent 




153. Benest, A.V., et al., Angiopoietin-2 is critical for cytokine-induced vascular leakage. PLoS One, 
2013. 8(8): p. e70459. 
154. Le, C.T., et al., Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-alpha 
in suppressing remodeling of blood vessels and lymphatics in airway inflammation. Am J 
Pathol, 2015. 185(11): p. 2949-68. 
155. Aiello, L.P., et al., Vascular endothelial growth factor in ocular fluid of patients with diabetic 
retinopathy and other retinal disorders. N Engl J Med, 1994. 331(22): p. 1480-7. 
156. Gerhardt, H., et al., VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J 
Cell Biol, 2003. 161(6): p. 1163-77. 
157. Liu, H., et al., Notch3 is critical for proper angiogenesis and mural cell investment. Circ Res, 
2010. 107(7): p. 860-70. 
158. Felcht, M., et al., Angiopoietin-2 differentially regulates angiogenesis through TIE2 and 
integrin signaling. J Clin Invest, 2012. 122(6): p. 1991-2005. 
159. Yun, J.H., et al., Angiopoietin 2 induces astrocyte apoptosis via alphavbeta5-integrin 
signaling in diabetic retinopathy. Cell Death Dis, 2016. 7: p. e2101. 
160. Hakanpaa, L., et al., Endothelial destabilization by angiopoietin-2 via integrin beta1 
activation. Nat Commun, 2015. 6: p. 5962. 
161. Park, S.W., et al., Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin 
signaling in diabetic retinopathy. Diabetes, 2014. 63(9): p. 3057-68. 
162. Potente, M., et al., Involvement of Foxo transcription factors in angiogenesis and postnatal 
neovascularization. J Clin Invest, 2005. 115(9): p. 2382-92. 
163. Berg, P. and W.K. Joklik, Transphosphorylation between nucleoside polyphosphates. Nature, 
1953. 172(4387): p. 1008-9. 
164. Krebs, H.A. and R. Hems, Some reactions of adenosine and inosine phosphates in animal 
tissues. Biochim Biophys Acta, 1953. 12(1-2): p. 172-80. 
165. Morera, S., et al., Mechanism of phosphate transfer by nucleoside diphosphate kinase: X-ray 
structures of the phosphohistidine intermediate of the enzymes from Drosophila and 
Dictyostelium. Biochemistry, 1995. 34(35): p. 11062-70. 
166. Tepper, A.D., et al., Investigation of the active site and the conformational stability of 
nucleoside diphosphate kinase by site-directed mutagenesis. J Biol Chem, 1994. 269(51): p. 
32175-80. 
167. Bosnar, M.H., R. Bago, and H. Cetkovic, Subcellular localization of Nm23/NDPK A and B 
isoforms: a reflection of their biological function? Mol Cell Biochem, 2009. 329(1-2): p. 63-71. 
168. Lacombe, M.L., et al., The human Nm23/nucleoside diphosphate kinases. J Bioenerg 
Biomembr, 2000. 32(3): p. 247-58. 
169. Lacombe, M.L., et al., The mitochondrial nucleoside diphosphate kinase (NDPK-D/NME4), a 
moonlighting protein for cell homeostasis. Lab Invest, 2018. 98(5): p. 582-588. 
170. Gilles, A.M., et al., Nucleoside diphosphate kinase from human erythrocytes. Structural 
characterization of the two polypeptide chains responsible for heterogeneity of the 
hexameric enzyme. J Biol Chem, 1991. 266(14): p. 8784-9. 
171. Janin, J., et al., Three-dimensional structure of nucleoside diphosphate kinase. J Bioenerg 
Biomembr, 2000. 32(3): p. 215-25. 
172. Bilitou, A., et al., The NM23 family in development. Mol Cell Biochem, 2009. 329(1-2): p. 17-
33. 
173. Fan, Z., et al., Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-
mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell, 2003. 
112(5): p. 659-72. 
174. Lee, M.Y., et al., NM23H2 inhibits EGF- and Ras-induced proliferation of NIH3T3 cells by 
blocking the ERK pathway. Cancer Lett, 2009. 275(2): p. 221-6. 
107 
 
175. Marino, N., J.C. Marshall, and P.S. Steeg, Protein-protein interactions: a mechanism 
regulating the anti-metastatic properties of Nm23-H1. Naunyn Schmiedebergs Arch 
Pharmacol, 2011. 384(4-5): p. 351-62. 
176. Mochizuki, T., et al., Xenopus NM23-X4 regulates retinal gliogenesis through interaction with 
p27Xic1. Neural Dev, 2009. 4: p. 1. 
177. Postel, E.H., et al., Human c-myc transcription factor PuF identified as nm23-H2 nucleoside 
diphosphate kinase, a candidate suppressor of tumor metastasis. Science, 1993. 261(5120): 
p. 478-80. 
178. Thakur, R.K., et al., Metastases suppressor NM23-H2 interaction with G-quadruplex DNA 
within c-MYC promoter nuclease hypersensitive element induces c-MYC expression. Nucleic 
Acids Res, 2009. 37(1): p. 172-83. 
179. Boissan, M., et al., Increased lung metastasis in transgenic NM23-Null/SV40 mice with 
hepatocellular carcinoma. J Natl Cancer Inst, 2005. 97(11): p. 836-45. 
180. Steeg, P.S., et al., Evidence for a novel gene associated with low tumor metastatic potential. J 
Natl Cancer Inst, 1988. 80(3): p. 200-4. 
181. Clapham, D.E. and E.J. Neer, G protein beta gamma subunits. Annu Rev Pharmacol Toxicol, 
1997. 37: p. 167-203. 
182. Hamm, H.E., The many faces of G protein signaling. J Biol Chem, 1998. 273(2): p. 669-72. 
183. Wieland, T. and M.C. Michel, Can a GDP-liganded G-protein be active? Mol Pharmacol, 2005. 
68(3): p. 559-62. 
184. Wieland, T., Interaction of nucleoside diphosphate kinase B with heterotrimeric G protein 
betagamma dimers: consequences on G protein activation and stability. Naunyn 
Schmiedebergs Arch Pharmacol, 2007. 374(5-6): p. 373-83. 
185. Cuello, F., et al., Activation of heterotrimeric G proteins by a high energy phosphate transfer 
via nucleoside diphosphate kinase (NDPK) B and Gbeta subunits. Complex formation of NDPK 
B with Gbeta gamma dimers and phosphorylation of His-266 IN Gbeta. J Biol Chem, 2003. 
278(9): p. 7220-6. 
186. Hippe, H.J., et al., Regulation of cardiac cAMP synthesis and contractility by nucleoside 
diphosphate kinase B/G protein beta gamma dimer complexes. Circ Res, 2007. 100(8): p. 
1191-9. 
187. Hippe, H.J., et al., Activation of heterotrimeric G proteins by a high energy phosphate 
transfer via nucleoside diphosphate kinase (NDPK) B and Gbeta subunits. Specific activation 
of Gsalpha by an NDPK B.Gbetagamma complex in H10 cells. J Biol Chem, 2003. 278(9): p. 
7227-33. 
188. Hippe, H.J., et al., Through scaffolding and catalytic actions nucleoside diphosphate kinase B 
differentially regulates basal and beta-adrenoceptor-stimulated cAMP synthesis. Cell Signal, 
2011. 23(3): p. 579-85. 
189. Hippe, H.J., et al., Nucleoside diphosphate kinase B is required for the formation of 
heterotrimeric G protein containing caveolae. Naunyn Schmiedebergs Arch Pharmacol, 2011. 
384(4-5): p. 461-72. 
190. Abu-Taha, I.H., et al., Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in 
Human Heart Failure. Circulation, 2017. 135(9): p. 881-897. 
191. Hippe, H.J., et al., The interaction of nucleoside diphosphate kinase B with Gbetagamma 
dimers controls heterotrimeric G protein function. Proc Natl Acad Sci U S A, 2009. 106(38): p. 
16269-74. 
192. Wagner, P.D. and N.D. Vu, Phosphorylation of ATP-citrate lyase by nucleoside diphosphate 
kinase. J Biol Chem, 1995. 270(37): p. 21758-64. 
193. Cai, X., et al., Regulation of the epithelial Ca(2)(+) channel TRPV5 by reversible histidine 
phosphorylation mediated by NDPK-B and PHPT1. Mol Biol Cell, 2014. 25(8): p. 1244-50. 
194. Muimo, R., et al., Histidine phosphorylation of annexin I in airway epithelia. J Biol Chem, 
2000. 275(47): p. 36632-6. 
108 
 
195. Srivastava, S., et al., Histidine phosphorylation of the potassium channel KCa3.1 by 
nucleoside diphosphate kinase B is required for activation of KCa3.1 and CD4 T cells. Mol Cell, 
2006. 24(5): p. 665-675. 
196. Di, L., et al., Nucleoside diphosphate kinase B knock-out mice have impaired activation of the 
K+ channel KCa3.1, resulting in defective T cell activation. J Biol Chem, 2010. 285(50): p. 
38765-71. 
197. Couet, J., M. Sargiacomo, and M.P. Lisanti, Interaction of a receptor tyrosine kinase, EGF-R, 
with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase 
activities. J Biol Chem, 1997. 272(48): p. 30429-38. 
198. Feng, Y., et al., Nucleoside diphosphate kinase B regulates angiogenesis through modulation 
of vascular endothelial growth factor receptor type 2 and endothelial adherens junction 
proteins. Arterioscler Thromb Vasc Biol, 2014. 34(10): p. 2292-300. 
199. Fujita, T., et al., Accumulation of molecules involved in alpha1-adrenergic signal within 
caveolae: caveolin expression and the development of cardiac hypertrophy. Cardiovasc Res, 
2001. 51(4): p. 709-16. 
200. Insel, P.A., et al., Compartmentation of G-protein-coupled receptors and their signalling 
components in lipid rafts and caveolae. Biochem Soc Trans, 2005. 33(Pt 5): p. 1131-4. 
201. Liao, W.X., et al., Compartmentalizing VEGF-induced ERK2/1 signaling in placental artery 
endothelial cell caveolae: a paradoxical role of caveolin-1 in placental angiogenesis in vitro. 
Mol Endocrinol, 2009. 23(9): p. 1428-44. 
202. Kowluru, A., R.A. Kowluru, and A. Yamazaki, Functional alterations of G-proteins in diabetic 
rat retina: a possible explanation for the early visual abnormalities in diabetes mellitus. 
Diabetologia, 1992. 35(7): p. 624-31. 
203. Kowluru, A. and R.A. Kowluru, Subcellular localization and characterization of nucleoside 
diphosphate kinase in rat retina: effect of diabetes. Biosci Rep, 1998. 18(4): p. 187-98. 
204. Kowluru, A., R. Veluthakal, and D.M. Kaetzel, Regulatory roles for nm23/nucleoside 
diphosphate kinase-like enzymes in insulin secretion from the pancreatic islet beta cell. J 
Bioenerg Biomembr, 2006. 38(3-4): p. 227-32. 
205. Kowluru, A., Defective protein histidine phosphorylation in islets from the Goto-Kakizaki 
diabetic rat. Am J Physiol Endocrinol Metab, 2003. 285(3): p. E498-503. 
206. Veluthakal, R., M.V. Suresh, and A. Kowluru, Down-regulation of expression and function of 
nucleoside diphosphate kinase in insulin-secreting beta-cells under in vitro conditions of 
glucolipotoxicity. Mol Cell Biochem, 2009. 329(1-2): p. 121-9. 
207. Arnaud-Dabernat, S., et al., Knockout mice as model systems for studying nm23/NDP kinase 
gene functions. Application to the nm23-M1 gene. J Bioenerg Biomembr, 2003. 35(1): p. 19-
30. 
208. Boissan, M. and M.L. Lacombe, Learning about the functions of NME/NM23: lessons from 
knockout mice to silencing strategies. Naunyn Schmiedebergs Arch Pharmacol, 2011. 384(4-
5): p. 421-31. 
209. Postel, E.H., et al., Double knockout Nme1/Nme2 mouse model suggests a critical role for 
NDP kinases in erythroid development. Mol Cell Biochem, 2009. 329(1-2): p. 45-50. 
210. Postel, E.H., et al., Targeted deletion of Nm23/nucleoside diphosphate kinase A and B reveals 
their requirement for definitive erythropoiesis in the mouse embryo. Dev Dyn, 2009. 238(3): 
p. 775-87. 
211. Zhou, X.B., et al., Nucleoside diphosphate kinase B-activated intermediate conductance 
potassium channels are critical for neointima formation in mouse carotid arteries. 
Arterioscler Thromb Vasc Biol, 2015. 35(8): p. 1852-61. 
212. Gross, S., et al., Nucleoside diphosphate kinase B regulates angiogenic responses in the 
endothelium via caveolae formation and c-Src-mediated caveolin-1 phosphorylation. J Cereb 
Blood Flow Metab, 2017. 37(7): p. 2471-2484. 
109 
 
213. Qiu, Y., et al., Nucleoside diphosphate kinase B deficiency causes a diabetes-like vascular 
pathology via up-regulation of endothelial angiopoietin-2 in the retina. Acta Diabetol, 2016. 
53(1): p. 81-9. 
214. MATSUMURA, T., et al., Hyperglycemia increases angiopoietin-2 expression in retinal muller 
cells through superoxide-induced overproduction of [Alpha]-Oxoaldehyde age precursors. 
Diabetes, 2000. 49(5): p. A55-A55. 
215. Qiu, Y., et al., Mediation of FoxO1 in Activated Neuroglia Deficient for Nucleoside 
Diphosphate Kinase B during Vascular Degeneration. Neuroglia, 2018. 1(1): p. 19. 
216. Shan, S., et al., O-GlcNAcylation of FoxO1 mediates nucleoside diphosphate kinase B 
deficiency induced endothelial damage. Sci Rep, 2018. 8(1): p. 10581. 
217. Kochanowski, N., et al., Intracellular nucleotide and nucleotide sugar contents of cultured 
CHO cells determined by a fast, sensitive, and high-resolution ion-pair RP-HPLC. Anal 
Biochem, 2006. 348(2): p. 243-51. 
218. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402-8. 
219. Findley, C.M., et al., VEGF induces Tie2 shedding via a phosphoinositide 3-kinase/Akt 
dependent pathway to modulate Tie2 signaling. Arterioscler Thromb Vasc Biol, 2007. 27(12): 
p. 2619-26. 
220. Arshavsky, V.Y., T.D. Lamb, and E.N. Pugh, Jr., G proteins and phototransduction. Annu Rev 
Physiol, 2002. 64: p. 153-87. 
221. Fuhs, S.R. and T. Hunter, pHisphorylation: the emergence of histidine phosphorylation as a 
reversible regulatory modification. Curr Opin Cell Biol, 2017. 45: p. 8-16. 
222. Besant, P.G. and P.V. Attwood, Mammalian histidine kinases. Biochim Biophys Acta, 2005. 
1754(1-2): p. 281-90. 
223. Wehrle, C., P. Van Slyke, and D.J. Dumont, Angiopoietin-1-induced ubiquitylation of Tie2 by c-
Cbl is required for internalization and degradation. Biochem J, 2009. 423(3): p. 375-80. 
224. Tuo, Q.H., et al., Angiopoietin-1 protects myocardial endothelial cell function blunted by 
angiopoietin-2 and high glucose condition. Acta Pharmacol Sin, 2011. 32(1): p. 45-51. 
225. Singh, H., N.P. Brindle, and V.A. Zammit, High glucose and elevated fatty acids suppress 
signaling by the endothelium protective ligand angiopoietin-1. Microvasc Res, 2010. 79(2): p. 
121-7. 
226. Hansen, T.M., et al., Effects of angiopoietins-1 and -2 on the receptor tyrosine kinase Tie2 are 
differentially regulated at the endothelial cell surface. Cell Signal, 2010. 22(3): p. 527-32. 
227. Daly, C., et al., Angiopoietins bind thrombomodulin and inhibit its function as a thrombin 
cofactor. Sci Rep, 2018. 8(1): p. 505. 
228. Ruan, H.B., Y. Nie, and X. Yang, Regulation of protein degradation by O-GlcNAcylation: 
crosstalk with ubiquitination. Mol Cell Proteomics, 2013. 12(12): p. 3489-97. 
229. Qiu, Y., et al., Mediation of FoxO1 in Activated Neuroglia Deficient for Nucleoside 
Diphosphate Kinase B during Vascular Degeneration. Neuroglia, 2018. 1(1): p. 280-291. 
230. Potente, M. and P. Carmeliet, The Link Between Angiogenesis and Endothelial Metabolism. 
Annu Rev Physiol, 2017. 79: p. 43-66. 
231. Hawkins, M., et al., The tissue concentration of UDP-N-acetylglucosamine modulates the 
stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem, 1997. 272(8): p. 
4889-95. 
232. Campochiaro, P.A. and K.G. Peters, Targeting Tie2 for Treatment of Diabetic Retinopathy and 
Diabetic Macular Edema. Curr Diab Rep, 2016. 16(12): p. 126. 
233. Campochiaro, P.A., et al., Treatment of diabetic macular edema with an inhibitor of vascular 
endothelial-protein tyrosine phosphatase that activates Tie2. Ophthalmology, 2015. 122(3): 
p. 545-54. 
234. Shen, J., et al., Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin 
Invest, 2014. 124(10): p. 4564-76. 
110 
 
235. Campochiaro, P.A., et al., Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 
Activation Combined with Vascular Endothelial Growth Factor Suppression. Ophthalmology, 
2016. 123(8): p. 1722-1730. 
236. Thomas, M., et al., Angiopoietin-2 stimulation of endothelial cells induces alphavbeta3 
integrin internalization and degradation. J Biol Chem, 2010. 285(31): p. 23842-9. 
237. Marshall, S., O. Nadeau, and K. Yamasaki, Dynamic actions of glucose and glucosamine on 
hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-
phosphate, UDP-N-acetylglucosamine, and ATP levels. J Biol Chem, 2004. 279(34): p. 35313-
9. 
238. Weigert, C., et al., Palmitate-induced activation of the hexosamine pathway in human 
myotubes: increased expression of glutamine:fructose-6-phosphate aminotransferase. 
Diabetes, 2003. 52(3): p. 650-6. 
239. Cooksey, R.C. and D.A. McClain, Increased hexosamine pathway flux and high fat feeding are 
not additive in inducing insulin resistance: evidence for a shared pathway. Amino Acids, 
2011. 40(3): p. 841-6. 
240. Ma, J. and G.W. Hart, Analysis of Protein O-GlcNAcylation by Mass Spectrometry. Curr Protoc 
Protein Sci, 2017. 87: p. 24 10 1-24 10 16. 
241. Chen, C.W., et al., Two separate functions of NME3 critical for cell survival underlie a 
neurodegenerative disorder. Proc Natl Acad Sci U S A, 2019. 116(2): p. 566-574. 
 
 
